<SEC-DOCUMENT>0000879407-25-000013.txt : 20251010
<SEC-HEADER>0000879407-25-000013.hdr.sgml : 20251010
<ACCEPTANCE-DATETIME>20251010160242
ACCESSION NUMBER:		0000879407-25-000013
CONFORMED SUBMISSION TYPE:	10-K/A
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240930
FILED AS OF DATE:		20251010
DATE AS OF CHANGE:		20251010

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		251388088

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K/A
<SEQUENCE>1
<FILENAME>arwr-20240930.htm
<DESCRIPTION>10-K/A
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:90d8cf58-09bf-4ffe-85e6-3e61bc93c31b,g:f79393e3-6fdf-4c70-89e4-574c2bfaeb5d,d:ed6c21fce27e4152aa85d0d2377cea12-->
<html xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20240930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-36">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-true" id="f-37">true</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20240930.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-10-01</xbrli:startDate><xbrli:endDate>2024-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-11-20</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="ied6c21fce27e4152aa85d0d2377cea12_1"></div><div style="min-height:31.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K/A</ix:nonNumeric><br/>Amendment No. 1</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:3.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">September 30</ix:nonNumeric>, 2024</ix:nonNumeric></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:3.300%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.500%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:114%">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-38042</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:14.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-10">626</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-11">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-12">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-13">Suite 700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-14">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-15">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-16">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">(Address and telephone number of principal executive offices) </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:37.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.116%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.293%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:115%">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ARWR</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act: None </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.657%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.072%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.079%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">Smaller reporting company</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">Emerging growth company</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">x</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-29">&#9744;</ix:nonNumeric></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#9744;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">The aggregate market value of issuer&#8217;s voting and non-voting outstanding common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" scale="9" id="f-30">3.0</ix:nonFraction> billion based upon the closing stock price of issuer&#8217;s common stock on March 31, 2024. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">As of November&#160;20, 2024, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">124,434,442</ix:nonFraction> shares of the issuer&#8217;s Common Stock were issued and outstanding.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27.78pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="margin-top:6pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">None.</span></div></ix:nonNumeric><div style="text-indent:30.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="text-indent:30.6pt"><span><br/></span></div><div style="text-align:center;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">EXPLANATORY NOTE</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="dei:AmendmentDescription" id="f-33"><div style="text-align:justify;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Arrowhead&#8221;) is filing this Amendment No. 1 on Form 10-K/A (this &#8220;Amendment&#8221;) to its Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 26, 2024 (the &#8220;Original Report&#8221;) solely to include the information required by Items 10 through 14 of Part III of Form 10-K (the &#8220;Part III Information&#8221;) not included in the Original Report in order to comply with General Instruction G.3 of Form 10-K. The Company&#8217;s Definitive Proxy Statement on Schedule 14A containing the Part III Information was filed with the SEC on January 29, 2025 (the &#8220;Proxy Statement&#8221;) was filed three minutes after the filing deadline on the 120th day after the Company&#8217;s fiscal year end. Except as noted below, the Part III Information included in this Amendment is as of January 28, 2025.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), this Amendment also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are filed herewith. Because no financial statements have been included in this Amendment, and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27.35pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Except as described above, no other changes have been made to the Original Report and this Amendment does not modify, amend or update in any way any of the financial or other information contained in the Original Report or the Proxy Statement. This Amendment does not reflect events that may have occurred subsequent to the date of filing of the Original Report or the Proxy Statement. Accordingly, this Amendment should be read in conjunction with the Original Report and the Proxy Statement.</span></div></ix:nonNumeric><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ied6c21fce27e4152aa85d0d2377cea12_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:80.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.961%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_88">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_91">ITEM 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ied6c21fce27e4152aa85d0d2377cea12_91">DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_91">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_94">ITEM 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ied6c21fce27e4152aa85d0d2377cea12_94">EXECUTIVE COMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_94">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_97">ITEM 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ied6c21fce27e4152aa85d0d2377cea12_97">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_97">41</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_100">ITEM 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ied6c21fce27e4152aa85d0d2377cea12_100">CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTORS INDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_100">42</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_103">ITEM 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ied6c21fce27e4152aa85d0d2377cea12_103">PRINCIPAL ACCOUNTANT FEES AND SERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_103">43</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_106">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_109">ITEM 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ied6c21fce27e4152aa85d0d2377cea12_109">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_109">44</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="#ied6c21fce27e4152aa85d0d2377cea12_115">SIGNATURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:none" href="#ied6c21fce27e4152aa85d0d2377cea12_115">45</a></span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ied6c21fce27e4152aa85d0d2377cea12_88"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="ied6c21fce27e4152aa85d0d2377cea12_91"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE<br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Code of Conduct</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s employees, officers, and directors are subject to the Company&#8217;s Corporate Code of Conduct, which is available on the Company&#8217;s website at www.arrowheadpharma.com. The code meets the requirements of Nasdaq Marketplace Rules, as well as the code of ethics requirements of the Securities and Exchange Commission (&#8220;SEC&#8221;). We intend to disclose future amendments to certain provisions of the Corporate Code of Conduct, and waivers of the Corporate Code of Conduct granted to officers and directors, on the Company&#8217;s website within four business days following the date of the amendment or waiver.<br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-38">Insider Trading Policy</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our insider trading policy governs the purchase, sale and other transactions in our securities by our directors, officers and employees, and other covered persons, as well as the Company itself, and is designed to promote compliance with insider trading laws, rules and regulations, and Nasdaq listing rules, as applicable. As part of this policy, we prohibit our directors, officers, and employees from engaging in (a) short-term trading; (b) short sales; (c) options trading; (d) trading on margin; (e) pledging our common stock as collateral (except as noted below); and (f) all hedging transactions with respect to our securities. Subject to approval of our Board of Directors (the &#8220;Board&#8221;), directors and executive officers may pledge up to 75% owned and vested stock as collateral for a loan.<br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee and Audit Committee Financial Expert</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Board has a separately designated Audit Committee. The members of the Audit Committee for fiscal 2024 were William Waddill (Committee Chair), Mauro Ferrari, and Victoria Vakiener. The current members of the Audit Committee for fiscal 2025 are William Waddill (Committee Chair), Mauro Ferrari, and Victoria Vakiener. The Board has determined that all members of the Audit Committee who served during 2024 were independent directors under the rules of the SEC and the listing standards of Nasdaq Marketplace Rules and are financially literate. The Board has determined that Mr. Waddill is an &#8220;audit committee financial expert&#8221; in accordance with the applicable regulations, based on his experience as noted below.<br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Information Concerning Directors</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Biographical and other information regarding our directors serving as of January 28, 2025 is set forth below.  Douglass Given resigned as director of the Company as of December 31, 2024. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">None of the directors are related by blood, marriage or adoption to any other director or any executive officer of the Company.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:29.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.971%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone, PhD</span></div><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Chief Executive Officer, President, Director &amp; Board Chair</span></div><div style="margin-bottom:1pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:135pt"><td colspan="3" rowspan="2" style="border-bottom:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Age:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"> 55</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Director&#160;since:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"> 2007</span></div><div><span><br/></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Experience&#160;&amp; Expertise</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Dr.&#160;Anzalone has been President, Chief Executive Officer and Director of the Company since December&#160;1, 2007 and has led the Company&#8217;s business and technical development since then. Prior to joining Arrowhead, Dr.&#160;Anzalone formed and served as CEO of the Benet Group LLC, a private equity firm focused on creating and building new nano-biotechnology companies from university-generated science. Before his tenure at the Benet Group, from 1999 to 2003, he was a partner at the Washington, DC-based private equity firm Galway Partners, LLC, where he was responsible for sourcing, structuring and building new business ventures. Dr.&#160;Anzalone holds a PhD. in Biology from UCLA and a B.A. in Government from Lawrence University.</span></div><div><span><br/></span></div></td></tr><tr style="height:78pt"><td colspan="3" style="background-color:#e5e5e5;border-bottom:0.75pt solid #0071ce;border-top:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:8.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Qualifications</span></div><div style="padding-left:8.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Dr.&#160;Anzalone&#8217;s qualifications to serve on the Board include his deep understanding of the business through his role as Chief Executive Officer; in addition, Dr.&#160;Anzalone has extensive experience in business development, biotechnology, drug development, company-building and venture capital.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:29.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.971%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Mauro Ferrari, PhD</span></div><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Independent Director</span></div><div style="margin-bottom:1pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:209pt"><td colspan="3" rowspan="2" style="border-bottom:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Age:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> 6</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">5</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Director since:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> 2010</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Serves&#160;on:</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.5pt">Science Committee (Co-Chair)</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.5pt">Audit Committee</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:232%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:232%;padding-left:5.5pt">Nomination Committee</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Experience&#160;&amp; Expertise</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Dr.&#160;Ferrari currently serves as Affiliate Professor of Pharmaceutics at the University of Washington in Seattle, Washington and as President, CEO, and Board Member of BrYet US, Inc., a biotech company,  in Houston, Texas. He also serves as Chairman of the Board of BrYet Europe, a wholly-owned subsidiary of BrYet US, based in Italy. From 2010 to 2019, Dr. Ferrari served in several different capacities at the Houston Methodist Hospital, including President and CEO of The Houston Methodist Hospital Research Institute (TMHRI), Executive Vice President of Houston Methodist Hospital, and Senior Associate Dean of the hospital&#8217;s academic affiliate, Weill Cornell Medical College in New York. Dr. Ferrari is an internationally recognized expert in cancer therapeutics, nanomedicine and biomedical nanotechnology. His previous academic appointments include tenured professorships at his graduate Alma Mater UC Berkeley, The Ohio State University, as Professor and Chair of The Department of NanoMedicine and Biomedical Engineering at The University of Texas Health Science Center, Professor of Experimental Therapeutics at the MD Anderson Cancer Center, as Adjunct Professor of Bioengineering at Rice University, and as Adjunct Professor of Business at the University of Saint Thomas. From 2003 to 2005, Dr. Ferrari served as Special Expert on Nanotechnology and Eminent Scholar at The National Cancer Institute. He has received many National and International awards and recognitions.</span></div></td></tr><tr style="height:111pt"><td colspan="3" style="background-color:#e5e5e5;border-bottom:0.75pt solid #0071ce;border-top:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:8.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Qualifications:</span></div><div style="padding-left:8.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Dr.&#160;Ferrari&#8217;s qualifications to serve on the Board include his extensive training and experience in the fields of nanotechnology, biotechnology and biomedical applications. Dr.&#160;Ferrari has significant technical training, several academic appointments, over 500 published articles, over 30 issued patents, and is the recipient of most prestigious academic awards in nanomedicine and drug delivery technology. Additionally, Dr.&#160;Ferrari has extensive experience in developmental stage organizations having founded several startup companies.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:29.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.971%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Hongbo Lu</span></div><div style="margin-bottom:1pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Independent Director</span></div></td></tr><tr style="height:230pt"><td colspan="3" rowspan="2" style="border-bottom:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Age:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">54</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Director since:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">2024</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Serves&#160;on:</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.5pt">Science Committee</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Nomination Committee</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:232%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:232%;padding-left:5.85pt">Compensation Committee</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Other Public Company Boards:</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.5pt">Terns Pharmaceuticals, Inc.</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#026dce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Zenas Biopharma Inc</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Experience&#160;&amp; Expertise</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Hongbo Lu, Ph.D., has served as a member of our board of directors since March 2024. Dr. Lu is the founding member of NEXTBio Capital, a newly launched biotech investment firm. Dr. Lu has over 20 years of healthcare investment management experience in both public securities and private companies, including prior roles previously served as Managing Partner at Vivo Capital LLC (&#8220;Vivo Capital&#8221;), a Palo Alto-based investment firm, a position she has held since December 2020, Managing Partner at Lilly Asia Ventures (LAV), a venture capital firm, from January 2017 to December 2020, and Managing Director at OrbiMed Advisors. Over her investment career, Dr. Lu served on the boards of over 20 healthcare companies, including Turning Point Therapeutics, Crown Bioscience Inc (6554.TT), Avedro, Inc., Rgenta, Ronovo Surgical, Avistone, and BlossomHill Therapeutics Inc. Dr. Lu currently serves on the board of directors for, Terns Pharmaceuticals Inc. (Nasdaq: TERN), where she has served as director since 2020, Zenas BioPharma (Nasdaq: ZBIO), where she has served as director since 2022,  Ribox Therapeutics, where she has served as director since 2021, Visirna Therapeutics, where she has served as director since 2021, and Createrna Science and Technology. Dr. Lu started her Wall Street career as a biotechanalyst at Piper Jaffray &amp; Co. and was involved in biotech start-up Zyomyx in the San Francisco Bay Area previously. Dr. Lu earned a Ph.D. in Bioengineering from the University of Washington, an M.B.A. from the Haas School of Business at the University of California, Berkeley, and graduated with honors from Tsinghua University. </span></div></td></tr><tr style="height:68pt"><td colspan="3" style="background-color:#e5e5e5;border-bottom:0.75pt solid #0071ce;border-top:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:8.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Qualifications: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Dr. Lu&#8217;s qualifications to serve on the Board include her deep experience in international business and the pharmaceutical industry, her expertise with venture and  capital markets, and her executive leadership experience.</span></div><div style="padding-left:8.05pt"><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:29.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.971%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Adeoye Olukotun, MD, MPH</span></div><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Independent Director</span></div><div style="margin-bottom:1pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:176pt"><td colspan="3" rowspan="2" style="border-bottom:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Age:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">80</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Director since:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> 2020</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Serves on:</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.5pt">Science Committee (Co-Chair)</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.5pt">Nomination Committee</span></div><div style="text-indent:9pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Other Public Company Boards:</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.5pt">Tonix Pharmaceuticals Holding Corp.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Experience&#160;&amp; Expertise</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Dr.&#160;Olukotun is a Mayo Clinic trained cardiologist who has served as Chief Executive Officer of CR Strategies, LLC, which consults on clinical trial design and FDA strategy for pharmaceutical development, since 2001. Dr.&#160;Olukotun currently serves on the board of directors of Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a clinical-stage biopharmaceuticals company. He served as CEO of Epigen Pharmaceuticals, Inc., a discovery phase biotechnology company, from 2014 to 2017, and Vice Board Chair of CardioVax, Inc., a clinical-stage biopharmaceutical company, from 2012 to 2016. He spent the first 20 years of his career in roles of increasing responsibility in clinical development, including multiple product approvals, at Pfizer, Bristol-Myers Squibb, and Mallinckrodt. He has over 35 years of experience in the pharmaceutical industry and has been instrumental in the approval and success of numerous cardiology and metabolic medicines, including the first daily beta blocker and the first approved ACE inhibitor, among others. Dr.&#160;Olukotun received his Medical Doctor degree from the Albert Einstein College of Medicine in New York, and a Masters in Public Health from Harvard University School of Public Health.</span></div></td></tr><tr style="height:78pt"><td colspan="3" style="background-color:#e5e5e5;border-bottom:0.75pt solid #0071ce;border-top:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:8.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Qualifications</span></div><div style="padding-left:8.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Dr.&#160;Olukotun&#8217;s qualifications to serve on the Board include his extensive background in biopharmaceutical development, particularly in the cardiometabolic field, his scientific and public health expertise, and his board and executive leadership experience.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:29.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.971%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Michael S. Perry, DVM, PhD</span></div><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Independent Director</span></div></td></tr><tr style="height:314pt"><td colspan="3" rowspan="2" style="border-bottom:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Age:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> 65</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Director since:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%"> 2011</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Serves on:</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#026dce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.5pt">Compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Committee (Chair)</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#026dce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.5pt">Nomination&#160;Committee</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#026dce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.5pt">&#8202;Science Committee</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Experience and Expertise</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Dr. Perry is currently a Venture Partner with Bioscience Managers, a global venture capital firm. He also serves as Chairman and board member of 7 Hills Pharma, a private clinical stage pharmaceutical company. Dr. Perry was Chief Executive Officer of Avita Medical, Inc., a regenerative medicine company based in Valencia, CA (Nasdsaq: RCEL) from 2017 to 2022. From 2014 to 2017, he served as Chief Scientific Officer of Novartis' Cell and Gene Therapy Unit, and from 2012 to 2014 he served as Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp, the US affiliate of Switzerland-based Novartis AG, a global pharmaceutical company. Dr. Perry has also served as SVP and Global Head of R&amp;D at Baxter Healthcare, President and as CEO of Cell &amp; Gene Therapy at Novartis AG. Earlier in his career he served as VP Regulatory Affairs at Novartis, Sandoz Pharmaceuticals, and Syntex Corporation. He also served as Director of Regulatory Affairs at Schering-Plough Corporation. Dr. Perry also served as a Venture Partner with Bay City Capital, LLC for eight years.  Dr. Perry has previously served as a board member for the following companies: Ampliphi Bioscience Corp, Gamida Cell Ltd, Targeted Genetics, Inc., American Xeno, Inc., BioTransplant, Inc., ltamar Biomedical Ltd, Systemix, Inc., Genetic Therapy, Inc., Extropy Pharmaceuticals, Inc, and Pharsight Corporation. Dr. Perry holds an Honors Bachelor of Science in Physics and Engineering and a PhD in Biomedical Pharmacology from the University of Guelph. He also holds a Doctor of Veterinary Medicine &amp; Surgery from Ontario Veterinary College and is a graduate of the International Advanced Management Program at Harvard Business School. Dr. Perry currently serves as Adjunct Professor at the Gates Center for Regenerative Medicine at the University of Colorado Anschutz Medical Campus and as Faculty at Houston Methodist and Chair of the Translational Medicine Advisory Board of the Houston Methodist Research Institute.</span></div></td></tr><tr style="height:77pt"><td colspan="3" style="background-color:#e5e5e5;border-bottom:0.75pt solid #0071ce;border-top:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:8.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Qualifications</span></div><div style="padding-left:8.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Dr.&#160;Perry&#8217;s qualifications to serve on the board include his medical expertise and his extensive experience in preclinical and clinical drug development, including executive level leadership roles and directorships in several publicly held biotech companies.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:29.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.971%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Victoria Vakiener</span></div><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Independent Director</span></div><div style="margin-bottom:1pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:162pt"><td colspan="3" rowspan="2" style="border-bottom:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Age:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">61</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Director since:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"> 20</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">22</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Serves on:</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#026dce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Nomination Committee (Chair)</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#026dce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:5.85pt">Audit Committee </span></div><div style="text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Other Public Company Boards:</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#026dce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%;padding-left:5.85pt">Chimerix, Inc.</span></div><div><span><br/></span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Experience&#160;&amp; Expertise</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Ms. Vakiener currently serves on the board of directors of Chimerix (Nasdaq: CMRX), a clinical-stage biopharmaceutical company. From November 2018 through September 2021, she served as Chief Commercial Officer of Epizyme, Inc., a biopharmaceutical company that was acquired in 2022, where she built the commercial organization and launched TAZVERIK for two indications within six months. Prior to joining Epizyme, Ms. Vakiener was an executive at Johnson &amp; Johnson (NYSE: JNJ) for more than twenty years where she held positions of leadership with increasing responsibility across the company&#8217;s pharmaceutical and diagnostics businesses. Ms. Vakiener began her pharmaceutical career at Schering-Plough, where she spent nine years in both scientific and commercial roles. Ms. Vakiener received a BS in Biochemistry from Albright College.</span></div></td></tr><tr style="height:63pt"><td colspan="3" style="background-color:#e5e5e5;border-bottom:0.75pt solid #0071ce;border-top:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:8.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Qualifications</span></div><div style="padding-left:8.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Ms. Vakiener&#8217;s qualifications to serve on the Board include her deep commercial experience and expertise, her scientific development experience, and her board and executive leadership experience.</span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:29.829%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:67.971%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">William Waddill</span></div><div><span style="color:#026dce;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">Lead I</span><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:100%">ndependent Director</span></div><div style="margin-bottom:1pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr style="height:180pt"><td colspan="3" rowspan="2" style="border-bottom:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Age:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"> 6</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">7</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Director since:</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%"> 2018</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Serves on:</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Audit Committee (Chair)</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:5.85pt">&#8202;Compensation Committee </span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:5.85pt">Nomination Committee</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Other Public Company Boards:</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:5.85pt">Protagonist Therapeutics, Inc.</span></div><div style="padding-left:13.5pt;text-indent:-9pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:5.85pt">&#8202;Annexon Biosciences</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Experience&#160;&amp; Expertise</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Mr.&#160;Waddill began his career over 35 years ago in commercial banking and public accounting and has been in the biotechnology industry for over 30 years. He currently serves on the boards of Protagonist Therapeutics (Nasdaq: PTGX), Annexon Biosciences (Nasdaq: ANNX) and Turnstone Biologics (Nasdaq: TSBX), all clinical-stage biopharmaceutical companies. Mr.&#160;Waddill was Senior Vice President and CFO of Calithera Bioscience (Nasdaq: CALA), from 2014 to 2016 and Senior Vice President and CFO at OncoMed Pharmaceuticals from 2007 to 2014, both of which were public clinical-stage biopharmaceutical companies. Prior to that, he served as the Senior Vice President and CFO of Ilypsa, Inc., a biotechnology company that was acquired in 2007 by Amgen, Inc. Before joining Ilypsa, he served as the founder and principal at Square One Finance, a financial consulting business. Mr.&#160;Waddill received a BS in accounting from the University of Illinois, Chicago, and certification as a public accountant (inactive) after working at PriceWaterhouseCoopers and Deloitte in Boston.                                      </span></div></td></tr><tr style="height:63pt"><td colspan="3" style="background-color:#e5e5e5;border-bottom:0.75pt solid #0071ce;border-top:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:120%">Qualifications</span></div><div style="padding-left:8.05pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Mr.&#160;Waddill&#8217;s qualifications to serve on the Board include his extensive background in the biopharma industry, his financial and audit expertise, executive leadership roles and experience as a director of other public companies.</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers of the Registrant</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The names, ages, and positions of our executive officers serving as of January 28, 2025 are provided below. Biographical information regarding these officers is set forth under the following table, except for Dr. Anzalone, whose biography is set forth above with our other directors. </span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.545%"><tr><td style="width:1.0%"/><td style="width:26.944%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.867%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.601%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:65.088%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-indent:6pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Name</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Age</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-right:0.75pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Position&#160;with&#160;Arrowhead</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Christopher&#160;Anzalone</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">55</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer&#160;&amp; President and Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Kenneth A. Myszkowski</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">James Hamilton</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">47</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief of Discovery and Translational Medicine</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patrick O&#8217;Brien</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">61</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief Operating Officer and General Counsel</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Kenneth A. Myszkowski,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Chief Financial Officer, joined the Company in 2009. Prior to joining Arrowhead, Mr. Myszkowski served as the corporate controller for Broadwind Energy, a public energy company which provides products and services to the wind energy industry. Previous to his position at Broadwind, Mr. Myszkowski was controller for Epcor USA, the U.S. headquarters for Epcor Utilities, Inc., a public energy company. Prior to Epcor, Mr. Myszkowski was controller for two start-up ventures: NanoInk, specializing in Dip Pen Nanolithography, a nanofabrication technology, and Delphion, which provided on-line tools for intellectual property research. Mr. Myszkowski also held several corporate roles at FMC Corporation and Premark International, both Fortune 500 conglomerates. He began his career in the audit practice of Arthur Andersen &amp; Co. in Chicago, Illinois. Mr. Myszkowski received his undergraduate degree from the University of Illinois, and his MBA from the University of Chicago Booth School of Business. He is a certified public accountant (inactive). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Patrick C. O&#8217;Brien,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Chief Operating Officer and General Counsel, joined the Company in December 2014, where he has served as Chief Operating Officer since July 2022 and as General Counsel since 2014. Mr. O&#8217;Brien has practiced in the healthcare legal field for over 30 years. Before joining the Company, from 2012 to 2014, Mr. O&#8217;Brien was with Shire, a global pharmaceutical company, where he was Group Vice President, Law. Immediately prior to working with Shire he was a partner with the international law firm of Holland &amp; Knight LLP in its Washington, DC office. In 2010, Mr. O&#8217;Brien co-founded the law firm O&#8217;Brien Gould PLLC which joined Holland &amp; Knight in 2011. From 2009 to 2010, Mr. O&#8217;Brien was a partner in Burke O&#8217;Neil LLC. From 2001 to 2009, Mr. O&#8217;Brien served in several legal roles with Johnson &amp; Johnson, including serving as Vice President of Law for J&amp;J&#8217;s Centocor Ortho-Biotech unit. Mr. O&#8217;Brien previously served as Regulatory Counsel with the United States Food &amp; Drug Administration. Mr. O&#8217;Brien was awarded a BS in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pharmacy and a PharmD from the University of Arizona before completing a residency in Clinical Pharmacy with the University of Illinois at Chicago Hospital. He was also awarded his JD from the University of Arizona. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">James Hamilton,</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Chief of Discovery &amp; Translational Medicine, joined the Company in 2014. He is responsible for target discovery as well as non-clinical and early clinical development. Previously, Dr. Hamilton served as Vice President, Clinical Development, responsible for clinical strategy, clinical trial design and execution including early translational and mid-stage development of all Arrowhead programs. He is experienced in multiple disease areas including virology, hepatology, cardiovascular disease, rare disease and oncology. Dr. Hamilton led the clinical development of ARO-HBV (now JNJ-3989), which was licensed to Janssen Pharmaceuticals. In parallel, Dr. Hamilton served as Head of Corporate Development and led Arrowhead&#8217;s in-licensing transaction of Novartis&#8217;s RNAi assets, as well as the out-licensing of ARO-LPA (now AMG890) to Amgen and the ARO-AAT partnership with Takeda. Dr. Hamilton started his employment at Arrowhead as Medical Director and Head of Corporate development. He holds both MD and MBA degrees from The Ohio State University. He is a licensed physician and completed residency training with board certification in emergency medicine.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"><br/>Delinquent Section 16(a) Reports</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Section 16(a) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), requires our directors, executive officers, and greater-than-10% stockholders to file forms with the SEC to report their ownership of </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> shares and any changes in ownership. We have reviewed all forms filed electronically with the SEC. Based on that review and on written information given to us by our executive officers and directors, we believe that all of our directors and executive officers filed the required reports on a timely basis under Section 16(a) during fiscal 2024, except for the inadvertent late filing of one Form 5 reporting one transaction for Dr. Lu. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ied6c21fce27e4152aa85d0d2377cea12_94"></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">EXECUTIVE COMPENSATION<br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Discussion and Analysis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following compensation discussion and analysis contains statements regarding future individual and Company performance targets and goals. These targets and goals are disclosed in the limited context of Arrowhead&#8217;s executive compensation program and should not be understood to be statements of management&#8217;s expectations or guidance. Arrowhead cautions investors not to apply these statements to other contexts. Fiscal years are denoted as fiscal years, all other year references refer to calendar years. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Compensation Discussion and Analysis describes the compensation program for our named executive officers (&#8220;NEOs&#8221;). During fiscal 2024, these individuals were: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Christopher Anzalone, our President and Chief Executive Officer (our &#8220;CEO&#8221;);</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">James Hamilton, our Chief of Discovery and Translational Medicine (our &#8220;CDTM&#8221;);</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Kenneth Myszkowski, our Chief Financial Officer (our &#8220;CFO&#8221;);</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Patrick O&#8217;Brien, our Chief Operating Officer and General Counsel (our &#8220;COO&#8221; and &#8220;GC&#8221;); </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Tracie Oliver, our former Chief Commercial Officer (our &#8220;CCO&#8221;); and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Javier San Martin, our former Chief Medical Officer (our &#8220;CMO&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">This Compensation Discussion and Analysis describes the material elements of our executive compensation program during fiscal 2024. It also provides an overview of our executive compensation philosophy and objectives and summarizes our executive compensation policies and practices. Finally, it analyzes how and why the Compensation Committee of our Board arrived at the specific compensation decisions for our executive officers, including our NEOs, for fiscal 2024, including the key factors that the Compensation Committee considered in determining their compensation. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Company </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We develop medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, our therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead&#8217;s RNAi-based therapeutics leverage this natural pathway of gene silencing. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins. The depth and versatility of our RNAi technologies enable us to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and Biologics. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2024 Business Highlights</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented new pivotal Phase 3 Data from PALISADE study of plozasiran in patients with familial chylomicronemia syndrome (FCS) at the European Society of Cardiology (ESC) Congress 2024 and simultaneously published in The New England Journal of Medicine. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company submitted a New Drug Application to the U.S. Food and Drug Administration (FDA) on November 16, 2024, which was accepted for filing on January 17, 2025. The FDA provided a Prescription Drug User Fee Act (PDUFA) action date of November 18, 2025, and indicated it is not currently planning to hold an advisory committee meeting.</span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Entered into a global and collaboration agreement with Sarepta Therapeutics, Inc. Upon closing, Arrowhead will receive $825 million, consisting of $500 million cash and $325 million as an equity investment. Arrowhead will also receive $250 million to be paid in equal installments over five years and is eligible to receive an additional $300 million in near-term payments. Additionally, Arrowhead is eligible to receive royalties on commercial sales and up to approximately $10 billion in future potential milestone payments.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented preclinical data and detailed plans to advance two next generation RNAi-based candidates, ARO-INHBE and ARO-ALK7, into upcoming clinical studies for the treatment of obesity and metabolic diseases. In preclinical studies to date, these candidates demonstrated the potential to reduce body weight and fat mass with a novel mechanism of action that may lead to improved preservation of lean muscle mass compared to currently approved obesity therapies. On September 23, 2024, the Company filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE and subsequently on December 3, 2024, filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced successful top-line results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS). The Company highlighted recent data for its cardiometabolic pipeline at its June 25, 2024, Cardiometabolic event.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran in patients with mixed hyperlipidemia.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced that new interim clinical data on ARO-RAGE achieves high level of gene knockdown in patients with asthma.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Amgen completed enrollment in Amgen&#8217;s Phase 3 OCEAN(a) - outcomes trial of olpasiran, triggering a $50.0 million milestone payment to the Company from Royalty Pharma, which was paid in the third quarter of fiscal 2024.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Presented final data from the double-blind treatment period of the Company&#8217;s Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe Hypertriglyceridemia. Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announced an Expanded Access Program (&#8220;EAP&#8221;) to make investigational plozasiran available outside of a clinical trial for qualifying patients with familial chylomicronemia syndrome (FCS). </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Initiated a Phase 1/2a clinical trial of ARO-DM1, being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, being developed as a potential treatment for complement mediated renal disease.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Entered into an Amended and Restated License Agreement with GSK, pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989). Daplusiran/tomligisiran had previously been licensed to Janssen Pharmaceuticals, Inc.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Development </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sarepta Therapeutics, Inc. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">On November 25, 2024, the Company entered into an Exclusive License and Collaboration Agreement (the &#8220;Sarepta Collaboration&#8221;) with Sarepta Therapeutics, Inc. (&#8220;Sarepta&#8221;) for the co-development and commercialization of ARO-DUX4, ARO-DM1, ARO-MMP7, and ARO-ATXN2 clinical stage programs. Sarepta has also received an exclusive sublicensable worldwide license to the Company&#8217;s ARO-HTT, ARO-ATXN1, and ARO-ATXN3 preclinical stage programs.</span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Sarepta Collaboration, Sarepta may select up to six gene targets for which the Company will perform discovery, optimization and preclinical development activities to identify RNAi compounds against each selected target. Upon completion of the Company&#8217;s preclinical activities, Sarepta will receive an exclusive license to the Company&#8217;s intellectual property rights to exploit those compounds and be wholly responsible for clinical development and commercialization of each compound.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Closing of the Sarepta Collaboration is subject to clearance under the Hart-Scott Rodino Antitrust Improvements Act.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Sarepta Collaboration, on November 25, 2024, the Company entered into a Stock Purchase Agreement (the &#8220;Stock Purchase Agreement&#8221;) with an affiliate of Sarepta for a private placement of shares of common stock of the Company (the &#8220;Private Placement&#8221;). Pursuant to the Stock Purchase Agreement, the Company sold 11,926,301 shares of common stock, at a price per share of $27.25, for an aggregate value of approximately $325.0 million. The Private Placement is expected to close concurrently with the Sarepta Collaboration.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreements taken together, the Company expects to receive $500.0 million as an upfront payment under the Sarepta Collaboration, $325.0 million in the form of an equity investment under the Stock Purchase Agreement, and $250.0 million to be paid in annual installments of $50.0 million over 5 years. The Company is also eligible to receive $300.0 million in near-term payments associated with the continued enrollment of certain cohorts of a Phase 1/2 study, which the Company is on track to achieve. Further, for each of the 13 programs, the Company is eligible to receive development milestone payments between $110.0 million and $180.0 million per program and sales milestone payments between $500.0 million and $700.0 million per program. The Company is also eligible to receive tiered royalties on net sales of licensed products of up to the low double digits.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Platform </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In fiscal 2024, the Company continued to develop and deploy its Targeted RNAi Molecule platform (&#8220;TRiM&#8482;&#8221;) to identify and develop new therapeutics. TRiM&#8482; utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting, while being structurally simple. Targeting has been core to the Company&#8217;s development philosophy and the TRiM&#8482; platform builds on more than a decade of work on actively targeted drug delivery vehicles. The TRiM&#8482; platform is designed to offer several potential competitive advantages including: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A more sophisticated RNAi trigger selection and screening process that identifies potent sequences rapidly in locations that RNAi competitors may miss;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Multiple routes of administration including subcutaneous, intravenous and inhaled;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Faster time to clinical candidates;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Optimal pharmacologic activity and long duration-of-effect;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Potentially wide safety margins;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Simplified manufacturing at reduced cost; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The ability to take RNAi to tissues beyond the liver.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of Arrowhead&#8217;s RNAi technologies enables Arrowhead to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologics. Arrowhead is focused on bringing the promise of RNAi to address diseases outside of the liver, and its pipeline now includes disease targets in the liver, lung, muscle and CNS.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The timing of our planned and already filed clinical trial applications (&#8220;CTA&#8221;) discussed below are based on calendar years, not fiscal years. </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Arrowhead Proprietary Clinical Stage Candidates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Plozasiran (ARO-APOC3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including Very Low Density Lipoprotein (VLDL) and chylomicrons, a key regulator of triglyceride metabolism. The Company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. The Company is currently investigating plozasiran in one Phase 2 clinical trial and four Phase 3 clinical trials. In the Phase 3 PALISADE trial in patients with familial chylomicronemia syndrome (FCS), plozasiran has met its primary endpoint of triglyceride reduction as well as all of its key (alpha controlled) secondary endpoints. The Company is currently in the process of seeking regulatory approval for plozasiran for the treatment of FCS.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-APOC3 in Adults With Dyslipidemia</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase 2 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of ARO-APOC3 in Adults With Dyslipidemia <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05413135</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-APOC3 in Adults With FCS (PALISADE)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05089084  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia (SHASTA-3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT06347003</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of Plozasiran in Adults With Severe Hypertriglyceridemia (SHASTA-4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT06347016  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia (MUIR-3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Hypertriglyceridemia</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT06347133<br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Zodasiran (ARO-ANG3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce production of angiopoietin-like protein 3 (&#8220;ANGPTL3&#8221;), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum and liver triglyceride and has genetic validation as a novel target for cardiovascular disease. Arrowhead is currently investigating zodasiran in two Phase 2b clinical trials.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Dyslipidemia and Hypertriglyceridemia</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: Dyslipidemia and hypertriglyceridemia are risk factors for atherosclerotic coronary heart disease and cardiovascular events.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (ARCHES-2) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04832971</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">(GATEWAY) Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05217667<br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-INHBE</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E. INHBE is a promising genetically validated target in which loss-of-function INHBE variants in humans are associated with lower risk of obesity and metabolic diseases, such as type 2 diabetes. The Company has filed for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-INHBE.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Phase 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-INHBE in Adult Volunteers With Obesity With and Without Diabetes Mellitus <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT06700538</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-ALK7</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to silence adipocyte expression of the ACVR1C gene to reduce production of Activin receptor-like kinase 7 (ALK7), which acts as a receptor in a pathway that regulates energy homeostasis in adipose tissue. In large genetic datasets, reduced ACVR1C expression has been associated with healthier adipose distribution and reduced risk of obesity-related metabolic complications. Treatment with investigational ARO-ALK7 has the potential to reduce visceral adiposity and improve lipid and glycemic parameters.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-C3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce production of complement component 3 (&#8220;C3&#8221;) as a potential therapy for patients with various complement mediated or complement associated renal. Arrowhead is currently investigating ARO-C3 in a Phase 1/2a clinical trial. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Complement-Mediated Renal Disease</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: A number of rare renal diseases result from uncontrolled activation of the alternative pathway of complement, leading to progressive glomerular damage, proteinuria, hematuria, and impaired kidney function, and often resulting in end-stage renal disease (ESRD). In addition, dysregulation of the alternative complement pathway has been shown to play a role in the pathogenesis and progression of disease in some of the more common glomerulopathies. Silencing C3 may be a therapeutic approach for treatment of these conditions.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement-Mediated Renal Disease</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05083364</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-CFB</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce hepatic expression of complement factor B (CFB), which plays an important regulatory role in amplifying complement alternative pathway activation and has been identified as a promising therapeutic target. ARO-CFB is being developed as a potential treatment for complement mediated kidney diseases such as immunoglobulin A nephropathy (IgAN), which is the most common glomerular disease worldwide and carries a high lifetime risk of progression to end-stage renal disease. Additionally, ARO-CFB may have clinical applications in non-renal diseases involving complement activation. The Company is currently investigating ARO-CFB in a Phase 1/2a clinical trial. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Complement-Mediated Disease</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: A number of rare renal diseases result from uncontrolled activation of the alternative pathway of complement, leading to progressive glomerular damage, proteinuria, hematuria, and impaired kidney function, and often resulting in end-stage renal disease (ESRD). In addition, dysregulation of the alternative complement pathway has been shown to play a role in the pathogenesis and progression of disease in some of the more common glomerulopathies. Silencing CFB may be a therapeutic approach for treatment of these conditions.  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ARO-CFB in Adult Healthy Volunteers and Adult Patients With Complement-Mediated Kidney Disease <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT06209177</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-RAGE </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">is designed to reduce production of the Receptor for Advanced Glycation End products (&#8220;RAGE&#8221;) as a potential treatment for various inflammatory pulmonary diseases. Arrowhead is currently investigating ARO-RAGE in a Phase 1/2a clinical trial. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase 1/2a Study Evaluating the Effects of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease</span></div><div style="margin-top:6pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05276570</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-PNPLA3 (formerly JNJ-75220795)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is an investigational RNAi therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with metabolic-dysfunction associated steatohepatitis (MASH). PNPLA3 has strong genetic and preclinical validation as a driver of fat accumulation and damage in the livers of patients who carry the common I148M mutation. Former licensee Janssen Pharmaceuticals, Inc. investigated ARO-PNPLA3 in two Phase 1 clinical trials.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">MASH</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: MASH is a subgroup of steatotic liver disease (MASLD) in which hepatic cell injury and inflammation has developed over background steatosis. The I148M genetic variant in the PNPLA3 gene is involved with the underlying pathophysiology and is a known risk factor for hepatic steatosis, steatohepatitis, elevated plasma liver enzyme levels, hepatic fibrosis and cirrhosis. The rising prevalence of MASH presents a significant health burden in many developed countries.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Partnered Programs </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Sarepta Therapeutics, Inc.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-DUX4 </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Facioscapulohumeral Muscular Dystrophy</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disease associated with the failure to maintain complete epigenetic suppression of DUX4 expression in differentiated skeletal muscle, leading to overexpression of DUX4, which is myotoxic and can lead to muscle degeneration. As DUX4 expression is recognized as the cause of muscle pathology in FSHD patients, the Company believes that the selective targeting and knockdown of DUX4 using RNAi may prevent or reverse downstream myotoxicity and lead to muscle repair and improvement in muscle function in patients. There are currently no effective treatments specifically for FSHD.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 in Adult Patients With Facioscapulohumeral Muscular Dystrophy Type 1. </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT06131983</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-DM1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce expression of the dystrophia myotonica protein kinase (DMPK) gene. There is currently no approved disease-modifying therapy for type 1 myotonic dystrophy (DM1). Treatments have focused on symptomatic management, including physical therapy, exercise, ankle-foot orthoses, wheelchairs, and other assistive devices. The Company is currently investigating ARO-DM1 in a Phase 1/2a clinical trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Type 1 Myotonic Dystrophy</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: Type 1 myotonic dystrophy is an autosomal dominant, debilitating, chronic progressive multisystem disorder characterized by an expansion of a highly unstable CUGexp in the DMPK gene. Patients with DM1 have muscle weakness and wasting, myotonia, cataracts, and often have cardiac conduction abnormalities, and may become physically disabled and have a shortened life span.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who Are &#8805;18 to &#8804; 65 Years <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT06138743</span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-MMP7</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic Pulmonary Fibrosis (IPF). The Company is currently investigating ARO-MMP7 in a Phase 1/2a clinical trial.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05537025</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-ATXN2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce the expression of the ATXN2 gene as a potential treatment for spinocerebellar ataxia 2 (SCA2). SCA2 is a progressive cerebellar ataxia with instability of stance, speech and swallow disorder, pain, spasticity, and ocular signs, caused by gain of function of mutant expanded polyQ ATXN2 protein. The Company is currently investigating ARO-ATXN2 in a Phase 1 clinical trial.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase 1 Placebo-Controlled Dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-ATXN2 in Adult Subjects With Spinocerebellar AtaxiaType 2 <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT06672445</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-HTT</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce the expression of the Huntingtin gene as a potential treatment for Huntington&#8217;s disease.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-ATXN1</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce the expression of the ATXN1 gene as a potential treatment for spinocerebellar ataxia 1 (SCA1). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ARO-ATXN3</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce the expression of the ATXN3 gene as a potential treatment for spinocerebellar ataxia 3 (SCA3).</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Takeda Pharmaceuticals U.S.A., Inc. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Fazirsiran (formerly ARO-AAT)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is a clinical-stage RNAi therapeutic candidate for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. ARO-AAT is designed to knock down the Alpha-1 antitrypsin (&#8220;AAT&#8221;) gene transcript and reduce the hepatic production of the mutant AAT protein. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05677971  </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05899673  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F1 Fibrosis <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT06165341</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Amgen Inc.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Olpasiran (formerly AMG 890 and ARO-LPA)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Olpasiran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial</span></div><div style="margin-top:6pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing the Impact of Olpasiran on Major Cardiovascular Events in Participants With Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a) </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05581303</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">GlaxoSmithKline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GSK-4532990 (formerly ARO-HSD)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to reduce production of HSDPublished human genetic data indicate that a loss of function mutation in HSD17B13 provides strong protection against metabolic-dysfunction associated steatohepatitis (MASH) cirrhosis and alcoholic hepatitis and cirrhosis. GSK is conducting Phase 2b clinical trials in patients with MASH and alcohol-related liver disease (ALD).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Metabolic-Dysfunction Associated Steatohepatitis</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">: MASH is liver inflammation and damage caused by a buildup of fat in the liver. This can cause scarring of the liver and in advanced cases can lead to cirrhosis. Alcochol-related liver disease (ALD) represents a spectrum of liver injury resulting from alcohol use, ranging from hepatic steatosis to more advances forms including alcoholic hepatitis (AH), alcohol-associated cirrhosis (AC), and acute AH presenting as acute-on-chronic liver failure.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: Phase 2b Study of GSK4532990 in Adults With MASH (HORIZON)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> 17 &#946;-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of MASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Pre-Cirrhotic Metabolic-Dysfunction Associated Steatohepatitis <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05583344</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">GSK5637608 (formerly JNJ-3989 and ARO-HBV)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> is designed to silence all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogues act. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Study Name: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB) (B-UNITED)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> A Phase 2b, Multi-centre, Randomized, Partially Placebo-controlled, Double-blind Study to Investigate the Safety and Efficacy of Sequential Therapy With Daplusiran/Tomligisiran Followed by Bepirovirsen in Participants With Chronic Hepatitis B Virus on Background Nucleos(t)Ide Analogue Therapy (B-United) <br/></span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05583344</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Financial Results </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Revenue</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Generated revenue of $3.6 million, compared to revenues of $240.7 million in fiscal 2023 and $243.2 million in fiscal 2022;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Net Loss attributable to Arrowhead Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Recorded net loss of $599.5 million, compared to net losses of $205.3 million in fiscal 2023 and $176.1 million in fiscal 2022;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Net Loss Per Share attributable to Arrowhead Pharmaceuticals, Inc.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Recorded net loss per share (diluted) of ($5.00), compared to net loss per share (diluted) of ($1.92) in fiscal 2023 and ($1.67) in fiscal 2022;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Cash at end of fiscal 2024</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Cash and investments of cash totaled $681.0 million at September 30, 2024; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Total Stockholder Return</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Achieved a three-year total stockholder return (&#8220;TSR&#8221;) at the 28th percentile of our peer group as measured in September 2024. </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify"><img src="arwr-20240930_g1.jpg" alt="549755960964" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px" id="i-1"/></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">The comparisons in the above graph are based on historical data and are not intended to forecast the possible future performance of our common stock.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Executive Compensation Highlights </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Say-on-Pay Vote and Ongoing Response to Stockholder Feedback</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">At our 2024 Annual Meeting of Stockholders, 94% of the stockholder votes cast on our non-binding, advisory proposal (the &#8220;Say-on-Pay&#8221; vote) on the executive compensation program were in favor of the program. Our Board of Directors was pleased with this result. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We value the opinions of our stockholders and will continue to consider the outcome of future Say-on-Pay votes, as well as feedback received throughout the year, when making compensation decisions for our executive officers. The Compensation Committee is committed to being responsive to stockholder feedback regarding our executive compensation program, policies, and practices, including concerns expressed through the Say-on-Pay vote. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholder Engagement</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During the summer and fall of 2023, our Corporate Secretary and Mr. Waddill, the Compensation Committee Chair, requested meetings with our top 10 stockholders to discuss our executive compensation program. On the basis of that feedback, and the stockholder vote during our 2024 Annual Meeting of Stockholders, we believe stockholders are pleased with our current compensation approach. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Aggressive Performance Fueled by Incentives</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee expects and has observed aggressive performance from the entire executive management team. Our philosophy has been to foster this expectation with reasonably aggressive incentive compensation. Based on our overall operating environment, feedback from our stockholders, and stockholder return results, the Compensation Committee took the following key actions and maintained key policies with respect to the compensation of all of our NEOs for fiscal 2024:  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Base Salary</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Approved base salary increases for our current NEOs based on performance and market adjustments.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Annual Incentive Compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Certified performance and Approved annual cash bonuses for our NEOs for fiscal 2024 in amounts of up to 140% of their target annual cash incentive compensation opportunities, including an annual cash bonus for our CEO in the amount of $1,152,000, equal to 120% of his target annual cash incentive compensation opportunity.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Equity Compensation</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - The Compensation Committee granted our CEO entirely performance-based restricted stock unit awards (&#8220;PRSUs&#8221;) and granted our other NEOs long-term incentive compensation opportunities in the form of time-based RSU awards that may be settled for shares of our common stock with grant date values described below in the Compensation Tables section. The awards vest in four equal annual installments beginning in 2025.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Clawback Policy</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Maintained our clawback policy which allows Arrowhead to recover incentive compensation from our executive officers, on a non-fault basis, in the event a financial restatement is required to correct any accounting errors made by any such executive officer. </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">Stock Ownership Guidelines</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Maintained guidelines mandating ownership of Arrowhead stock in amounts equal to, for our CEO, six times annual base salary and, for our CFO, two times annual base salary.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;padding-left:14.5pt">&#8220;Double Trigger&#8221; Feature for Acceleration of Equity Awards</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> - Maintained the agreements for outstanding equity awards granted to our CEO pursuant to our 2013 and 2021 Incentive Plans to provide that, upon a change in control of Arrowhead, the vesting of such awards will accelerate only in the event of a subsequent involuntary termination of employment (i.e., on a &#8220;double-trigger&#8221; basis).</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pay-for-Performance Analysis </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe our executive compensation program is reasonable, competitive, and appropriately balances the goals of attracting, motivating, rewarding, and retaining our executive officers with the objective of aligning their interests with those of our stockholders. To ensure this alignment and to motivate and reward individual initiative and effort, a significant portion of our executive officers&#8217; target total direct compensation opportunity is both performance-based and &#8220;at-risk.&#8221; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We emphasize performance-based compensation that appropriately rewards our executive officers, including our NEOs, through two separate compensation elements: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First, we provide the opportunity to participate in our annual incentive compensation plan which provides cash payments if executive officers produce short-term financial, operational, and strategic results that meet or exceed the objectives set forth each year in our annual operating plan.</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In addition, we grant equity awards as long-term incentive compensation. These require substantial performance and are themselves substantial awards, designed to drive our financial and operational performance and long-term growth. In the case of our CEO, these awards are heavily performance weighted, and in the case of our other executive officers, are either dependent on the future appreciation in value of our common stock or are subject to the risk of fluctuations in the value of our common stock and, therefore, are &#8220;at risk.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that, ultimately, the creation of sustainable long-term stockholder value will depend on our ability to successfully bring to market the products we develop or our success in partnering with strategic collaborators to bring them to market. Consequently, the Compensation Committee strives to incent our executive officers to create that value through the discovery and development of a robust and attractive pipeline of drug candidates. To achieve that end, our executive compensation program is designed to provide incentives that facilitate these efforts. Particularly for our CEO, the Compensation </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Committee has awarded 100% of his long term incentive compensation for fiscal 2024 as performance-based equity awards designed to produce stockholder value. The Compensation Committee closely tracks the progress against these objectives and, in conjunction with the independent members of our Board, ensures the objectives are met using sound, ethical business practices before certifying performance achievement of the awards. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">To ensure that we remain faithful to our compensation philosophy, the Compensation Committee regularly evaluates the relationship between the reported values of the equity awards granted to our executive officers, the amount of compensation realizable (and, ultimately, realized) from such awards in subsequent years, and our total stockholder return over this period. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Executive Compensation Policies and Practices </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We endeavor to maintain sound governance standards consistent with our executive compensation policies and practices. The Compensation Committee evaluates our executive compensation program on a regular basis to ensure that it is consistent with our short-term and long-term goals given the dynamic nature of our business and the market in which we compete for executive talent. The following summarizes our executive compensation and related policies and practices: </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.700%"><tr><td style="width:1.0%"/><td style="width:47.856%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.886%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.858%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WHAT&#160;WE&#160;DO</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#3fae2a;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WHAT&#160;WE&#160;DON&#8217;T&#160;DO</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10003;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Maintain an Independent Compensation Committee.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;The Compensation Committee consists solely of independent directors.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10003;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Retain an Independent Compensation Advisor.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;The Compensation Committee engaged its own compensation advisor to provide information and analysis with its fiscal 2024 compensation review, and other advice on executive compensation independent of management. This consultant performed no consulting or other services for us in fiscal 2024.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10003;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Annual Executive Compensation Review.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;The Compensation Committee conducts an annual review and approval of our compensation strategy, including a review and determination of our compensation peer group and a review of our compensation-related risk profile to ensure that our compensation programs do not encourage excessive or inappropriate risk-taking.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10003;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Compensation At-Risk.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> Our executive compensation program is designed so that a significant portion of compensation is &#8220;at risk&#8221; based on our performance, as well as short-term cash and long-term equity incentives to align the interests of our executive officers and stockholders.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10003;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">CEO Annual Incentive Compensation Cap. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Our CEO&#8217;s annual cash incentive compensation opportunity is capped at 150% of his base salary.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10003;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Stock Ownership Policy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;We maintain a stock ownership policy that requires our CEO and CFO to maintain a minimum ownership level of our common stock.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10003;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Compensation Recovery (&#8220;Clawback&#8221;) Policy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;We maintain a clawback policy to allow Arrowhead to recover incentive compensation from our executive officers, on a non-fault basis, in the event a financial restatement is required to correct any accounting errors made by any such executive officer. </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10003;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Conduct an Annual Stockholder Advisory Vote on NEO Compensation.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;We conduct an annual stockholder advisory vote on the compensation of our NEOs.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10003;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">Use a Pay-for-Performance Philosophy.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;The majority of our CEO&#8217;s compensation is directly linked to achievement of milestones to the benefit of all stakeholders; we also structure target total direct compensation opportunities with a significant long-term equity component, thereby making a substantial portion of our CEO&#8217;s and each additional executive officer&#8217;s target total direct compensation dependent upon our stock price and/or total stockholder return.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-bottom:1pt;padding-left:24pt;text-indent:-18pt"><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10003;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#0071ce;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">&#8220;Double Trigger&#8221; Feature for Acceleration of CEO Equity Awards</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"> &#8212; The outstanding equity awards granted to our CEO pursuant to our 2013 Incentive Plan and 2021 Incentive Plan provide that, upon a change in control of the Company, the vesting of such awards will accelerate only in the event of a subsequent involuntary termination of employment (a &#8220;double-trigger&#8221; arrangement).</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10008;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">No Executive Retirement Plans.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;We do not offer pension arrangements or retirement plans or arrangements to our executive officers that are different from or in addition to those offered to our other employees.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10008;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">No Perquisites.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;We do not provide perquisites or other personal benefits to our executive officers.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10008;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">No Special Welfare or Health Benefits.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Our executive officers participate in broad-based Company-sponsored health and welfare benefits programs generally on the same basis as our other full-time, salaried employees.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10008;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">No Post-Employment Tax Payment Reimbursement.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;We do not provide any tax reimbursement payments (including &#8220;gross-ups&#8221;) on any severance or change-in-control payments or benefits.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10008;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">No Hedging and Limit on Pledging of Our Equity Securities.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;We prohibit our employees, executive officers and the non-employee members of our Board from hedging our equity securities. Our board members and executive officers may pledge up to 75% of owned and vested shares with the approval of our Board.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:24pt;text-indent:-18pt"><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10008;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">No Dividends or Dividend Equivalents Payable on Unvested Equity Awards.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;We do not pay dividends or dividend equivalents on unvested RSU awards or PRSU awards.</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-bottom:1pt;padding-left:24pt;text-indent:-18pt"><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#10008;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8202;</span><span style="color:#3fae2a;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:100%">No Stock Option Re-pricing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Our employee stock plan does not permit options to purchase shares of our common stock to be repriced to a lower exercise or strike price without the approval of our stockholders.</span></div></td></tr></table></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Executive Compensation Philosophy</span><span style="color:#4c4c4c;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"> </span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our executive compensation philosophy reflects our two fundamental objectives: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to attract, motivate and retain a highly skilled team of executives; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">to align our executive officers&#8217; interests with those of our stockholders by rewarding short-term and long-term performance and aligning compensation to increases in stockholder value.</span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that the compensation of our executive officers should be directly linked to the achievement of specific objectives that are expected to increase stockholder value. In furtherance of this goal, the Compensation Committee has established the following guidelines as a foundation for compensation decisions:  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide a competitive total compensation package that enables us to attract, retain and motivate highly-qualified executives with the skills and experience required for the achievement of business goals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">promote the achievement of key strategic and financial performance measures by linking short-term and long-term compensation to the achievement of measurable goals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reward significant achievements outside of pre-established goals;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">recognize that pharmaceutical research, development and commercialization require sustained and focused effort over many years, and involve a high degree of risk and therefore balance incentives for short-term and long-term compensation;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employ external compensation expertise and market data from industry peers to help assure that our compensation policies and practices are consistent with industry practice and meet our goals for our compensation program;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">consider our cash resources and cost of capital to balance cash and equity compensation; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">align our executives&#8217; incentives with the creation of stockholder value.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Executive Compensation Program Design </span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Our practice is to combine a mixture of compensation elements that balance achievement of our short-term goals with our longer-term performance. Currently, our executive compensation program consists of three principal elements: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">base salary;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">an annual cash incentive compensation opportunity; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">long-term incentive compensation in the form of equity awards.<br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We believe that cash compensation in the form of base salary and an annual incentive compensation opportunity provides our executive officers with short-term rewards for success in operations, and that long-term incentive compensation in the form of RSU and PRSU awards that may be settled for shares of our common stock, and options to purchase shares of our common stock, align the objectives of our executive officers with those of our stockholders with respect to long-term performance and success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee takes into consideration, among other things, our financial and working capital condition when approving performance objectives and making compensation decisions for our executive officers. Since we seek to invest our cash prudently and do not have marketed </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">products, overall target total direct compensation opportunities are weighted more heavily toward long-term incentive compensation in the form of equity awards. Thus, a significant portion of each executive officer&#8217;s target total direct compensation opportunity is &#8220;at risk,&#8221; and dependent on the increase in the value of our common stock. The Compensation Committee periodically reassesses the appropriate weighting of cash and equity compensation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In the case of long-term incentive compensation, typically the Compensation Committee designs these awards to vest, or be earned, over a multi-year period, meaning that long-term value creation, contrasted with short-term gain, presents the best opportunity for our executive officers to benefit from their awards. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not maintain a specific policy on the percentage allocation between short-term and long-term incentive compensation elements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Governance of Executive Compensation Program </span></div><div><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Role of the Compensation Committee </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee discharges many of the responsibilities of our Board relating to the compensation of our executive officers, including our NEOs, and the non-employee members of our Board. The Compensation Committee has overall responsibility for overseeing our compensation and benefits philosophy and policies generally, overseeing and evaluating the compensation plans, policies and practices applicable to our CEO and our other executive officers, and ensuring that the target total direct compensation opportunities of our executive officers, including our NEOs, are consistent with our compensation philosophy, policies and objectives. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The members of the Compensation Committee are appointed by our Board, and each member is an independent director (as &#8220;independence&#8221; is currently defined in Rule 5605(a)(2) of Nasdaq listing standards). Currently, the members of the Compensation Committee are Michael Perry (Committee Chair), Hongbo Lu, and William Waddill. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee reviews our executive compensation program annually on a calendar year basis, generally in December. The Compensation Committee draws on a number of resources to assist in the evaluation of the various elements of our executive compensation program including, but not limited to, feedback from our stockholders, input from our CEO, the advice of an external compensation consultant (as identified below) retained by the Compensation Committee, information provided in the public filings of industry peers and industry data compiled yearly by Radford in its Global Life Sciences Survey, which represents a nationally-based assessment of executive compensation widely used within the pharmaceutical and biotechnology industry sectors. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee relies upon the judgment of its members in making compensation decisions. In addition, the Compensation Committee incorporates its members&#8217; judgment in the assessment process to respond to and adjust for the evolving business environment. The members of the Compensation Committee have extensive experience in executive management, as well as compensation practices and policies. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Compensation-Setting Process </span></div><div><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee develops recommendations for the target total direct compensation opportunities for our executive officers, including our NEOs. The Compensation Committee does not use a single method or measure in making its compensation decisions, nor does it ordinarily position compensation levels based upon a specific or target level relative to a compensation peer group or other companies. Nonetheless, the pay practices at other companies are an important factor that the Compensation Committee considers in assessing the reasonableness of compensation and ensuring that our compensation practices are competitive in the marketplace. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Generally, the Compensation Committee evaluates the compensation of our executive officers relative to the median of the competitive market. However, as discussed hereafter, various other factors are taken into consideration in determining our executive officers&#8217; compensation and the Compensation Committee does not target compensation at any specific level relative to the competitive market. When reviewing our current executive </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">compensation arrangements and approving each compensation element and the target total direct compensation opportunity for our executive officers, the Compensation Committee considers the following factors: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our performance against the financial and operational objectives established by the Compensation Committee and our Board;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Each individual executive officer&#8217;s skills, experience and qualifications relative to other similarly-situated executives at the companies in our compensation peer group and in selected broad-based compensation surveys;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The scope of each executive officer&#8217;s role compared to other similarly-situated executives at the companies in our compensation peer group and in selected broad-based compensation surveys;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The performance of each individual executive officer, based on a subjective assessment of his or her contributions to our overall performance, ability to lead his or her business unit or function and work as part of a team, all of which reflect our core values;</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The compensation practices of our compensation peer group and the companies in selected broad-based compensation surveys and the positioning of each executive officer&#8217;s compensation in a ranking of peer company compensation levels; and</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The recommendations provided by our CEO with respect to the compensation of our other executive officers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">These factors provide the framework for compensation decision-making and final decisions regarding the compensation opportunity for each executive officer. No single factor is determinative in setting pay levels, nor was the impact of any factor on the determination of pay levels quantifiable.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Role of Chief Executive Officer </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In discharging its responsibilities, the Compensation Committee works with members of our management, including our CEO. Our management assists the Compensation Committee by providing information on corporate and individual performance, market compensation data and management&#8217;s perspective on compensation matters. The Compensation Committee solicits and reviews our CEO&#8217;s recommendations with respect to the compensation levels for individual executive officers other than himself based on his performance evaluation of each executive officer. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Compensation Committee reviews and discusses these recommendations and proposals with our CEO and considers them as one factor in determining the compensation for our executive officers, including our other NEOs. Our CEO recuses himself from all discussions and recommendations regarding his own compensation. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Role of Compensation Consultant </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Compensation Committee engages an external compensation consultant to assist it by providing information, analysis and other advice relating to our executive compensation program and the decisions resulting from its annual executive compensation review. The Compensation Committee has the final authority to engage and terminate the engagement of any compensation consultant that it retains. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Since October 2018, the Compensation Committee has engaged Compensia as its external compensation consultant. Compensia assisted the Compensation Committee in its review of executive officer and non-employee director compensation practices for fiscal 2024, including the competitiveness of compensation levels, executive compensation design, comparisons with our industry peers, and other technical considerations. Such assistance included: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Reviewing and updating our compensation peer group;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Reviewing and analyzing the compensation arrangements for our executive officers, including our NEOs;</span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Reviewing and analyzing the compensation arrangements for the non-employee members of our </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Board</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Reviewing and updating of the Compensation Discussion and Analysis section of our proxy statement for our 2025 Annual Meeting of Stockholders; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Supporting on other ad hoc matters.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The terms of Compensia&#8217;s engagement include reporting directly to the Compensation Committee and to the Compensation Committee Chair. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2024, Compensia did not provide any services to us other than those described above. The Compensation Committee has evaluated Compensia&#8217;s independence pursuant to the listing standards of Nasdaq and the relevant SEC rules and has determined that no conflict of interest has arisen as a result of the work performed by Compensia.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Competitive Positioning </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For each of the past ten years, the Compensation Committee has directed its external compensation consultant to conduct a comparative study and report on compensation levels and practices relative to industry peers, including a competitive assessment of our executive compensation program as compared to the market data for base salaries, target total cash compensation, long-term incentive compensation and target total direct compensation. Typically, the findings of this study are presented to the Compensation Committee by the compensation consultant in conjunction with the Compensation Committee&#8217;s annual review of our executive compensation program. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Because the biotechnology sector is dynamic, the comparator group used by the Compensation Committee to assess the competitive positioning of the compensation of our executive officers is updated annually to ensure that peer companies continue to meet the established criteria. For purposes of its review of our executive compensation program in fiscal 2024, the Compensation Committee directed Compensia to update the compensation peer group reflecting the competitive market for executive talent based on the following criteria: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Publicly-held, U.S. biotechnology companies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Companies with lead assets that are in mid to late clinical stage or early commercialization stage;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Companies with market capitalizations between 0.25x to 4.0x our market capitalization at the time of the peer selection; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">Companies with between 92 to 1,311 employees.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The compensation peer group was selected in such a manner that our market capitalization was very near the median for all peer companies. Consideration was also given to the frequency or infrequency with which a company was identified as a peer with other peer companies. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For fiscal 2024, the compensation peer group was generated in the first quarter of fiscal 2024 and consisted of the following companies:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.906%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">ACADIA Pharmaceuticals, Inc.</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Insmed</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Amicus Therapeutics</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Intellia Therapeutics</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Apellis Pharmaceuticals</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Ionis Pharmaceuticals</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Arcus Biosciences</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Ironwood Pharmaceuticals</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">BioCryst Pharmaceuticals</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Mirati Therapeutcis</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Blueprint Medicines</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Madrigal Pharmaceuticals</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">BridgeBio Pharma</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">REGENXBIO</span></div></td></tr></table></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:66.906%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">CRISPR Therapeutics AG</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Sarepta Therapeutics</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Deciphera Pharmaceuticals</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Ultragenyx Pharmaceuticals</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Denali Therapeutics</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Vir Biotechnology</span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Halozyme Therapeutics</span></div></td><td colspan="9" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Ironwood Pharmaceuticals, and Madrigal Pharmaceuticals were added to the compensation peer group and Chemo Centryx, FibroGen, Novavax, amd Reata Pharmaceuticals were removed from the compensation peer group due to changes in our business complexity, employee base and market capitalization, as well as mergers, changes to business complexity, employee base and market capitalization among our prior peer group.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The compensation study prepared by Compensia and presented in October 2023 provided an assessment of our compensation practices as compared to industry peers. Compensation levels for our executive officers, in the aggregate, were determined to be within the range of compensation provided to similarly placed executives and consistent with our compensation philosophy. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Individual Compensation Elements </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In 2024, the principal elements of our executive compensation program were as follows:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">base salary;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">an annual cash incentive compensation opportunity;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">long-term incentive compensation in the form of equity awards;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">welfare and health benefits; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:13.8pt">post-employment compensation arrangements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Base Salary </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Base salary represents the fixed portion of the compensation of our executive officers, including our NEOs, and is an important element of compensation intended to attract and retain highly-talented individuals. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The initial base salaries for our executive officers were negotiated on an individual basis at the time of hire. Thereafter, using the competitive market data provided by its external compensation consultant, the Compensation Committee reviews and determines adjustments to the base salaries for each of our executive officers, including our NEOs, as part of its annual executive compensation review. In addition, the base salaries of our executive officers may be adjusted by the Compensation Committee in the event of a promotion or significant change in responsibilities. Generally, the Compensation Committee sets base salaries with reference to the competitive range of the market median of our compensation peer group and applicable executive compensation survey data, as well as its assessment of the factors described in &#8220;Governance of Executive Compensation Program - Compensation-Setting Process&#8221; above. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The base salaries of our NEOs for fiscal 2024 and fiscal 2023 were as follows:</span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.901%"><tr><td style="width:1.0%"/><td style="width:45.446%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.169%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.853%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-indent:6pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Named&#160;Executive</span></div><div style="text-indent:6pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Officer</span></div><div style="margin-bottom:1pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal&#160;2024<br/>Base&#160;Salary</span></div><div style="margin-bottom:1pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal 2023 Base Salary</span></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Percentage&#160;&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Adjustment&#160;</span></div><div style="margin-bottom:1pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Christopher Anzalone</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">President&#160;&amp; CEO</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$960,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$913,868</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Kenneth Myszkowski</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$582,400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$560,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4%</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Patrick O&#8217;Brien</span></div><div style="margin-bottom:1pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Chief Operating Officer and </span><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">General Counsel</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$600,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$560,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">James Hamilton</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief of Discovery and Translational Medicine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$582,400</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$525,000</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">11%</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Javier San Martin (1)</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Former Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$582,400</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$560,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Tracie Oliver (2)</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;Former Chief Commercial Officer</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$488,880</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$470,000</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Dr. San Martin left the Company on February 1, 2024.<br/>(2) Ms. Oliver served as the Company's Chief Commercial Officer until October 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The actual base salaries paid to our NEOs in fiscal 2024 are set forth in the &#8220;Fiscal 2024 Summary Compensation Table&#8221; below. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Annual Cash Incentive Compensation </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We provide our executive officers, including our NEOs, with the opportunity to earn performance-based annual incentive awards, payable in cash, which are designed to reward them for our overall corporate performance as well as their individual performance. Generally, our executive officers are evaluated each year for eligibility to receive an annual cash incentive compensation opportunity. Through a collaborative planning process involving our Board and management, corporate performance objectives are established at the beginning of each year and evaluated regularly by our Board for their continued relevance to our status. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Target Annual Cash Incentive Award Opportunities</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For purposes of the fiscal 2024 performance-based incentive awards, each of our NEOs was assigned a target annual cash incentive award opportunity based upon a percentage of his or her base salary. The target annual cash incentive award opportunities for our executive officers, including our NEOs, were recommended by our CEO (except with respect to his own target annual cash incentive award opportunity) based on each executive officer&#8217;s accountability, scope of responsibilities, and potential impact on our performance, and approved by the Compensation Committee. The determination of target annual cash incentive award opportunities was also based on the factors described in &#8220;Governance of Executive Compensation Program - Compensation-Setting Process&#8221; above. Our NEOs&#8217; target annual cash incentive award opportunities did not change from fiscal 2023. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The target cash annual incentive award opportunities for our NEOs were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.700%"><tr><td style="width:1.0%"/><td style="width:46.251%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.065%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Named&#160;Executive Officer</span></div></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal&#160;2024&#160;Target&#160;Annual Incentive&#160;Award<br/>Opportunity (as&#160; a<br/>percentage&#160;of&#160;base<br/>salary)</span></div></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fiscal&#160;2023&#160;Target&#160;Annual<br/>Incentive&#160;Award<br/>Opportunity&#160;(as&#160; a<br/>percentage&#160;of&#160;base<br/>salary)</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Dr.&#160;Anzalone (1)</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">100%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mr.&#160;Myszkowski</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mr.&#160;O&#8217;Brien</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Dr.&#160;Hamilton</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Dr. San Martin</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ms. Oliver</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">40%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">40%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%">(1) Dr. Anzalone' annual cash incentive compensation opportunity is capped at 150% of his base salary.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Performance Objectives </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In determining the amount of the annual cash incentive award for each of our executive officers, including each of our NEOs, the Compensation Committee evaluated the corporate performance objectives that had been established at the beginning of the calendar year (as set forth below) as well as other corporate and individual achievements and performance throughout the year. These performance objectives addressed milestones for our lead products, research and development milestones for our drug pipeline and business development objectives. In December 2024, the Compensation Committee determined our performance against our primary business objectives set for calendar 2024, as described below. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.700%"><tr><td style="width:1.0%"/><td style="width:48.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.820%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-indent:6pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Goal</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-right:0.75pt solid #0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Achievement Highlights</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Corporate/</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Business Development  - </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weight: 40%</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Meet certain goals related to business development, capitalization, long-term financial planning, preparation for commercialization, and utilization of recent capital improvements</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Met</span></div><div style="margin-top:3.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:120%">Substantial business development transaction leading to significant recapitalization.                                                                               Manufacturing supply commitments, utilizing our Verona manufacturing facility, for commercial product.             Fully deployed a medical affairs field force and other commercially oriented operations.</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Clinical Development and Regulatory Affairs - </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weight: 40%</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Meet certain goals relating to Phase 3 studies in our clinical Cardiometabolic programs.</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Met</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Launched three Phase 3 studies for plozasiran.                                                                                                                 Established an Early Access Program for plozasiran in patients with FCS.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Submitted a New Drug Application with the U.S. Food and Drug Administration</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Discovery and Early Development&#160;- </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Weight: 20%</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Meet certain goals with regard to progress on our pre-clinical and early clinical programs</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Met.</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Achieved clinical milestone timelines for seven Phase 1 clinical assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-top:6.05pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:232%">Filed three new clinical trial applications                                                                                                          Nominated six new drug candidates                                                                </span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Annual Incentive Award Payments</span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The actual annual cash incentive award payments earned by our incumbent NEOs totaled 127% of the respective target award opportunities. Except for the annual incentive award for our CEO, these awards were recommended by our CEO and approved by the Compensation Committee based on the overall achievement of our goals, their contributions to the goals and the overall performance of each executive officer during the year. The following table sets forth the target annual cash incentive award opportunities, the target award expressed as a percentage of each NEO&#8217;s base salary and the actual award payment made in cash or cash equivalents to each of our NEOs based on their performance in fiscal 2024: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.700%"><tr><td style="width:1.0%"/><td style="width:48.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.432%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.473%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:6pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Named&#160;Executive</span></div><div style="text-indent:6pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Officer</span></div><div style="margin-bottom:1pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Target&#160;Annual<br/>Incentive&#160;Award<br/>Opportunity&#160;(as&#160;a<br/>percentage&#160;of&#160; base<br/>salary)</span></div></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Achievement target bonus</span></div></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Actual&#160;Annual<br/>Incentive&#160;Award<br/>($)</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Dr.&#160;Anzalone (1)</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">100%</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">120%</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$1,152,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mr.&#160;Myszkowski</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">120%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$314,496</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Mr.&#160;O&#8217;Brien</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">140%</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$378,000</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Dr.&#160;Hamilton</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">120%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$314,496</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Dr. San Martin (2)</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45%</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">Ms. Tracie Oliver (3)</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">40%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;%</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 7pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">$&#8212;</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:107%">&#160;(1) Dr. Anzalone received an initial bonus of $960,000, which was paid in December 2024 and an additional bonus of $192,000 which will be paid upon receipt of Hart Scott Rodino clearance of the Sarepta transaction. </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:107%">(2) Dr. San Martin left the Company on February 1, 2024 and did not receive an annual incentive award.</span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:107%">(3) Ms. Oliver served as the Company's Chief Commercial Officer until October 2024 and did not receive an annual incentive award.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The annual cash incentive award payments made to our NEOs for fiscal 2024 are set forth in the &#8220;Fiscal 2024 Summary Compensation Table&#8221; below. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Long-Term Incentive Compensation </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We view long-term incentive compensation in the form of equity awards as a critical element of our executive compensation program. The realizable value of these equity awards over time bears a direct relationship to our stock price, and, therefore, these awards are an incentive for our executive officers, including our NEOs, to create value for our stockholders. Equity awards also help us retain qualified executive officers in a competitive market. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Long-term incentive compensation opportunities in the form of equity awards are granted to our executive officers by the Compensation Committee. The amount and forms of such equity awards are determined by the Compensation Committee after considering the factors described in &#8220;Governance of Executive Compensation Program - Compensation-Setting Process&#8221; above. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">2024 Long-Term Incentive Awards </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Performance-Based RSU Award for Chief Executive Officer</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Annual equity awards granted to our executive officers are solely in the form of RSU awards that may be settled for shares of our common stock.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our CEO&#8217;s fiscal 2024 award was designed entirely as a performance-based award consisting of 340,000 PRSUs that will only vest upon the completion of a single performance trigger of a cash inflow to the </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%">Company</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> of $1 billion by June 30, 2025. The CEO&#8217;s fiscal 2024 award was also designed with the intention that the Compensation Committee would not certify performance prior to December 21, 2024, without good reasons, in accordance with the Company&#8217;s 2021 Incentive Compensation Plan. </span></div><div><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Results from PRSU Awards Previously Granted</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2024, the Compensation Committee certified achievement of the performance milestones relating to the following PRSU awards: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:75.059%"><tr><td style="width:1.0%"/><td style="width:31.807%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:32.925%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.876%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:27.816%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Performance&#160;Goal</span></div></td><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Achievement</span></div><div style="margin-bottom:1pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#0071ce;border-right:0.75pt solid #0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">No.&#160;of&#160;Shares</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Certified&#160;as&#160;Vested</span></div><div style="margin-bottom:1pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-bottom:2pt solid #0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Maintain clinical trials concurrently in four different tissue types (hepatic, pulmonary, and two others).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Issued 12/2022</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:2pt solid #0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:2pt solid #0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Certified in October 2023</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:2pt solid #0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:2pt solid #0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">46,805 shares pursuant to a PRSU award</span></div></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">RSU Awards for Other Named Executive Officers</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Compensation Committee approved the following aggregate RSU awards for our other NEOs for 2024:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.820%"><tr><td style="width:1.0%"/><td style="width:53.547%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.130%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.791%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.132%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-indent:6pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Named&#160;Executive</span></div><div style="text-indent:6pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Officer</span></div><div style="margin-bottom:1pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Restricted&#160;Stock&#160;Unit<br/>Awards<br/>(number&#160;of&#160;shares)</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Restricted&#160;Stock&#160;Unit&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Awards<br/>($)</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.8pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mr.&#160;Myszkowski</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$2,589,750</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.8pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Mr.&#160;O&#8217;Brien</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">85,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$2,935,050</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.8pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dr.&#160;Hamilton</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$2,589,750</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 17.8pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Dr. San Martin</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$2,589,750</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 1pt 2px 17.8pt;text-align:left;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Ms. Tracie Oliver</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">75,000</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;text-indent:-12pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$2,589,750</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">RSUs granted to our NEOs in fiscal 2024 vest over four years in equal annual installments, subject to the NEO&#8217;s continued employment on each applicable vesting date. Dr. San Martin and Ms. Oliver forfeited their fiscal 2024 equity awards upon their respective departures.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The equity awards granted to our NEOs in fiscal 2024 are set forth in the &#8220;Fiscal 2024 Summary Compensation Table&#8221; and the &#8220;Fiscal 2024 Grants of Plan-Based Awards Table&#8221; below. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Welfare and Health Benefits </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our executive officers, including our NEOs, are eligible to participate in all of our employee benefit plans, including medical, dental, vision, life and disability insurance, in each case on the same basis as our other employees, subject to applicable law. In addition, we provide an additional life insurance benefit to our CEO for the benefit of his heirs. We also provide vacation and other paid holidays to all our employees, including our executive officers, all of which we believe to be comparable to those provided the companies in our compensation peer group. These benefit programs are designed to enable us to attract and retain our workforce in a competitive marketplace. Our health, welfare and vacation benefits are designed to ensure that we have a productive and focused workforce through reliable and competitive health and other benefits. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our retirement savings plan (&#8220;401(k) plan&#8221;) is a tax-qualified retirement savings plan, pursuant to which qualified employees, including our NEOs, are able to contribute certain amounts of their annual compensation, subject to limits prescribed by the Internal Revenue Service. Historically, we have </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">made matching contributions of 100% of the first 3% of base salary and of 50% of the next 2% of base salary contributed to the plan. The value of these benefits for each of our NEOs is reflected in the &#8220;All Other Compensation&#8221; column of the &#8220;Fiscal 2024 Summary Compensation Table&#8221; below. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Perquisites and Other Personal Benefits </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Currently, we do not view perquisites or other personal benefits as a significant component of our executive compensation program. Accordingly, we do not provide significant perquisites or other personal benefits to our executive officers, including our NEOs, except as generally made available to our employees, or in situations where we believe it is appropriate to assist an individual in the performance of his or her duties, to make our executive officers more efficient and effective and for recruitment and retention purposes. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In the future, we may provide perquisites or other personal benefits in limited circumstances, such as those described in the preceding paragraph. All future practices with respect to perquisites or other personal benefits will be approved and subject to periodic review by the Compensation Committee. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Employment Arrangements </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into a written employment agreement with our CEO and have written employment offer letters with our other executive officers. In filling each of our executive positions, we recognized the need to develop competitive compensation packages to attract qualified candidates in a dynamic labor market. At the same time, in formulating these compensation packages, we were sensitive to the need to integrate new executive officers into the executive compensation structure that we were seeking to develop, balancing both competitive and internal equity considerations. Each of these arrangements provides for &#8220;at will&#8221; employment. For detailed descriptions of the employment arrangements we maintained with our NEOs during fiscal 2024, see &#8220;Termination Benefits - Potential Payments Upon Termination or Change in Control&#8221; below. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-indent:27pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Post-Employment Compensation Arrangements </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  <br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">We have entered into a written employment agreement with our CEO, and we also have agreements with our CFO and Chief Operating Officer &amp; General Counsel that provide for certain payments and benefits in the event of certain involuntary terminations of employment. We believe that having in place reasonable and competitive post-employment compensation arrangements are essential to attracting and retaining highly-qualified executive officers. These agreements are designed to provide reasonable compensation these to executive officers if they were to leave our employ under certain circumstances to facilitate their transition to new employment. Further, in some instances we seek to mitigate any potential employer liability and avoid future disputes or litigation by requiring a departing executive officer to sign a separation and release agreement acceptable to us as a condition to receiving post-employment compensation payments or benefits.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Compensation Committee does not consider the specific amounts payable under these agreements when establishing annual compensation. We do believe, however, that these arrangements are necessary to offer compensation packages that are competitive. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In addition, our 2013 Incentive Plan and our 2021 Incentive Plan each provides for the acceleration of vesting of outstanding and unvested equity awards in the event of a change in control of the Company, as defined in the plans, except as otherwise determined by our Board. However, the agreements for equity awards granted to our CEO pursuant to our 2013 Incentive Plan and our 2021 Incentive Plan provide that, upon a change in control of the Company, the vesting of such awards will accelerate only in the event of a subsequent involuntary termination of employment (a &#8220;double-trigger&#8221; arrangement). For detailed descriptions of the post-employment compensation arrangements we maintained with our NEOs during fiscal 2024, as well as an estimate of the potential payments and benefits payable under these arrangements, see &#8220;Termination Benefits - Potential Payments Upon Termination or Change in Control&#8221; below. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Compensation Policies and Practices </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Equity Awards Grant Policy </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any program, plan, or obligation that requires us to grant equity awards on specified dates, although historically we have granted such awards to our existing executive officers and employees at least annually and to newly-hired employees upon the commencement of their employment. </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We do not have any program, plan or practice to grant equity awards of our common stock to our executive officers in coordination with the release of material nonpublic information. Equity awards may occasionally be granted following a significant change in job responsibilities or to meet other special retention or performance objectives. Authority to grant equity awards to our employees rests with the Compensation Committee, although the Compensation Committee has delegated authority to our CEO to grant equity awards to non-executive employees within prescribed limits set by the Compensation Committee. With respect to our executive officers, except for our CEO, recommendations for equity awards are made by our CEO and reviewed and approved by the Compensation Committee. Under the terms of our 2021 Incentive Plan, pursuant to which new equity awards are granted, the exercise price of any option to purchase shares of our common stock awarded under the plan must be equal to at least 100% of the fair market value of our common stock (which is determined based on the closing sales price of our common stock on the Nasdaq Global Market) on the date of grant. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock Ownership Policy </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a stock ownership policy for our CEO and CFO to further align their respective interests with the interests of our stockholders, and to further promote our commitment to sound corporate governance. This policy requires our CEO to own a minimum number of shares of our common stock equal to a value of six times his annualized base salary and our CFO to own a minimum number of shares of our common stock equal to a value of twice his annualized base salary. Our CEO and CFO have each achieved the respective required ownership level. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Recovery (&#8220;Clawback&#8221;) Policy </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we updated our compensation recovery (&#8220;Clawback&#8221;) policy, in accordance with new Nasdaq listing rules. The updated policy allows for the Company to recover incentive compensation from our executive officers, on a non-fault basis, in the event a financial restatement is required to correct any accounting errors made by any such executive officer.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our 2013 Incentive Plan and our 2021 Incentive Plan each provides for the recovery of awards made under the plan in accordance with any applicable compensation recovery or recoupment policy, including as required by law, regulation or national securities exchange rule. </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Tax and Accounting Considerations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductibility of Executive Compensation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Section 162(m) of the Internal Revenue Code limits the federal income tax deductibility of certain compensation amounts in excess of $1 million paid to certain executive officers. While the Compensation Committee generally seeks to pay compensation that is tax-deductible, it reserves the right to pay non-deductible compensation to the extent it deems appropriate. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Stock-Based Compensation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">We follow the Financial Accounting Standard Board&#8217;s Accounting Standards Codification Topic 718 (&#8220;FASB ASC Topic 718&#8221;) for our stock-based compensation awards. FASB ASC Topic 718 requires us to measure the compensation expense for all share-based payment awards made to our employees and non-employee members of our Board, including options to purchase shares of our common stock and other stock awards, based on the grant date &#8220;fair value&#8221; of these awards. This calculation is performed for accounting purposes and reported in the executive compensation tables required by the federal securities laws, even though the recipient of the awards may never realize any value from their awards. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Risk Assessment </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">In reviewing our various compensation programs, the Compensation Committee considers how our compensation policies and practices may affect our risk profile and whether such policies and practices may encourage undue risk-taking by our employees. More specifically, the Compensation Committee considers the general design philosophy of our policies and practices for our employees whose conduct would be most affected by incentives established pursuant to these compensation policies. In considering these issues, the Compensation Committee concluded that the use of a performance-based annual incentive compensation plan and long-term incentive compensation opportunities in the form of equity <br/>awards did not appear to create undue risks for us or encourage excessive risk-taking behavior on the part of our NEOs. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the annual incentive awards for our executive officers, the amount of an individual&#8217;s award depends principally on overall Company performance, as determined by the Compensation Committee, which reduces the ability and incentive for an individual to take undue risks at the expense of our performance in an effort to increase the amount of his or her annual incentive award. Our performance objectives are reviewed regularly by the Compensation Committee and our Board and are considered to be generally of the nature that promote the steady progression of our development programs and would not encourage or reward excessive risk-taking. In addition, our Board has the ability to intervene in instances where actions by our executive officers vis-&#224;-vis Company performance objective attainment would be considered unduly risky to prevent or penalize such actions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee Report </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee of the Company has reviewed and discussed with management the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K. Based on this review and discussion, the Compensation Committee recommended to our Board that the foregoing Compensation Discussion and Analysis be included in the proxy statement. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Submitted by the Compensation Committee of the Board of Directors</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> Michael Perry, Committee Chair </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Hongbo Lu</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">William Waddill </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Committee Interlocks and Insider Participation </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2024, Mr. Waddill, Dr. Ferrari, and Dr. Perry, served on the Compensation Committee. During fiscal year 2024 and through December 2024, there were no compensation committee interlocks between the Company and other entities involving the Company&#8217;s executive officers and directors. For information regarding a transaction involving the brother of Dr. Douglass Given, the Company&#8217;s former Director and Chairman of the Board, which is required to be disclosed under Item 404 of Regulation S-K, see &#8220;Certain Relationships and Related Transactions, and Director Independence.&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Fiscal 2024 Summary Compensation Table</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table summarizes compensation earned for services rendered during fiscal 2024, 2023, and 2022 by our Chief Executive Officer, our Chief Financial Officer, our Chief Operating Officer and General Counsel, our Chief of Discovery and Translational Medicine, and our former Chief Medical Officer and former Chief Commercial Officer, collectively our &#8220;Named Executive Officers&#8221;: </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.136%"><tr><td style="width:1.0%"/><td style="width:11.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.839%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.142%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.627%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.809%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.633%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.35pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name and</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"><br/></span><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Principal Position</span></div></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Salary<br/>($)</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Bonus<br/>(S)</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Awards&#160;(1)</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">($)</span></div></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Non-Equity<br/>Incentive&#160;Plan<br/>Compensation&#160; (2)</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">($)</span></div></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">All&#160;Other<br/>Compensation&#160;(3)</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">($)</span></div></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total ($)</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:4.5pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Christopher Anzalone</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">951,012</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10,319,000</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,152,000</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,461</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12,423,473&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">902,522</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8,314,056</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(5)</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">700,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,515</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">9,918,093&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">863,417</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10,382,549</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(7)</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">783,315</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">(6)</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,688</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12,031,969&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:4.5pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Kenneth Myszkowski</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">592,369</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,589,750</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">314,496</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,761</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,512,376&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">568,128</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,284,800</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">252,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,215</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,119,143&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">509,648</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,978,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">238,106</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,798</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,739,552&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:4.5pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Patrick O&#8217;Brien</span></div><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:4.5pt"><span><br/></span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">605,259</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,935,050</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">378,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,261</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,933,570&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief Operating Officer and General Counsel</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">568,422</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,475,200</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">252,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,715</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,310,337&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">500,466</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,978,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">235,599</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,798</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,727,863&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div><div style="padding-left:4.5pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">James Hamilton</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">567,937</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,589,750</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">314,496</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">15,261</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,487,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chief of Discovery and Translational Medicine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">511,178</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,284,800</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">236,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,715</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,046,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">450,436</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,646,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">212,580</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,798</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,323,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Javier San Martin (8)</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">260,529</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,589,750</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">606,285</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,456,564&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Former Chief Medical Officer</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">544,467</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,284,800</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">252,000</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">14,715</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,095,982&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">479,170</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">225,574</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">704,744&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Tracie Oliver (8)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">484,065</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,589,750</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,965</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,076,780&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Former Chief Commercial Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">647,261</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">19,040</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">188,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">19,521</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">873,822&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">111,154</span></td><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">16,344</span></td><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,517,200</span></td><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">94,874</span></td><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4,899</span></td><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #0071ce;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,744,471&#160;</span></td><td style="border-bottom:1pt solid #0071ce;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">This column represents the total grant date fair value, computed in accordance with ASC 718, of RSUs granted during fiscal years 2024, 2023 and 2022. The assumptions used to calculate the value of the stock underlying the RSU awards are set forth in Note 9 of the Notes to the Consolidated Financial Statements included with the Company&#8217;s Annual Report on Form 10-K filed with the SEC on November 26, 2024 (the &#8220;Original Report&#8221;).</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">These bonus amounts represent the amounts earned for performance under the Company&#8217;s Annual Bonus Incentive Plan during calendar years 2024, 2023 and 2022 and paid in fiscal years 2025, 2024 and 2023, respectively. The Annual Bonuses are described in more detail in the &#8220;Bonus Incentive&#8221; section.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Amounts consist of 401(k) matching contribution, as well as life insurance premiums for the benefit of each executive officer.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">The amount reported for Christopher Anzalone in the Stock Awards column includes the grant date fair value of a fiscal 2024 RSU award that is subject to vesting upon the achievement of a specific performance condition. We determined the performance condition was 100% probable of being achieved as of the grant date, as defined under applicable accounting guidance, and assigned a grant date fair value of $10,319,000 based on this evaluation. The amount reported in the Summary Compensation Table for this award may not represent the amount that Christopher Anzalone will realize from the award. Whether, and to what extent, an NEO realizes the value will depend on our actual operating performance, stock price fluctuations and the NEO&#8217;s continued employment.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">The amount reported for Christopher Anzalone in the Stock Awards column includes the grant date fair value of a fiscal 2023 RSU award that is subject to vesting upon the achievement of specific performance conditions. We determined the performance conditions that were probable and not probable of being achieved as of the grant date, as defined under applicable accounting guidance, and assigned a grant date fair value of $4,625,270 based on this evaluation. If we had determined that as of the date of the grant it was probable that 100% of the performance conditions would be achieved, we would have assigned a grant date fair value of $8,314,056 for the performance-based RSUs. The amount reported in the Summary Compensation Table for this award may not represent the amount that Christopher Anzalone will realize from the award. Whether, and to what extent, an NEO realizes the value will depend on our actual operating performance, stock price fluctuations and the NEO&#8217;s continued employment.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(6)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Dr. Anzalone&#8217;s Fiscal Year 2022 bonus, totaling $783,315, was paid as $200,000 cash and the remaining balance as immediately vested Arrowhead stock. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(7)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">In July of 2022, our CEO&#8217;s fiscal 2022 compensation was revised by reducing his equity award and re-formulating the equity award to consist 60% of performance-based RSUs and 40% of time-based RSUs. The CEO&#8217;s Stock Awards are described in more detail in the &#8220;Our CEO&#8217;s Fiscal 2022 Equity Award&#8221; section in our 2023 proxy statement. The amounts reported for Christopher Anzalone in the Stock Awards column reflect the grant date fair value of a July 2022 RSU award that is subject to vesting upon the achievement of specific performance conditions, as described in the Compensation Discussion and Analysis section in our 2023 proxy statement. We determined the performance conditions that were probable and not probable of being achieved as of the grant date, as defined under applicable accounting guidance, and assigned a grant date fair value of $6,229,538 based on this evaluation. The amounts reported in the Summary Compensation Table for these awards may not represent the amounts that Christopher Anzalone will realize from the awards. Whether, and to what extent, an NEO realizes value will depend on our actual operating performance, stock price fluctuations and the NEO&#8217;s continued employment.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(8)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Dr. San Martin left the Company on February 1, 2024 and Ms. Oliver served as the Company&#8217;s Chief Commercial Officer until October 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Fiscal 2024 Grants of Plan Based Awards Table</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth cash bonus and equity grants made to the NEOs in fiscal 2024: </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:82.254%"><tr><td style="width:1.0%"/><td style="width:20.911%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.812%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.104%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.528%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.337%"/><td style="width:0.1%"/></tr><tr style="height:45pt"><td colspan="3" style="background-color:#0071ce;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="6" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated&#160;Future&#160; Payouts<br/>Under Non-Equity<br/>Incentive&#160;Plan&#160;Awards&#160;(1)</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Estimated</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Future&#160;Payouts<br/>Under&#160;Equity<br/>Incentive&#160;Plan<br/>Awards&#160; (2)</span></div></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">All&#160;Other&#160;Stock<br/>Awards:&#160;Number<br/>of Shares of<br/>Stock or Units<br/>(#) (3)</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Grant</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date Fair<br/>Value</span></div></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:5.35pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></div><div style="margin-bottom:1pt;padding-left:5.35pt"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:2pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Grant&#160;Date</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Target ($)</span></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Maximum ($)</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Target (#)</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="background-color:#e5e5e5;color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Christopher Anzalone</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:22.5pt"><span style="background-color:#e5e5e5;color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash Bonus</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$960,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$1,440,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">PRSUs</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12/22/2023</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">340,000&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$10,319,000&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Kenneth Myszkowski</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash Bonus</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$262,080</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">01/04/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">75,000</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$2,589,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="background-color:#e5e5e5;color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Patrick O&#8217;Brien</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash Bonus</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$270,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">01/04/2024</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">85,000&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$2,935,050&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="background-color:#e5e5e5;color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">James Hamilton</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash Bonus</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$262,080</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">01/04/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$2,589,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Javier San Martin </span><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(4)</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash Bonus</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$262,080</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">RSUs</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">01/04/2024</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,589,750&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Tracie Oliver</span><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%"> (4)</span></div></td><td colspan="3" style="padding:0 1pt 0 23.5pt"/><td colspan="3" style="padding:0 1pt 0 23.5pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt 0 23.5pt"/><td colspan="3" style="padding:0 1pt 0 23.5pt"/><td colspan="3" style="padding:0 1pt 0 23.5pt"/><td colspan="3" style="padding:0 1pt 0 23.5pt"/><td colspan="3" style="padding:0 1pt 0 23.5pt"/><td colspan="3" style="padding:0 1pt 0 23.5pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Cash Bonus</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$195,552</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;RSUs</span></td><td colspan="3" style="border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">01/04/2024</span></td><td colspan="3" style="border-bottom:1pt solid #026dce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="border-bottom:1pt solid #026dce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #026dce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></div></td><td colspan="3" style="border-bottom:1pt solid #026dce;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #026dce;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">75,000&#160;</span></td><td style="border-bottom:1pt solid #026dce;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-bottom:1pt solid #026dce;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #026dce;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$2,589,750&#160;</span></td><td style="border-bottom:1pt solid #026dce;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Amounts listed represent cash award targets for our NEOs in fiscal 2024. Actual payments were made in fiscal 2025 and the amounts are reported in the Summary Compensation Table above. There are no thresholds or maximum levels applicable under our annual cash incentive awards except with respect to Dr. Anzalone, whose target opportunity is capped at 150%.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">These PRSUs are described above in the &#8220;Compensation Discussion and Analysis&#8221; under the heading &#8220;Equity Compensation.&#8221;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">RSUs granted in fiscal 2024 vest in four equal annual installments beginning 1 year from the grant date.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Dr. San Martin and Ms. Oliver forfeited their fiscal 2024 equity awards upon their respective departures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Fiscal 2024 Outstanding Equity Awards at Fiscal Year End Table</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table provides information, with respect to the NEOs, concerning the outstanding equity awards covering shares of the Company&#8217;s common stock as of September 30, 2024.</span></div><div><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.654%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.341%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.701%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.379%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.706%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;border-left:0.75pt solid #0071ce;border-top:2pt solid #0071ce;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="21" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Stock Awards</span></td></tr><tr><td colspan="3" style="background-color:#0071ce;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Grant</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></div></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of<br/>Shares&#160;or<br/>Units&#160;of<br/>Stock</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">That<br/>Have&#160;Not<br/>Vested</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(#)&#160;(1)</span></div></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Market</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;of</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Shares&#160;or<br/>Units&#160;of<br/>Stock</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">That<br/>Have</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Not<br/>Vested</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">($)&#160;(2)</span></div></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>Incentive<br/>Plan<br/>Awards:<br/>Number&#160;of<br/>Unearned<br/>Shares&#160;or<br/>Units of<br/>Stock</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">That<br/>Have</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Not<br/>Vested</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">(#)&#160;(3)</span></div></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>Incentive<br/>Plan<br/>Awards:<br/>Market</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Value<br/>of<br/>Unearned<br/>Shares&#160;or<br/>Units&#160;of<br/>Stock</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">That<br/>Have</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Not<br/>Vested<br/>($)&#160;(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="background-color:#e5e5e5;color:#0071ce;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Christopher&#160;Anzalone</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/01/2020</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">700,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">13,559,000&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/01/2021</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">800,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#ee2724;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">15,496,000&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">07/08/2022</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">49,761</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">963,871&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">149,282</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">2,891,592&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12/20/2022</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">70,208</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,359,929&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">93,610</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,813,226&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12/22/2023</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">340,000</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">6,585,800&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Kenneth&#160;Myszkowski</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/01/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">15,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">290,550&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/01/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">581,100&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/04/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">871,650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/04/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">75,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,452,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="background-color:#e5e5e5;color:#0071ce;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Patrick O&#8217;Brien</span></div></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/01/2021</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">15,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">290,550&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/01/2022</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">30,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">581,100&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/04/2023</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">48,750</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">944,288&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/04/2024</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">85,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,646,450&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">James Hamilton</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/01/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">12,500</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">242,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/01/2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">27,500</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">532,675&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/04/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">45,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">871,650&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/04/2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">75,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,452,750&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Javier San Martin</span></td><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/04/2024</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="2" style="background-color:#dbdbdb;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#dbdbdb;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#dbdbdb;padding:0 1pt"/><td colspan="3" style="background-color:#dbdbdb;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#0071ce;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Tracie Oliver</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">07/01/2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">35,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">677,950&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/04/2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">375</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">7,264&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">01/04/2024</span></td><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">75,000</span></td><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="2" style="border-bottom:1pt solid #026dce;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">1,452,750&#160;</span></td><td style="border-bottom:1pt solid #026dce;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">RSUs have various vesting parameters but generally vest in four equal annual installments beginning one year from the grant date. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Value is based on our Company&#8217;s Common Stock closing price of $19.37 on September 30, 2024.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">The amounts reported for Christopher Anzalone in this column reflect the January 2020, January 2021, July 2022, December 2022, and December 2023 awards that contain performance-based vesting conditions. These awards and their vesting conditions are described above in the &#8220;Compensation Discussion and Analysis&#8221; under the heading &#8220;Equity Compensation&#8221; and in prior proxy statements, as applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Fiscal 2024 Options Exercises and Stock Vested Table</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table provides information, with respect to the NEOs, concerning options exercised or RSUs or PRSUs vested during fiscal 2024. </span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:44.849%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.978%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.983%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;border-left:0.75pt solid #0071ce;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Option&#160;Awards</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="9" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Stock&#160;Awards</span></td></tr><tr><td colspan="3" style="background-color:#0071ce;border-left:0.75pt solid #0071ce;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:4pt;font-weight:400;line-height:100%">&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares<br/>Acquired&#160;on<br/>Exercise</span></div></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;Realized&#160;on<br/>Exercise&#160;(1)</span></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;of&#160;Shares<br/>Acquired&#160;on<br/>Vesting</span></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Value&#160;Realized&#160;on&#160;&#160;</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Vesting&#160;(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Christopher Anzalone</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">57,499</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,024,000&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">95,087</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,603,325&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Kenneth Myszkowski</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">66,250</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,212,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patrick O&#8217;Brien</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">63,750</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,139,688&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 6.3pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">James Hamilton</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">52,500</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,773,225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Javier San Martin</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">52,500</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">1,570,200</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Tracie Oliver</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #026dce;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">17,625</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #026dce;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #026dce;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #026dce;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">460,191&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #026dce;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Value is calculated as the price of our Common Stock upon exercise, less the exercise price, multiplied by the number of shares exercised.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Value is calculated as the price of our Common Stock upon vesting, multiplied by the number of shares vested.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Termination Benefits - Potential Payments Upon Termination or Change in Control </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company has the following severance or change of control arrangements with its NEOs: </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Anzalone&#8217;s employment agreement with the Company provides that, if the Company terminates Dr. Anzalone&#8217;s employment without Cause or if Dr. Anzalone terminates his employment for Good Reason, on his date of termination, Dr. Anzalone will receive a one-time lump sum payment equal to the sum of: (i) one month of base salary and (ii) premiums for thirty (30) days of medical and dental benefits. To receive such payments Dr. Anzalone is required to execute a general release in favor of the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">For purposes of Dr. Anzalone&#8217;s employment agreement: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Cause</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means (i) the conviction (by trial or upon a plea of nolo contendere) of a felony or other crime involving moral turpitude or the commission of any other material act or omission involving dishonesty, disloyalty or fraud with respect to the Company or any of its subsidiaries or any of their customers or suppliers, (ii) reporting to work under the influence of alcohol or illegal drugs, the use of illegal drugs (whether or not at the workplace) or other repeated conduct causing the Company or any of its subsidiaries substantial public disgrace or disrepute or economic harm, (iii) the engaging of gross misconduct and the failure to cease such conduct and rectify any harm to the Company resulting therefrom within 30 days after written demand therefor by the Company identifying with reasonable particularity such conduct and harm, or (iv) any other material breach by Dr. Anzalone of his employment agreement and the failure to cease such breach and rectify any harm to the Company within 30 days after written demand by the Company identifying with reasonable particularity such breach and harm; and </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Good Reason</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">&#8221; means (i) Dr. Anzalone&#8217;s duties, responsibilities, titles or offices are diminished as compared to those described in his employment agreement without his written consent, and the Company fails to reinstate such duties, responsibilities, titles or offices within 30 days after written demand by Dr. Anzalone identifying with reasonable particularity the diminishment, (ii) the relocation of Dr. Anzalone&#8217;s base office to an office that is more than thirty (30) highway miles from Pasadena, CA, (iii) the failure of the Company to obtain a satisfactory agreement from any successor to assume and agree to perform the obligations under the employment agreement and (iv) any other material breach of Dr. Anzalone&#8217;s employment agreement by the Company and the failure to cease such breach and rectify any harm to Dr. Anzalone resulting within 30 days after written demand by Dr. Anzalone identifying with reasonable particularity the breach and harm. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to his offer of employment by the Company, Mr. Myszkowski is entitled to severance pay equal to three months&#8217; base salary plus an amount equal to the premiums on his medical and dental benefits for the same period upon termination of his employment without cause.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to his offer of employment by the Company, Mr. O&#8217;Brien is entitled to severance pay equal to six months&#8217; base salary upon a qualifying termination of his employment without cause only upon change of control as defined in the Company&#8217;s 2013 Incentive Plan. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company has not entered into a severance arrangement with Dr. San Martin or Dr. Hamilton or Ms. Oliver. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, pursuant to the 2004 Equity Incentive Plan, the 2013 Incentive Plan, and the 2021 Incentive Plan, any unvested awards held by plan participants, including the NEOs, become fully vested upon a change of control of the Company, except as otherwise determined by the Board and except with respect to the outstanding awards held by the CEO whose awards will only become fully vested if he experiences a qualifying termination of employment following a change of control. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following tables set forth information regarding potential termination and change of control arrangements with our executive officers had their employment been terminated or a change in control of the Company taken place on September 30, 2024: </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Termination Payments</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.237%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.969%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.378%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.975%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;border-left:0.75pt solid #0071ce;border-top:2pt solid #0071ce;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Triggering&#160;Event</span></td><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Salary<br/>($)</span></td><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Benefits<br/>($)</span></td><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Stock<br/>Awards<br/>(1)($)</span></td><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Option<br/>Awards<br/>(1)($)</span></td><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Termination by Employer without Cause</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Christopher Anzalone (2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">82,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Kenneth Myszkowski</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">140,000&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8,848&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">148,848&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patrick O&#8217;Brien</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">James Hamilton</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Change in Control</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Christopher Anzalone (2)</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Kenneth Myszkowski</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">140,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,196,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,344,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patrick O&#8217;Brien</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,462,388&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,462,388&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">James Hamilton</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,099,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,099,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Involuntary Termination Following a Change in Control</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Christopher Anzalone</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">42,669,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">42,751,725&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patrick O&#8217;Brien</span></td><td colspan="2" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">280,000&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">280,000&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">For stock awards the value is calculated as the number of unvested shares multiplied by the Company&#8217;s closing stock price at September 30, 2024 of $19.37.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Dr. Anzalone&#8217;s employment contract also provides for payment of the values set forth above upon his resignation for &#8220;good reason&#8221; as defined in his employment agreement.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Dr. San Martin entered into a standard separation and release of claims agreement with the Company, under which he received a one-time payment of $603,200 in exchange for the release claims. Ms. Oliver did not receive any payments or benefits in connection with her departure from the Company. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">CEO Pay Ratio</span></div><div><span><br/></span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to Item 402(u) of Regulation S-K, we are required to calculate and disclose the median of the annual total compensation of all of our employees (excluding our CEO, Dr. Anzalone), the annual total compensation of Dr. Anzalone, and the ratio of these two amounts. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%"> Based on the fact that we had a significant number of new hires during fiscal 2024, we did not elect to use the same median employee as the prior year. Our median employee was identified using the entire population of our employees as of September 30, 2024 based on a consistently applied compensation measure, or CACM, that reasonably reflects the annual compensation of our employees. The CACM selected by us for our disclosure included annual base salary, the cash bonus amount for fiscal 2024, the grant-date fair value for stock-based awards (calculated in accordance with requirements for the Summary Compensation Table), and welfare and health benefits for fiscal 2024. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Based on the CACM methodology described above, we identified the median employee and calculated the fiscal 2024 compensation for this selected employee in the same manner we determine the annual total compensation of our NEOs for purposes of the Summary Compensation Table. The median of the annual total compensation of all our employees was $174,364.00. Dr. Anzalone&#8217;s fiscal 2024 annual total compensation as disclosed in the Fiscal 2024 Summary Compensation Table was $ 12,423,473. As a result, our CEO to median employee pay ratio for fiscal 2024 is 70:1. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">This pay ratio is a reasonable estimate calculated by a method consistent with the SEC requirements, described above, based on our payroll and employment records. As a result of a variety of factors, including employee populations, potential differences in the components used for the CACM, compensation philosophies and certain assumptions, pay ratios reported by other companies may not be comparable to our pay ratio. The pay ratio is not utilized by our management or our compensation committee for compensation-related decisions. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Director Compensation</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Directors who are also employees of the Company receive no separate compensation from the Company for their service as members of the Board. For 2024, the Company maintained the structure of director compensation it adopted in 2019 to provide a base retainer for each director with higher base retainers for service by the Board Chair and committee leadership. The average total compensation paid to the Company&#8217;s non-executive directors for service in 2024 is at or below the 60th percentile of the total compensation paid to non-executive directors of its peer group. The Compensation Committee believes the structure aligns compensation according to the level of service contributions by each director. The fees payable to directors for service on the Board and for service on each committee of the Board on which the director serves are as follows:</span></div><div style="text-align:justify;text-indent:27pt"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.820%"><tr><td style="width:1.0%"/><td style="width:45.214%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.662%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:25.824%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#026dce;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Board of Directors:</span></td><td colspan="3" style="background-color:#026dce;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2023 Annual Retainer:</span></td><td colspan="3" style="background-color:#026dce;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">2024 Annual Retainer:</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">All non-employee directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$80,000</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$80,000</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Additional retainer for Non-Executive Chairman of the Board</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$15,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$15,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Audit Committee:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #026dce;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chairman</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #026dce;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$5,000</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #026dce;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$5,000</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%">Compensation Committee:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Chairman</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$5,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">$5,000</span></td></tr></table></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the total compensation paid to our non-employee directors in fiscal 2024. Dr. Anzalone&#8217;s compensation is set forth in the discussion of Executive Compensation and in the Summary Compensation Table. </span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:58.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.700%"><tr><td style="width:1.0%"/><td style="width:45.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.235%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.074%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.077%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Fee&#160;Earned</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">or</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Paid&#160;in&#160;Cash</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">($)</span></div></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Awards&#160;($)</span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">(1)&#160;(2)</span></div></td><td colspan="3" style="background-color:#0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Total&#160;($)&#160;&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Douglass Given </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">(3)</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$95,000</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$380,833</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:2pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$475,833</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Michael S. Perry</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$80,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$380,833</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$460,833</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Mauro Ferrari</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$80,000</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$380,833</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$460,833</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;William Waddill</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$90,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$380,833</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$470,833</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Hongbo Lu</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%"> (4)(5)</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$43,333</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$761,666</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$804,999</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Adeoye Olukotun </span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$80,000</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$380,833</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$460,833</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;Victoria Vakiener</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$80,000</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #026dce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$380,833</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #026dce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$460,833</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">This column represents the total grant date fair value, computed in accordance with ASC 718, of RSUs granted during fiscal year 2024 to each director. The assumptions used to calculate the value of the stock underlying the RSU awards are set forth in Note 9 of the Notes to the Consolidated Financial Statements included with the Original Report.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">The RSUs granted to non-employee directors vest one year from the date of grant, subject to continued service through the vesting date, with the exception of the RSUs granted to Dr. Lu in connection with her appointment to the Board, which vest in three equal installments on each anniversary of the date of grant, subject to continued service through each such vesting date.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Douglass Given retired from the Board effective as of December 31, 2024.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Dr. Lu joined the Board during fiscal year 2024 and her cash compensation was pro-rated for such fiscal year. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">In connection with her appointment, Dr. Lu received a sign-on grant of restricted stock units valued at $761,666.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of the last day of fiscal year 2024, the directors held the following outstanding restricted stock unit (&#8220;RSU&#8221;) grants in the aggregate: Douglass Given - - 19,583; Michael S. Perry - 19,583; Mauro Ferrari -19,583; William Waddill - 19,583; Adeoye Olukotun - 19,583; Victoria Vakiener - 24,722; and Hongbo Lu - 24,080 RSUs.</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of the last day of fiscal year 2024, the directors held the following outstanding option (&#8220;Options&#8221;) grants in the aggregate: Douglass Given - 4,593; Michael S. Perry - 4,593; Mauro Ferrari -4,593; William Waddill - 4,593; Adeoye Olukotun - 4,593; Victoria Vakiener - 4,593 Options; and Hongbo Lu - 0.</span></div><div style="height:9pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ied6c21fce27e4152aa85d0d2377cea12_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the beneficial ownership of the Company&#8217;s Common Stock as of January 17, 2025, by (i) each of the NEOs named in the table under &#8220;Executive Compensation and Related Information,&#8221; (ii) each director, (iii) all then-current directors and executive officers as a group, and (iv) the holders of greater than 5% of our total shares outstanding known to us. Unless otherwise specified in the footnotes to the table below, the persons and entities named in the table have sole voting and investment power with respect to all shares beneficially owned, subject to community property laws, where applicable, and the address of each stockholder is c/o Arrowhead Pharmaceuticals, Inc., 177 E. Colorado Blvd, Suite 700, Pasadena, CA, 91105 unless otherwise indicated. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"/><td style="width:68.241%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.602%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.830%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;border-left:0.75pt solid #0071ce;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Number&#160;and&#160;Percentage&#160;of&#160;Shares<br/>Beneficially Owned&#160;(1)</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#0071ce;border-left:0.75pt solid #0071ce;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Shares&#160;&#160;&#160;&#160;&#160;&#160;</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Percentage</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">5%&#160;Beneficial&#160;Owners</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">BlackRock Inc (2)</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">55 East 52nd Street, New York, NY 10055</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">13,303,281</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12.4%</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">The Vanguard Group (3)</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">100 Vanguard Blvd., Malvern, PA 19355</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">12,404,050</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">10.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Avoro Capital Advisors LLC (4)<br/>110 Greene Street, Suite 800, New York, NY 10012</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">8,888,888</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">7.2%</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">State Street Corporation (5)<br/>One Congress Street, Suite 1, Boston MA 02114</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">6,354,331</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5.1%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Named Executive Officers and Directors</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Christopher Anzalone (4)</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3,764,252</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">3.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Patrick O&#8217;Brien</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">527,201</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Kenneth Myszkowski<br/></span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">455,433</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">James Hamilton</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">272,122</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Javier San Martin</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">198,497</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Tracie Oliver</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">127,107</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Michael S. Perry</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">131,490</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Mauro Ferrari</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">77,514</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">William Waddill</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">57,111</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Hongbo Lu</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">47,163</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Victoria Vakiener</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">37,944</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Adeoye Olukotun</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">36,740</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">Douglas Ingram</span></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">All Executive Officers and Directors as a group (10 persons)</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #3051f2;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">5,406,970</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #3051f2;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:100%">4.3%</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:112%">*Less than 1%</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Based on 125,073,049 shares of Common Stock issued and outstanding as of January 17, 2024. Shares not outstanding but deemed beneficially owned by virtue of the right of a person to acquire them as of January 17, 2024, or within sixty days of such date are treated as outstanding only when determining the percentage owned by such individual and when determining the percentage owned by a group.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Based on Amendment No. 2 to Schedule 13G/A filed January 23, 2024 by BlackRock Inc. According to Amendment No. 2, BlackRock Inc. has sole voting power and sole dispositive power over 13,160,327 shares and 13,303,281 shares, respectively. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(3)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Based on Amendment No. 7 to Schedule 13G/A filed April 10, 2024. According to Amendment No. 7, The Vanguard Group has sole dispositive power over 12,062,313 shares, respectively, and has shared voting power and shared dispositive power over 211,103 shares and 341,737 shares, respectively.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(4)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Based on Schedule 13G filed November 14, 2024. According to Schedule 13G, Avoro Capital Advisors LLC and Behzad Aghazadeh, who serves as the portfolio manager and controlling person of Avoro Capital Advisors LLC, have sole voting power and sole dispositive power over 8,888,888 and 8,888,888 shares, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(5)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Based on Schedule 13G/A filed October 16, 2024. According to Schedule 13G, State Street Corporation has shared voting power and shared dispositive power over 5,936,957 shares and 6,354,331 shares, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Equity Compensation Plan Information</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table provides information as of September 30, 2024 with respect to shares of our Common Stock that may be issued under our equity compensation plans. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"/><td style="width:50.906%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.756%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#0071ce;border-left:0.75pt solid #0071ce;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="15" style="background-color:#0071ce;padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Equity&#160;Compensation&#160;Plan&#160;Information</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#0071ce;border-left:0.75pt solid #0071ce;padding:2px 1pt 2px 6.37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of<br/>shares&#160;to</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">be&#160;issued<br/>upon</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">exercise&#160;of<br/>outstanding</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">options,<br/>warrants</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">and&#160;rights</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Weighted<br/>average<br/>exercise&#160;price<br/>of&#160;outstanding<br/>options,<br/>warrants&#160; and<br/>rights</span></div><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#0071ce;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Number&#160;of&#160;&#160;<br/>securities&#160;&#160;<br/>remaining&#160;&#160;<br/>available&#160;for&#160; &#160;<br/>future&#160;issuance&#160;&#160;<br/>under&#160;equity&#160;&#160;<br/>compensation&#160;&#160;<br/>plans&#160;(excluding&#160;&#160;securities&#160;&#160;<br/>reflected&#160;in&#160;&#160;<br/>column&#160;(a))&#160;</span></div></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.8pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders (1)</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,600,427</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$41.75</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">4,600,465</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:16.8pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders (2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">291,401</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 17.8pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$49.61</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">510,600</span></td></tr><tr><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;border-top:1pt solid #0071ce;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:16.8pt;text-indent:-12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;border-top:1pt solid #0071ce;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">6,891,828</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;border-top:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;border-top:1pt solid #0071ce;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">$42.08</span></td><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;border-top:1pt solid #0071ce;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-bottom:1pt solid #0071ce;border-top:1pt solid #0071ce;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">5,111,065</span></td></tr></table></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(1)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Includes options outstanding representing 1,290,720 and 32,151 shares of Common Stock under the 2013 Incentive Plan and the 2021 Incentive Plan, respectively. Also includes 1,608,510 and 2,768,776 RSUs subject to the 2013 Incentive Plan and the 2021 Incentive Plan, respectively. There is no exercise price associated with a RSU award. Accordingly, these have been excluded from the column in the table reporting the weighted-average exercise price of outstanding awards.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">(2)</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">Includes 655,645 inducement option grants and 244,625 inducement RSU grants issued to newly hired employees granted outside of the Company&#8217;s Inducement Plan and 0 inducement option grants and 291,401 inducement RSU grants issued to newly hired employees pursuant to the Company&#8217;s Inducement Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Material Features of the Inducement Plan and Stand-Alone Inducement Awards</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s Inducement Plan was established by the Board during fiscal year 2024 to advance the interests of the Company by providing for the grant of stock-based awards. The Company has also granted inducement awards outside of the inducement plan. In accordance with Nasdaq rules, this plan and the stand-alone awards are used to offer equity awards as material inducements for new employees to join the Company. Subject to adjustment for certain changes in our capitalization, the maximum aggregate number of shares that may be issued under the inducement plan is 832,950. The equity awards granted as inducement awards both under and outside of the inducement plan are typically in the form of stock options with exercise prices equal to the fair market value of our common stock on the date of grant and/or restricted stock units. The inducement plan also provides for the granting of other types of equity awards, including stock appreciation rights and restricted stock awards.</span></div><div id="ied6c21fce27e4152aa85d0d2377cea12_100"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE<br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Review and Approval of Related-Party Transactions</span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Our Board has adopted written policies and procedures for the review and approval of related-party transactions and has delegated to the Audit Committee the authority to review and approve the material terms of any proposed related-party transactions. To the extent that a proposed related-party transaction may involve a non-employee director or nominee for election as a director and may be material to a consideration of that person&#8217;s independence, the matter may also be considered by the other disinterested directors. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Pursuant to our Corporate Code of Conduct and our Nomination Committee Charter, each of our officers, directors and employees must disclose related-party transactions to our Board. In order to avoid conflicts of interest, our executive officers and directors may not acquire any ownership interest in any supplier, customer or competitor (other than nominal amounts of stock in publicly traded companies), enter into any consulting or employment relationship with any customer, supplier or competitor, or engage in any outside business activity that is competitive with any of our businesses, without first disclosing the proposed transaction. After the proposed transaction has been disclosed, a determination will be made by our Board or Audit Committee as to what course to follow, depending on the nature or extent of the conflict. Furthermore, our executive officers and directors may not serve on any board of directors of any customer, supplier or competitor unless such board service has been disclosed to us and approved by our Board. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">In determining whether to approve or ratify a related-party transaction, the Board and/or Audit Committee may consider, among other factors it deems appropriate, the potential benefits to the Company, the impact on a director&#8217;s or nominee&#8217;s independence or an executive officer&#8217;s relationship with or service to the Company, whether the related-party transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances, and the extent of the related party&#8217;s interest in the transaction. In deciding to approve a transaction, the Board or Audit Committee may, in its sole discretion, impose such conditions as it deems appropriate on us or the related party in connection with its approval of any transaction. Any transactions involving the compensation of executive officers, however, are reviewed and approved by the Compensation Committee. If a related-party transaction will be ongoing, the Audit Committee may establish guidelines to be followed in our ongoing dealings with the related party. Thereafter, the Audit Committee reviews and assesses the ongoing relationship with each related party to see that it is in compliance with the Audit Committee&#8217;s guidelines and that the related-party transaction remains appropriate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:112%">Certain Relationships and Related Transactions, and Director Independence</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">As of September 30, 2024, a majority of the members of the Board are independent directors, as defined by the Nasdaq Marketplace Rules. The Board has determined that all of the Company&#8217;s directors are independent, except Dr. Anzalone, the Company&#8217;s Chief Executive Officer. Douglass Given was independent during the period he served on the Board. The Board has determined that all members of the Audit Committee who served during 2024 were independent directors under the rules of the SEC and the listing standards of Nasdaq Marketplace Rules. The Board has determined that all members of the Compensation Committee are independent directors under the listing rules of Nasdaq Marketplace Rules. Non-employee directors do not receive consulting, legal or other fees from the Company, other than Board compensation. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Dr. Bruce Given is the Company&#8217;s Chief Medical Scientist and the brother of Dr. Douglass Given, the Company&#8217;s former Director and Chairman of the Board, who stepped down effective as of December 31, 2024. Dr. Bruce Given earned base salary and bonus of $582,400 during fiscal year 2024. His current base salary is $605,696. In January 2025, Dr. Bruce Given was awarded 100,000 RSUs, and this award vests in four annual tranches from the grant date. The grant date fair value of this award is $1,979,000.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">Vincent Anzalone is the Company&#8217;s Vice President, Investor Relations and the brother of Christopher Anzalone, the Company&#8217;s Chief Executive Officer. Vincent Anzalone earned base salary and bonus of $382,955 during fiscal year 2024. His current base salary is $340,240. In January 2025, Vincent Anzalone was awarded 25,000 RSUs, and this award vests in four annual tranches from the grant date. The grant date fair value of this award is $494,750.</span></div><div id="ied6c21fce27e4152aa85d0d2377cea12_103"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee regularly reviews and determines whether specific projects or expenditures with our independent auditors may potentially affect their independence. The Audit Committee&#8217;s policy is to pre-approve all audit and permissible non-audit services provided by our independent auditors. Pre-approval is generally provided by the Audit Committee for up to one year, detailed to the particular service or category of services to be rendered and is generally subject to a specific budget. The Audit Committee may also pre-approve additional services of specific engagements on a case-by-case basis. All engagements of our independent registered public accounting firm in 2024 and 2023 were pre-approved by the audit committee. </span></div><div><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:112%">The following table sets forth the aggregate audit fees and other services provided during the indicated fiscal years. These include amounts billed and expected to be billed by our current independent auditors, KPMG, for fiscal year 2024, and by our former independent auditors, RS&amp;J, for fiscal year 2023:  </span></div><div><span><br/></span></div><div id="ied6c21fce27e4152aa85d0d2377cea12_106"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ied6c21fce27e4152aa85d0d2377cea12_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">        (3)             Exhibits. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed as part of this Form 10-K/A:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.121%"><tr><td style="width:1.0%"/><td style="width:9.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.424%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:86.731%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.425%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20240930xex311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20240930xex312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Instance Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">104*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#212529;font-family:'Times New Roman',serif;font-size:9pt;font-weight:400;line-height:114%">The cover page from the Company&#8217;s Annual Report on Form 10-K/A for the year ended September 30, 2024, formatted in Inline XBRL (included as Exhibit 101)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:36pt;text-indent:-36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="ied6c21fce27e4152aa85d0d2377cea12_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K/A to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Dated: October 10, 2025</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.295%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Anzalone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Anzalone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report on Form 10-K/A has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:29.203%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:29.204%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Anzalone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President and Director, Chairman of the Board of Directors  (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">October 8, 2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Daniel Apel</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">October 8, 2025</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Daniel Apel</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mauro Ferrari</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">October 8, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Mauro Ferrari</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Douglass Ingram</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">October 9, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Douglass Ingram</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Hongbo Lu</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">October 8, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Hongbo Lu</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adeoye Olukotun</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">October 8, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Adeoye Olukotun</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael S. Perry</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">October 9, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Michael S. Perry</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Victoria Vakiener</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">October 8, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">Victoria Vakiener</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William Waddill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%">October 8, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:100%">William Waddill</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>arwr-20240930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i593b884936324c69a4b6d0df24b5494d_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-top:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher Anzalone, Chief Executive Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:115%">1. I have reviewed this Annual Report on Form 10-K&#47;A of Arrowhead Pharmaceuticals, Inc.&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; October 10,2025</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Christopher Anzalone</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Chief Executive Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>arwr-20240930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ifdb48569157d486694fd13456e690a61_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13a-14(a) OR RULE 15d-14(a) </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">OF THE SECURITIES EXCHANGE ACT OF 1934 </font></div><div style="margin-top:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">I, Daniel Apel, Chief Financial Officer of Arrowhead Pharmaceuticals, Inc., certify that&#58; </font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K&#47;A of Arrowhead Pharmaceuticals, Inc.&#59; and</font></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; October 10, 2025</font></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Daniel Apel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Daniel Apel</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:10pt;font-weight:700;line-height:120%">Chief Financial Officer</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>arwr-20240930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:90d8cf58-09bf-4ffe-85e6-3e61bc93c31b,g:f79393e3-6fdf-4c70-89e4-574c2bfaeb5d-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20240930" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20240930">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20240930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20240930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.arrowheadresearch.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>arwr-20240930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:90d8cf58-09bf-4ffe-85e6-3e61bc93c31b,g:f79393e3-6fdf-4c70-89e4-574c2bfaeb5d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_bf1774e6-8466-4690-84a8-e2602c2d29f6_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_8951ff94-c267-4110-b7af-59a5829e8b04_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_85e1783f-7035-45b7-a1ed-aa031875313d_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_ca5d60e0-7820-43b2-ab63-9500ca10a2a3_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_f3c79834-1ef3-4d21-9d0d-660d5d93a3aa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentDescription_249e5212-0fd4-4f1f-aca1-1a3b575511d6_terseLabel_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:label id="lab_dei_AmendmentDescription_label_en-US" xlink:label="lab_dei_AmendmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Description</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentDescription" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentDescription" xlink:to="lab_dei_AmendmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_a8dbfaff-b768-4a1c-9fe1-da638f001c2a_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0e88e110-c663-4848-b1e3-4381c78aefb4_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_0fbdf819-aaff-4439-b44d-11b76ad2a586_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security12b Title</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_49dc342b-1b6c-499a-87c9-1368961b0f3f_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_f3758c6f-caef-41d1-8fa7-2c44f713ee6a_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_f534acf7-cf50-499d-b56c-2441f791c740_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_b773c42b-8853-4e24-9ae3-094b708c04a9_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_3d25dd6d-7584-486c-8910-2c536f3fc26d_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_2efc7df9-74c2-4a5e-bf7c-427c65077e51_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_825a1f22-7b09-45ba-b1a6-f8b24ad3ec9a_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Award Types</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_719da167-8034-4e88-9e26-bc77d7fe324f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_33a09313-4458-46ff-825a-ede689394e76_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a466b15d-b0fa-40dd-9fcb-e5fb390e8f58_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5c65a336-f126-4342-a600-12a8a3a19d8f_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_78076928-4bed-4d33-bc91-390309a6a08d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2643a670-8cf6-4ad3-b0ba-41e1fdd9df44_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_878bc580-f672-4ff8-b272-35c7c1299f74_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_04cbd1d1-d756-413c-a22a-e5a9aaf3c1f0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_f142d811-af14-4b46-8359-bfc45f09e0dc_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_98dd06bd-add6-4912-b663-74aa9d764bf7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_770cf45e-ee51-4c93-80e0-97222aade2ad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_36c7a4a0-7df6-46ca-8e60-105ae4169ddb_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_b2e0c9d7-01d4-4f69-b362-a5cc3b83a3b1_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_4a788064-7c6d-4528-a891-9d367cc1f3a8_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_6124cc36-fe7c-4cef-85fe-b0f3ffe3d1d9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_3f709c90-65e0-4b20-91f1-ca6fb06545c2_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_e22f68cb-f448-4eab-b98e-70223284479c_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_f2a768c5-6053-425e-9979-223609fa9dc7_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_ba2165c1-42bc-4410-9eec-5d8f725c873c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_f0cff6f9-147c-48a0-999b-a2bf6d1ce5a7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_c3043796-d3a1-492d-84b6-d35df66784de_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_3952c17d-f05e-47b7-b901-53601eb5be28_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>arwr-20240930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:90d8cf58-09bf-4ffe-85e6-3e61bc93c31b,g:f79393e3-6fdf-4c70-89e4-574c2bfaeb5d-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CoverPage" xlink:type="simple" xlink:href="arwr-20240930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_94af93bc-a7cf-4f92-acea-a2346b2dc2e9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_DocumentType_94af93bc-a7cf-4f92-acea-a2346b2dc2e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_b44252fe-7787-4c60-8214-e97a9d34f5cb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_DocumentAnnualReport_b44252fe-7787-4c60-8214-e97a9d34f5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_8e1929bd-8c15-47cf-a9b8-ae05d9ae6726" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_DocumentPeriodEndDate_8e1929bd-8c15-47cf-a9b8-ae05d9ae6726" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_cf3b523c-69a8-4fdc-a6d3-b7b7d325aa7d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_CurrentFiscalYearEndDate_cf3b523c-69a8-4fdc-a6d3-b7b7d325aa7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_711f6a1a-9473-44a0-b85d-7b9c0516a876" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_DocumentTransitionReport_711f6a1a-9473-44a0-b85d-7b9c0516a876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_10c33d66-089c-4d66-8c58-a7e34484f6ff" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityFileNumber_10c33d66-089c-4d66-8c58-a7e34484f6ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bae792d0-b860-4193-b70b-976168e6a458" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityRegistrantName_bae792d0-b860-4193-b70b-976168e6a458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_15c06b0a-841a-4850-bd7e-591a0fa3be71" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_15c06b0a-841a-4850-bd7e-591a0fa3be71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d651e5c2-08bf-44aa-a825-62e22114532f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityTaxIdentificationNumber_d651e5c2-08bf-44aa-a825-62e22114532f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_f906c1d7-4c17-40e9-94fe-bb03453ffcce" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_CityAreaCode_f906c1d7-4c17-40e9-94fe-bb03453ffcce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_30880356-b5c2-43ea-864c-d38fd36c3bb5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_LocalPhoneNumber_30880356-b5c2-43ea-864c-d38fd36c3bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_92b73234-2684-4f55-9300-98a9a6617e7c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityAddressAddressLine1_92b73234-2684-4f55-9300-98a9a6617e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_a0394fd9-3a38-433e-b19a-3cc93665492c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityAddressAddressLine2_a0394fd9-3a38-433e-b19a-3cc93665492c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_320349f3-2797-4c17-a9e3-844b60555c67" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityAddressCityOrTown_320349f3-2797-4c17-a9e3-844b60555c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_390b2cc0-96bf-4c2e-9831-70490437aa14" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityAddressStateOrProvince_390b2cc0-96bf-4c2e-9831-70490437aa14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_89dc0578-0f95-4b67-9f51-1e4c1f7a59cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityAddressPostalZipCode_89dc0578-0f95-4b67-9f51-1e4c1f7a59cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_68a83521-5428-45dd-961b-8f35f23d3c13" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_Security12bTitle_68a83521-5428-45dd-961b-8f35f23d3c13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f9785e1c-7412-44f0-b360-0661b6313ec5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_TradingSymbol_f9785e1c-7412-44f0-b360-0661b6313ec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_e57795b6-456f-4406-9166-a22c8003cc12" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_SecurityExchangeName_e57795b6-456f-4406-9166-a22c8003cc12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_a6202a15-69cf-4651-8f39-a6e786cc5cbf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_a6202a15-69cf-4651-8f39-a6e786cc5cbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_11137f48-5bc0-47cd-84e9-bbc9d3b8a38d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityVoluntaryFilers_11137f48-5bc0-47cd-84e9-bbc9d3b8a38d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_07fec3fa-053c-42b5-9fbc-1b16ceba17a9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityCurrentReportingStatus_07fec3fa-053c-42b5-9fbc-1b16ceba17a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_f6eccaa7-eaa9-445c-b7dd-96c117676655" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityInteractiveDataCurrent_f6eccaa7-eaa9-445c-b7dd-96c117676655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_f40c6eb7-e217-402f-b523-500f66fdf5a1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityFilerCategory_f40c6eb7-e217-402f-b523-500f66fdf5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_6a5cb10a-1e57-48d6-98a7-01d4952b747d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntitySmallBusiness_6a5cb10a-1e57-48d6-98a7-01d4952b747d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0abe7b70-afde-4ce2-bf97-732c45312c89" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityEmergingGrowthCompany_0abe7b70-afde-4ce2-bf97-732c45312c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_bd4b923a-b6ed-46c4-9afb-9735fec462e3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_bd4b923a-b6ed-46c4-9afb-9735fec462e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_052db588-90eb-454a-a7ef-51c83d1545f3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityShellCompany_052db588-90eb-454a-a7ef-51c83d1545f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_b2b67def-0087-46e3-8a75-fac3fda68d55" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_b2b67def-0087-46e3-8a75-fac3fda68d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f01a2e4d-0ee7-4cd6-8a21-6f97e9159a44" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityPublicFloat_f01a2e4d-0ee7-4cd6-8a21-6f97e9159a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_db37c88f-4ca3-4e81-b1b2-923f82c4749d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_db37c88f-4ca3-4e81-b1b2-923f82c4749d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fb439858-f17f-4d02-9461-b233c4a0acb7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fb439858-f17f-4d02-9461-b233c4a0acb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentDescription_351d87b2-da86-43f4-95af-debc388e42cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentDescription"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_AmendmentDescription_351d87b2-da86-43f4-95af-debc388e42cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_8df9386e-0f6b-4ad6-bcf9-97312d744ca6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_DocumentFiscalYearFocus_8df9386e-0f6b-4ad6-bcf9-97312d744ca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_84dc2a64-fbb7-4254-b202-814dff21bbd0" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_84dc2a64-fbb7-4254-b202-814dff21bbd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f2fc1ee2-5c40-4b14-9348-727cd0c7154f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_EntityCentralIndexKey_f2fc1ee2-5c40-4b14-9348-727cd0c7154f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_8f7ad2fb-5cc4-4199-aadb-f78683e94489" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fe6551f9-cc2b-4836-a241-dd31c70086d0" xlink:to="loc_dei_AmendmentFlag_8f7ad2fb-5cc4-4199-aadb-f78683e94489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>arwr-20240930_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 arwr-20240930_g1.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[@ .061O8F4 90     !_]L 0P " 0$!
M 0$" 0$! @(" @($ P(" @(%! 0#! 8%!@8&!08&!@<)" 8'"0<&!@@+" D*
M"@H*"@8("PP+"@P)"@H*_]L 0P$" @(" @(% P,%"@<&!PH*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*_\  $0@"
M^ 3* P$B  (1 0,1 ?_$ !\   $% 0$! 0$!           ! @,$!08'" D*
M"__$ +40  (! P,"! ,%!00$   !?0$" P $$042(3%!!A-180<B<10R@9&A
M""-"L<$54M'P)#-B<H()"A87&!D:)28G*"DJ-#4V-S@Y.D-$149'2$E*4U15
M5E=865IC9&5F9VAI:G-T=79W>'EZ@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>H
MJ:JRL[2UMK>XN;K"P\3%QL?(R<K2T]35UM?8V=KAXN/DY>;GZ.GJ\?+S]/7V
M]_CY^O_$ !\!  ,! 0$! 0$! 0$        ! @,$!08'" D*"__$ +41  (!
M @0$ P0'!00$  $"=P ! @,1! 4A,08205$'87$3(C*!"!1"D:&QP0DC,U+P
M%6)RT0H6)#3A)?$7&!D:)B<H*2HU-C<X.3I#1$5&1TA)2E-455976%E:8V1E
M9F=H:6IS='5V=WAY>H*#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6V
MM[BYNL+#Q,7&Q\C)RM+3U-76U]C9VN+CY.7FY^CIZO+S]/7V]_CY^O_:  P#
M 0 "$0,1 #\ _?RBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %?(G_  64_;3\7?L@?LSVUM\+]3-EXL\::@VFZ7J"8WV%NB;[
MBXCS_P M #&BG^$RAARHKZ[K\S/^#DOPCK5]\/\ X4^.[>W<Z=IFL:K8W<@'
MRK-<Q6TD0/N5M9<?0T 9/[)7_!"GP1\>O@9I?QR_:G^,'C(^*?&=@FK1PZ3>
M0 VT<ZB2(W#W$4KSRLA5FY3!8KR1NKV#Q[/\0O\ @C?_ ,$V_%&E1_%E_&&K
M?\).]G\.K_4;=A]A2Z2,11-&[.O[D17,P4$HS8& &('TY^QG\4?"/QD_97\
M^/\ P5J4-Q9W7A6RCD6%P?L\\<*1S0-CHT<BLA'JM?+?_!?VP7QU^PO%J?A7
M4(+Z/PI\2K&371:3K)]D)M;F#9+M)V,'NH/E.#^\7U% 'BW["O\ P2&T?]MK
MX2Q?M:_MF_%_QCJ.K>,Y);G3;>QU)!/Y =D$\\T\<I=G*ED10JJFWD[MJ\-X
MW\.?$;_@A]^W?X8M/ 7Q-U35OAKXJ\FYOK+4) !=6)F\FXCG1<1M<0C#I,JK
M]Y. "ZG]"?\ @D]\1/#/Q&_X)_?#:Z\-ZA#,VD:&NDZC%&X+6]S;,8W1Q_"2
M K@'JKJ>A%?#O_!?#6K'XW_M<?"W]F[X?7$=_P"(K6S-K<V]L=[17&H7,200
MMCH^(U?:>=LBGHPH U_^"_\ X=?QY^T_\$_A]<:E)!;ZM;26F]?F$)GO88FD
M"GC.,?7:*[__ (()_%_Q/X;MOB/^PY\3+N1=:\!:Y+=:?:3REC%%YIM[N% >
MB1W"(V/6Y)KD?^"W,2P?MM?L\0*20EQ H)/)QJ4%9O[9VOP_\$X?^"Q?A[]J
MEK:>+PAX]L?/U]+6(D,KI]EO5"CEV5EANB!U9Q]* &?\%HO&WB+]J7]K71_V
M.O ^JRC2_ 'A+4/$?B<1-\BW*6,EXV\=,K;11JA/1KIAWY[+_@B#?WL?_!,_
MXME+R4?9_$.LFW(D/[H_V/:G*^G//'>N$_X)W^#_ !#\<?A9^U5_P4(^(EH3
MJ/BCPSK^F:2S\B(26DEU<JF?X5!M(U(Z!&7U%=M_P1$_Y1G?&+_L8-9_],UK
M0!\Z?\$GO^"97P2_;W^'OC;Q%\4?&?BK2;[P_J5O:Z:= NK9(B)(G8M*DT$A
M?!4<*R\9^M>V?\$6/BY\9/A?^V7\0_V#_$_C^Z\2>&/#D6J1V#3S-)':7-A?
M);>;!N)\J*568E <9V'KG/A7_!*KX'?\%!?C%X%\91?L;_M':+X$T:/4;>'Q
M''J$TB3W$KQ/L>(I:RD87<,AT()R/6OT6_X)O?\ !,;PS^P?%K7CSQ+X[;Q5
MXY\10>3JFN- 8H;>WWB1H8@S,S;I K/(YRQ1/E7!R >"?\%P?%>O_'OXV_![
M_@GOX!U'9>>(]:BU+6"HW"$RR&UMI' (XC3[7(P/8*?0UG?\$#/B;K_PQ^('
MQ4_85^(4ODZGH.JRZE96KL?DG@E%G?(,_P"TMLP ]'/K7@GA+]M?5-:_X*E>
M,_VWM*^ ?B/XE:?I-S=6/ABS\/I(19Q>7]CM9V98I H:V25MN!EY"0>#G)E_
M:^U#P)_P57T']M#4?@GK_P -]*\0ZS ->T?7HW7?;RPK:7LREHH]XVL9L8XD
MYSTH ]S_ .#E220ZM\'(?,;9]GUX[<\9W:?SBN8_X*5?\$MO@_\ \$_O@UIW
M[27[.GQK\8:9K=GXAM[2*WU35H?-D,BN0UM+;Q0NDB[-Q^]E0QXQSTO_  <I
M,KZQ\'&5@0;772"#U^;3Z\D_X*(?L.>._P!A+QWX!^*OQA^(6J?&OP%<ZJ8+
MNS\27=U;,DJ@.]HSK.[)YL89D=&',3!E(7Y@#Z=_:O\ BSX]^./_  0%B^*7
MQ.D:37=5TK1CJ-PZ!6N6CUF")9R!@9D6-9#@ 9?@ 5RO@KXP_$SX(?\ !NYH
MOC3X4:E=6&JRRWM@VJV;%9;&"?Q#=122HPY1BK; PY4R @@@&O9_^"IGBCX>
M>-?^".NJ^+?A);V\/A?4=)\.SZ!;VL*QQP6C7]F8H@B\)M7"[!]TKCM6I_P2
M:\,_#[QU_P $GO /P^^)^G:??:-X@36M/NM-U)E\N\$FL7_[H D98@$C'S C
M(P1F@#Y,_P"">'_!,+]AW]MO]F2'Q9K/QRU^3XE3/<2>(+33=8MUETF43.(B
MUM)&SO&R!&,A/SEF 92"%^M?V\_CUXO_ .":W_!.C0_#WA+QG+K'B^.QL/">
MA^([Z']XTZV[>9?-&S/\PBAD90S, [)DL,Y^3/\ @HO_ ,$EM/\ V(?!E[^V
M/^R=\9-7T2S\.WUO)+H]U?,EY8^=.D*-:7<95VP\BC8XW;<G>Q&#F?MX?%SX
MJ?M:?\$@?A!^T'\08FN=4T_QO<:?KU]%$%6Y94NH([IE487=Y*AB !YCG  (
M% '=_L5?\$6O!_[4WP4T[]IK]L'XM>,[_P 0^.;8:I:Q:=J<8DCMI1F*6>:X
MBE::1TVR#H%# $-7">&(/BC_ ,$9?^"D?A[X+:1\2=0UCX;>,Y[)Y[6]?"3V
M%U.UOYTD8^1;FWD1CO0 LJ#[JR%1^CW_  3J^(GAGXF_L.?"W7_"VH0SQ6O@
MG3M-NUB<'R;JUMTMYHR!T*R1MP>V#WK\^?\ @K_JFG_M!?\ !4/X6_ KX<W*
M7^J:9'I>F:E]E;=]FN9[]I3&V.FR%DD;^Z&.>AH A_X+T^!?%'Q9_;R^&OPL
M\)J9M1UGP/;VNE6K,=LES+?WBHH]"[!%S],]*^C/^"&'[95Y\<_@'<_L]_$+
M59)?%GPZ"PP&[<F:ZTICMA8[N286S"WHHASRU>:_\%+/^4T7[.'^[H/_ *>K
MFN,_;9\+:S_P2T_X*<^&_P!LGP!ITL?@?QS?23:W9VJ83,A5=2M<#C+!EN8P
M>-YX&(Z .T_X-R&8Z;\:,DG_ (G6DGGZ7M?H5\;/BEHWP0^#_BCXQ>(8C)9>
M&-!NM3GA5L-,(8F?RU/]YBH4>["OST_X-QI(9=,^,\MO('C;6=(,;C^)=M[@
MU]E?\%&/"NK^-/V%?BKX?T&!Y;I_!=[-%%&,M)Y2><R@=R50@#OG% 'YR?L5
M_LD?$+_@LMX[\5_M0_M?_%S74\.Z;JQT_3M.T6=4Q.465K:W\U72V@BC>+("
M%G,F2=VYC!^WW^PMXF_X)*Z[X4_:M_8[^,'B.VT^;65T^ZBU.X1YK>Y*-,B.
MT2(EQ;RK%(K1NG&T EM_'T'_ ,&ZOQ$\,ZK^RSXL^%\.H0C6='\;2WUS9[QO
M-K<6MNL<N.I!>"5<]MH]:?\ \'$?Q/\ "FB_LK>&OA/-J,+:YKGC"&]MK'>/
M,6UMX)Q)-CJ 'EB3/?<?0T <[_P63^,MO\?O^"4GPP^-.G0?94\5>+-'OI[2
M-R1#(^F7[20Y[A) 5_X#FL?]ES_@A#^R[\<?V<? WQC\3?%/Q]:ZCXH\+66I
MWMM87MDL,4LT*NRH'M68*"QQDDX[FL#_ (*%^!=:^&W_  0Z^!GA'Q%;/#>P
M^(-(GN()1AXFGT_49]C#LRB0 CL016U^RO\ \$A/BW\4_P!GWP'\5]+_ ."A
MOC?0+37?#5CJ,&A6%E/Y=BDD2N((V%\HPH.T'8!Q]WM0!^G6AZ1:^']$L]!L
MGD:&QM8[>%I6W.510H+'N<#DU^:'_!97]J+XV_$W]I'PO_P3A_9[\17&F-K;
M647B*6TN6A:]NKUPL-M*Z_,MND161P.&\SY@0@S^G-?D#^VGKME^SY_P7HT'
MXO\ Q(E%GH-]JN@7XO;CB.*T-G%8O.2?X4DBE8GML- 'LS_\&Z?P4T[P% WA
MC]HCQE9^-[:%9(M=*6_V$7( (9;=$65%W#C$Y8=<G@5Y)_P7]\/>)/!_A/\
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MEY_P3O\ A'^W!\4/B!X(^)GB_P 1Z9;>$H87L)="GMTDE+SRQGS#+#(#P@Z
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M\*M$NV75_B+J\>FI'$?WGV*$K-<LN.H)$,1'<3FO1/\ @CQ_RC<^&'_7A?\
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M^ORZ+>:RVGVMY:_8Q/;V1*J UN7V$Q+D;\\G!'&/D'_@E#_P2\^"7[>?PO\
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MMU>,]!T6UFB^&GQ6\(ZG:VD$2DQ1VEY%(JH .-UI=%?5O)Q_STKZF_X-T_\
MDR?Q3_V5.]_]-NFT ??-%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1N9(6W;CCR\8^;(^E:* /C']LC_@DQK?[8?PT^$W@CQ-^TFUCJ'PUT%]-O\
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M<.DCX?"R#^'_ .P_/^W_ &:\DNEQ/YR^5N,FT_(V ,\]*] _;4_9%\"?ML_
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MF6/V$/B%XY\=GXSGQ0/& B2*U_X1_P"Q_9$2623EO/D\PGS,=%^[GO@?55%
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M:""&56'QNG_!"#]H>]T*+X3Z]_P44UV?P%"RA= &GW9@V*V0JVK7IA0\#!Y
M/.#BOTOHH \T_9._92^$_P"QM\'K3X-?"*QG6RBF:YO[^]</<ZA=.%#SRL
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17YY?\%(?VA/^"U/P
MX_::NO#/[#7P.&O> ET:TDM]0/AJ&ZS=,I\Y?,>12<''&.*\%_X; _X.:O\
MHUL?^$3;?_'J_3\K\*\RS7+J6,AF&#@JD5)1GB(QFKZVE&VC75=#Q*^>T:%:
M5-T:CL[74&U\F?K]J&KZ9I/E?VE?1P>?((XO,;&YCVJS7R_X \9?%7Q[\.=
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M !FFZM\:/@[H'A2R\=Z[\6/#5EH>I8_L[6;O7;>.TNL\CRYF<(^>VTFOG?\
M:N_9[^".G^/_ -G?X0:5\*]#L_"\OQ0G>YT*RTY(K:X,6AWA3S40 2_ZF,-O
MSO5-K9&16=\2;G]GGX+_ +>$E]^TWI_AG0O!A^%EK9_#6Y\064,6C6DXO+AM
M1MXMZ^3%<NIMF(&':, #(XH ^K(?&/A&XFTVVM_%6FO)K,+RZ/&E]&6OHU4.
MSP@']ZH4AB5R "#T-(?&G@X66J:D?%FF?9]#>1-:G^WQ[-/9(Q(XG;.(BJ,'
M(;&%()X-?!F@Z/+\+_V6;']K+PYHMWI_A7X=?M ZAXG\%VOV-XGB\%7EVUG<
MI#"P#1P-#<SW")@?(B$#!&>)TK1OB#9+:?!/6(M0\S]LB+3O$=XS%O\ 0&DU
M.:ZU>( <+MT>>VCV\8\N@#[9T']K7PI'\=OB'\.?B#XG\-:#H'A.U\/OH^MW
M^K1VZWSZC!<2E2\KA&QY*[ O)!/6O3_%'CGP5X'\/MXL\:>,-+T?2DV[]3U3
M4([>W7=]W,DC!1GMSS7S1X)^!OP?^)/[=WQ\?Q_\--&UG[%X2\+6%BNI:>DR
MV]O-9W8ECC5@0FX1Q@D '"@9Q7S[X9U/Q+%\'/V2O'?CWXB^&_#_ (1L?A]J
M%N/$?CWPS)JVCV.K%+>.V^T(+JV2*1K=)DAFDDPN)% RV0 ?HK+\0_ $'A ?
M$*?QSHZ: T(E77'U.(69C)P'\[=LVYXSG%.\+^/O OC?PY_PF'@OQKI.KZ00
MQ&J:7J45Q;87[W[V-BO'?GBOBA->^'?P'_9LE\1:%X]^&'Q+T+QC\<T<>)+O
MPF;?PCX,GN+8>;="#[3.#"DD;$,LZ)YUX?G3G/ 7\^H^*O@?^U5_P@FN:1XD
MT>X\1>%+W4KCX=>')]-T_4=.VVO]J26EL9YR5>VAF$DB2NLVQV!PP% 'V;)^
MU9X<UW]HSP+\(OAIKGA_Q%HOBK1->N[[6=)U1+G[-/8&R"Q*T3%,G[4VX'D8
M7I5O]I#]HOQ)\%/$7@?P1X(^%?\ PEFN>.]9N=/TRR?7$T^.(P6DMT[O*\;C
M[D3 #'7O7S_X$\2_LF>-?^"CGPQ\2?LI67AZ:T'P[\06^L:OX3TU8K&;;]@,
M$'F1J(GEB1GW(,O&LD8?&5%=U^W;H7BKQ+^T#^SQHG@GQO+X;U.?QOJXM=;A
MT^*Z:V(T2[9B(I@4?*AE^8<;LCD"@"3Q;^WUK>C_  >\=:]-\))= \<_#OQ3
MH&D>)/"FM7J7,4:ZG?6D45Q%<6[8EC>"Y9T;Y2&3#*,<^^^%?B+\/O'5Q?6G
M@CQUHVLRZ7/Y.IQ:5JD5PUI)S\DHC8F-N#PV#P:^3_VR_P!F'PW\)OV)OB-/
MKOBS5O%OB#QWXS\+7/C+Q)K9CCN-18:WID"1JEND:0Q1Q#8B(!M!/)/-;GB;
MP?X#^!7[=D$GPO\ A-8P69_9RUV2[\-^'M/C@75!::A8F"#RXUVL^))(U)!.
M),=.* /HSPM\6_A3XYUR[\,^"OB;X>UC4M/!-_I^EZU!<3VP!P?,CC<LG)QR
M!S2+\7OA,^HG2%^*'ATW:VMQ<M:C6X/,$%N[1SR[=^=D;HZNW1&1@Q!!KX0^
M GQ.\,?$K]JG]FWQ/X1UOX4P-=1:V+WPK\,?"4MK+X<BET*YE&GW]W]I='=7
MB'[EH(&W0LP4@5VWP"^%'PXTW]A?XW_$^U\$:;_PD>HZC\1!<ZY):*]V56ZU
M")8UE8%D0(H&Q2%R6.,LQ(!]<VGQ?^$M_J%[I%C\4?#LUWIEB+W4K6+6X&DM
M+8J&$\BA\QQ[2#O;"X(.:LZ3\1OA[KWA$^/]"\=Z->Z"L;2-K=IJD4EH$4X9
MO.5BF 0<G/&*^*8OV;O@0)?V-M.'PFT00ZO#,VM(+!?^)D3X>DOF^TG&;@&Z
MACF(D+ LN3G)J;Q%XH\+_L^:1^TY9:9\)/#VJ^'+/XL>'2FA:SIX;1=->[L=
M*>74+F%%.(8I2+E]H!S&#E?O  ^T/!/Q%^'WQ+TR36OASX[T;Q!9Q2F*6[T3
M5(KN))!R4+1,P#<],YIGA/XG_#7Q]>WNG>!?B'H>M7&FOLU&#2=6AN7M6Y&V
M18V)0\'AL=*_/Z.]\7^,]6_::MO@%XW\)^)=2U3X&Z:UIJ'PI\-3:9I]]<))
MJ,;BW7[5<BYG$>Z(3Q28+ ( KHPKT/QUXK_98^)W['GC/PO^P!9:!/X\@^#M
MS#:P^$=("ZC9Z>?($UG-)$@:*=L "!V$K.I*J2K$ 'U[X2^*7PR\?WU[I?@3
MXBZ%K=SIK[-1M](U>&YDM6SC$BQL2AR#PV*L)X\\#R:!;^*X_&>DMI=W.D-I
MJ0U&(V\TCR>4B))NVLS2$( #DL<#GBOCS]E'1_A!XY^/GPY\9?#W]K+X5:E=
M>%_#U];V_@[X=_#MM)OIK":V5#;WY.I7#1+#(L4@26,$21XR"QKS'1_C9\-[
M']@WX<?LQ3Z^3X^\/_%G1K/Q%X72VD:ZTEH?%*,SW2A?W$9W1A'?"NTJ*I).
M* /N'PC^U3\%/&OQK\2_ '1O&-H/$7A=K1+N"6^@"W4DZ2OY5N!(7D>+R7$J
M[04. ?:YX!^,UK?_  9L_BU\8)_#GA))!+]O*>++>\L+7;.\:XO0$C?<%4G@
M;68KR5S7A?PN3X&_#_\ X*:_%/0O&&E^'-*\2>)M-\.7W@>.\L88[G4'^S7P
MO9;0E=S-N!\TH<GDM7B?PJU#P1X9^$'[*WC/X]QVB_#/3M1\7C7+O680^F6>
MK27$RZ;-=;@44?\ 'VJ._"NX.0<$ 'WOJGQ@^$NA^$(/B%K7Q1\.6>@76/LN
MN76MP1V<V<_=F9PC=#T/8UQWQV_:(_X5UH/P_P#$G@$Z7KECXU^(FC^'_MJ7
M/FP_9;R1U:>)XVPS +P<E:\+^,_QX_9JT)_AM;?!C0?A+H_A+Q%J>O2V?Q*\
M;>%]^@Z5<1>4TZVR!K97FNG+;9%FC200.5:0\5YC\))UG_9W\$16=W:3647[
M:D?]FMINCRZ?:?9WU*65#;VDKN]M"V\ND3,Q17 +'J0#[Y?XG_#2/QLOPTD^
M(>A+XC:+S%\/G5H1?%-N[<(-WF8V\YQTYK<KXI\.^-?AM\(OVS?^$8^%OB_P
M/\1CXY^*MX^O>%Y]*7_A*O!^H-%(MQ>+*,L;.,Q$?O8T*I(HCD=2 ?K3X>?%
M?P!\5UUM_ &O_P!H#PYXBNM"UDBUEB^SZA;%1/#^\5=^TL!N7*'LQP: .9\"
M_M'^'?%?Q"^)G@G7+&#1+7X:ZS8V%WK%_J2+#=?:;&"Z$AW!1$ 9A'@L<D9R
M,X'7^'?B+\/O%^KZAX?\)>.]&U2_TF7R]5LM.U2*>:R?)&V5$8M&<@\, >*^
M&?VF$9OAM^V^OS#.N:!@J2#_ ,@K3>A'2O5_'OPF\&_!K]MSX1Z5\!?!.D^&
MI]1^&?C#3RNEV20)<);C3'MDEVC]X$D<L"V3EB<\T ?1FG_$_P"&NK>+[GX>
MZ5\0]#NM?LU+7FAV^K0O>0*.I>$,74<]Q6Y7QO\ \$ZO&'['D?PX^&GPUOM/
MT)/C-IL5TNMZ==:1OU^QUE89QJ,]TVPRP[]TX,LI".)%4,2RBOJ3X1_%WX>?
M'?X>Z?\ %7X4^(1JN@:H9A87XM98/-\J9X9/DF1'&)(W7E1G&1D$&@#I****
M "BBB@ HKY _X*^?%[_@I;\(OAQX/U+_ ()I_##_ (2C7+S6YX_$T']BQWOD
M6@AS&VV1U"Y?C(KX*_X;6_X.L/\ HTK_ ,L*U_\ CU?09?P[7S#"JO&O2BG?
M24U%Z:;6-Z>'E4C=-+U9^S.K_$7P;H.HR:5JNL>5<18\R/[/(V,@$<A2.A%&
MD?$7P;KVHQZ5I6L>;<2Y\N/[/(N< D\E0.@-?(/[(GC;]JSXB_L\>'O&/[;G
MA+^POB?>?:_^$GTK[ MKY&R[F2V_=(S!=ULL#<'G=GO1^UWXV_:L^'7[/'B'
MQC^Q'X2_MWXGV?V3_A&-*^P+=>?ONX4N?W3LH;;;-.W)XVY[5Y7U.?U_ZKS1
MOS<O-?W;WM>_\O6_;4SY'S\M^MC[9HK\2_\ AM;_ (.L/^C2O_+"M?\ X]7U
M_P#\$@_CQ_P6#^+OQ'\8:=_P4L^#/_"+Z'9Z)!)X9G_X1V&R\^[,Q$B[HW8M
MA.<&O8QO#6(P6%E7E7I24>D9IM]-%;4UGAY0CS<R^\^H_P!K_P#:5?\ 92^$
M"_%"W^'5[XKN9M<L=+LM#TZZ6&:YGNIA$@5F5AG)&!CDX''6J^J?M=^!I/!O
MPH^(7@BP;6]&^+/B>RTC2KJ.Y$1M%N+*ZNA*ZX;+)]E,;1Y!#,<GY2#SW_!0
M@$^ ?AY@?\UR\&?^GB"O ?BKX1\1?LZ?MA_##]G/3](G?P)XG^-\'C7P+-%&
M?)TJ4V&HQZIIOHBB>XBN8U  "W$@YVFOG#G/HK]IC]MKPU^S9\5_!?PRU/P5
M=:K%XCFCD\0ZO;W:QQ>&[&6\M[&&\G!4[T>YN4C !7A7.?EP=GX_?M(>(/A;
MX^\)_!OX9?"P^+_&'C""^NM/TZXUQ--M(+2S6,SS37#1R$<S1JJ)&Y8D] ,U
M\TW_ ,-?V@_VU+SXZ>/O 'A?P)>^$_'[2>"_#VI>*-=O;>YM['2FF@%S;+!:
MRH4-\UQ<*2PRR+D84$Z4WQJ_9*_:,_9K^&NK?MD?%"?P#X^TNSNH[3Q3'JDV
ME7VCZU9.;+4/(O0/+21I(BQ@<MO1D)1@ 0 >V_%3]JCXF_"GX<^!-9UK]G24
M>+O''C-?#<'A&7Q7;JEK<-'=R+*;M$='C9+7<ORAL2KN"L"M7?A;^U3JNO\
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MY^C0:Q=1Z1/_ ,(9;MYEJLK")LF7G*!3GO70_LV_M,_\%X/&/QIT7PS^U7\
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MO_#16I_L7:U#\,Q9C4I=6_X2JV.LPZ61O^W/I@3A!'^\*"<R!<DKP17C>M^
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MW)#K/P ^&7Q3\*?"B[U/Q/\ %GR8_"G@J'58T)E:![B4RW+( D,,4;N\NPG
M "$G%5X/V]].\)^#_B)<_'/X47WACQ3\-?L!U7POI^IQZE_:(U A+ V4X6,3
M>?+^Z&Y4*."& ZU\W? +Q3XA^'7P)_9$_:(^,6@6>A>#?!_]HZ7?:S;:D]W%
M;V=_I'DVE_=?N4%JIG5HG!+I&&4F0[\"Q^T1*?V@/$_Q=_:J^#-K/XC\'>&)
M? L<&HZ/"TT6NC2M5>^U%K8J/WZP12@%ER"48*3MH ^I/AE^U'\0-0^-&G_
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
M/C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\ ?H4?
MV=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ
M%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\ SXP_
M]^A1_9VG_P#/C#_WZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\
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MG_\ /C#_ -^A0!3_ .$Q\,?]!J#_ +ZH_P"$Q\,?]!J#_OJKG]G:?_SXP_\
M?H4?V=I__/C#_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C
M#_WZ%']G:?\ \^,/_?H4 4_^$Q\,?]!J#_OJC_A,?#'_ $&H/^^JN?V=I_\
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M_P!^A0!3_P"$Q\,?]!J#_OJC_A,?#'_0:@_[ZJY_9VG_ //C#_WZ%']G:?\
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MZ% %/_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZJY_9VG_\ /C#_ -^A1_9VG_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?[6'_ "6SX'_]
MCW+_ .DS5[I7A?[6'_);/@?_ -CW+_Z3-0![I1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5X7^UA_P EL^!__8]R_P#I,U>Z5X7^UA_R6SX'
M_P#8]R_^DS4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>%_M8?\ );/@?_V/<O\ Z3-7NE>%_M8?\EL^!_\ V/<O_I,U 'NE%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !7A?[6'_ "6SX'_]CW+_ .DS
M5[I7A?[6'_);/@?_ -CW+_Z3-0![I1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 5X7^UA_P EL^!__8]R_P#I,U>Z5X7^UA_R6SX'_P#8]R_^
MDS4 >Z4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%_M8?\
M);/@?_V/<O\ Z3-7NE>%_M8?\EL^!_\ V/<O_I,U 'NE%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH *\+_:P_Y+9\#_ /L>Y?\ TF:O=*\+_:P_Y+9\#_\ L>Y?_29J /=****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"1TNM$GM0JY#2D8;VXJ]10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !7A?[6'_);/@?\ ]CW+_P"DS5[I7A?[6'_);/@?_P!CW+_Z3-0![I11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5X7^UA_R6SX'_ /8]
MR_\ I,U>Z5X7^UA_R6SX'_\ 8]R_^DS4 >Z4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %>%_M8?\EL^!_P#V/<O_ *3-7NE>%_M8?\EL^!__
M &/<O_I,U 'NE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A
M?[6'_);/@?\ ]CW+_P"DS5[I7A?[6'_);/@?_P!CW+_Z3-0![I1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5X7^UA_R6SX'_ /8]R_\ I,U>
MZ5X7^UA_R6SX'_\ 8]R_^DS4 >Z4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %>%_M8?\EL^!_P#V/<O_ *3-7NE>%_M8?\EL^!__ &/<O_I,
MU 'NE%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 445S'Q$^(EKX0M3961674)5_=QGD1#^\W]!WK
M:A0JXFJJ=-7;,<1B*6&I.I4=DCIZ*YCX=_$2U\7VHLKTK%J$2_O(^@E']Y?Z
MCM73T5Z%7#573J*S08?$4L3252F[IA1116)L%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ML^!__8]R_P#I,U 'NE%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV:G;CCAF$J9P6RHBK];/@3^T#\&?VFOAS9_%CX$?$33?$V@7P_=7VG39\M\
MF*5#AX9!D9C<*RYY KYCB[@'/.$'"M6M5PM36G7IOFI372TEL_[KL][76IZ.
M7YMA<PO&-XS6\7I)?+]3L:***^(/3"BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBO'_VG?V^/V0OV.M.>Z_:$^.FB:'=B+?#
MHBSFXU&<8X*6D(:8@\#=M"C(RPJ93C!7D[(B<X4X\TW9>9[!5/Q!XB\/^$]%
MN?$GBK7+/3-.LXC)>7^H720PP(.K.[D*H]R<5^3?QI_X../B]\:_%3?"'_@F
MQ^RCJVMZM=92TU;7=.DO;MQT+Q:?:$[0.H>25AR-R#D5S7A__@CW_P %8/\
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M&OQN^,^@^&=-4'9/JEZ$:8CJL4?+S/\ ["*S>U?G)^T__P '+FDZIKA^%?\
MP3T^ VI>--<NY#!8:]K]A,(IG[&WL(?](GSU&]HB".4(K[#AC@+BOB^5\LPT
MI06]1^[3C;>\Y6CIU2;?D>?C<UP&7K]]-)]MV_DM3]4/$/B/P]X1T2Y\3>*]
M=L],TVRB,MYJ&HW20P0(.KO(Y"JH]20*^ _VP_\ @XU_8N_9_P#M7A?X%1W7
MQ6\10Y16T67[/I,3C^]>NI\T="# DBGIO%?*WA__ ()J_P#!4[_@I]KMMX^_
MX*)?M,R^"_#+2B>V\/7TBRSQ+V\C3+8I;VYQ\I>5EE'!97K[[_8\_P""4O\
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M_M2?\%Y/^"KS&S_9U\!7'PL\ W_":SIH?2H&A/1SJ4_^D3D9P?L@&>Z5Z_\
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M +ZH TJ*S?\ A,?#'_0:@_[ZJQI^MZ3JKM'IU_',R#+!#T% %JBBB@ HHHH
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MAZ\+_:P_Y+9\#_\ L>Y?_29J /;O[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ*
M(?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_
M +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L
M[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA
M_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?
M[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[
M]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3
M_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?
M^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.
MT_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"
MIJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^
M?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3_P#GQA_[]"IJ9//!:P/<W,R1QQH6
MDDD8!54#)))Z #O1N S^SM/_ .?&'_OT*/[.T_\ Y\8?^_0KXO\ VP_^"]/[
M!G[*?VKP[X?\:/\ $?Q1!E1HO@J1)[>*0=IKTGR$&<@A#(ZD<I7Q9/\ M;_\
M%R?^"O<[Z1^R_P" ;CX6_#J]<H=:TV:33[<Q$XS)JLH$UP1T9;15R#S'7Z;D
M?A1Q1F>$^OX[EP6$ZU<0_9JW]V+]Z3?V;*S[GBXK/L#0J>RI7J5/Y8*[^;V7
MF?I5^UO_ ,%'OV'_ -B:TEB^.OQ:TF#64CW1>%=)C%YJLN1D#[/'DQ ]GE*(
M?[U?G3\1?^"W_P"WI^W9XLN?@]_P2Z_91O--C9MC^()M,CU#48D;A9)&<?8[
M!3T)E,@!QB0&O8OV2/\ @VE_9V^'MW%XZ_;#^(&H?$WQ \GGW.DVTLEEI0E)
MR=[!OM%T=W.YGC5LG=&<U^B_PY^&/PY^$'A.V\!_"GP'I'AO1;,8M=*T/3H[
M6WC]2$C &3CDXR>]>S_:?A5P7IE]"6:8E?\ +RLG##I]XTOBFO*>G5,YO8Y[
MF7\6:H0[1UG\Y;+Y'Y1? C_@W0^-WQY\6)\:/^"G'[3FJZGJ=T0]QH.B:FU[
M>L,Y$<M].&2(#IY<*.N#\KKBOTD_9K_8B_92_9#\/#PY^SU\#]#\/*T82YU"
M*V\Z^NA_TVNI2TTO/.&8@=@*]5HKY#B?Q$XMXMC[+'8AJBMJ4%R4HI;)0C9.
MW1RNUW/0P648# /FI0][^9ZR?S?Z6(?[.T__ )\8?^_0H_L[3_\ GQA_[]"I
MJ*^(/3(?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?^_0H_L[3
M_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.T_\ Y\8?
M^_0H_L[3_P#GQA_[]"IJ* (?[.T__GQA_P"_0H_L[3_^?&'_ +]"IJ* (?[.
MT_\ Y\8?^_0KB_CW^S1\"/VGOAU=_"GX[?##2O$6AW@RUM>6X#PO@@2PR+AX
M9!DXD1E89//)KNJ*VPV)Q&#KQKT)N$XNZE%M--;--:I^:)G"%2#C-73W3/Q:
M_:!_X)6_MW?\$F/B-=_M3_\ !-#Q_K'BGPC$?-UCPV8!<7L-LI),5W: ;-0@
M S^\C42IDL%3;YE?6?\ P3:_X+C_ +-'[:QL?A=\6;#3_A[\2I=L2Z1?2 :?
MJTO3_0YWZ.3T@DP^2 IEP37WE7PK_P %)?\ @A7^SM^VU]N^)_PL%M\/OB5+
MNE;6;"VQ8:M+U_TR!,?.3UGCQ)SEA+@+7[+A^-^&^.Z$<#QI#DKI<L,;3C[Z
M[*M!:5(KNO>2V2;<CYV>68S*YNKEKO'=TV]/^W7T?X?D?<G]G:?_ ,^,/_?H
M4?V=I_\ SXP_]^A7XQ? ;_@J)^WS_P $BOB-9_LL_P#!3'X=:UXG\'H?*T;Q
M$9?/O8;92 );.[8A-0@ (_=2,)4R%W)M\NOUL_9]_:0^"'[5'PWM/BQ\ OB-
MIWB30[L8^TV,OSP28!,4T;8>&0 C,;JK#(.,$5\;Q=P!G?"*AB*G+6PM3^'7
MIOFI373WE\,O[KUT=KI7/0R_-L+F%X*\:BWA+22^75>9V/\ 9VG_ //C#_WZ
M%']G:?\ \^,/_?H5-17PQZA#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9
MVG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H
M5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_W
MZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG
M_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-
M10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SX
MP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%
M']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\
M^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10
M!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']G:?_ ,^,
M/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#_9VG_P#/
MC#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\ ?H5-10!#
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H5-10!#_9VG_\^,/_ 'Z%']G:?_SXP_\
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M\-"3GE37Z&?!W]G;X$?L^^%D\%_!'X0^'O"^F*!NM=&TJ.'S2!C?(RC=*_\
MM.2Q[FNSHKIHX:A07N1M^?WG;A\%A<*OW44O/K]^Y#_9VG_\^,/_ 'Z%']G:
M?_SXP_\ ?H5-16YU$/\ 9VG_ //C#_WZ%']G:?\ \^,/_?H5-10!#_9VG_\
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M O@=;&[^,WQM\)^%$"[@?$7B&VLRP_V1*ZEB>P&2>U>,V'_!0[]FK]IJ75?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M?@AKXT^.G_!S9^Q'X \ZP^"W@;Q=\0+M,^3<):+I=C)_VTN,S+_WXK#^!O\
MP:]?LN^$VBU+X_\ QQ\5^-+I2&EM-)ABTFS<]U8?OIF'NLJ$]>.E?9?P+_X)
MJ?L'?LW>3-\(OV6O"5C>6^/)U6_T_P"WWJ$=Q<W9DE7\&%*^8U>T%][_ ,@O
MG%?I&FO_  )_Y'YOG_@KM_P6M_;6/V7]BK]CC_A'-)NO^/77+3PY+?;,]-U_
M?[++\XQW/3HJ?\$9_P#@L5^V@XO?VX/VT_[$TRY.;C1+KQ!/JC0D]<65J8[(
M?\!D'2OV0  & , =!11]0Y_XTW+\%]R#^RO:_P"\593\KV7W(_.GX%_\&SW[
M"7P[\F_^,'B3Q;\0;M,>=!>:B--L7(](K7;,OXSFOLKX(?L9_LH?LVQ1CX%_
ML\^$?#,\:[1?Z;HD0NW'^W<,#*__  )S77^._BE\,OA=IW]L?$WXBZ%X<M-I
M/VK7=7ALX\#J=TK**^>/BE_P6O\ ^"57P?\ ,7Q7^V[X+NWBX9/#%S+K1)]!
M_9\<W->G@\HJU7_LM!R?]V+;_!,[\/E^'H_P::^[7[]SZDHK\ROBE_P=:?\
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MNU (R=#UN/;WJ9\'9E4BYX*<*\?[DDW\T[/Y:@\)4:O!J7HS]FJ*^.OV>O\
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M\1'X:_\ !/S]D+5_$>KW1*6%[XEMY;F>4],IIUB6=O4$S#ME>U<?_P ,0_\
M!??_ (*5_P"E?M1_&F?X;^$+[F31=1U 6$;PG^'^S; ;I"/2Z*MU^;U_6_X.
M?L_? []GKPZ/"?P,^$GA[PGI^ 'M]!TF*V\TC^*0HH,C?[3$D]S77T?\1,R'
MA_W>%<GI49+:M6_?UO\ $N;W8/R5T']BXK%ZX[$2DOY8^['\-7^!\@_L)_\
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M:T6/H#81S#]<>]?!O@'_ (-%-%U2_P#[>_:&_;LUK6+J<AKN+0/"RQ2$]_\
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M (-&+36]1_X2+]HO]O'5]8NYVW7D6A>%@LC'_KYNKB0O]3$*^B/A;_P:Z_\
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M>>')]):8C@[;^S62Q/\ P&(]?2OHW]GK_@ZH_P"">7Q0\C3OC5X<\8_#2^?
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MXB^'>H1S%+O0;K41>0A006MI2Z(+F$MNQ%-&63"Y=W&^OVA_X)L?\%^O@/\
MM:?V?\*/VC18_#SXA3;88))IRNCZS*>!Y$SG_1Y&/2&4\D@)(Y.T?6W[0/[$
M7[)'[4]L\/Q__9\\,>)9W39_:5WIRQWR+C&$NHMLZ#_=<=!Z5\&?M)_\&OO[
M.WC""ZUG]E_XR:[X-U JSV^D>(%&IZ>6Q\L8?Y)XE)P"[-,1UVGI7W>;<?YY
MQ%@XT,^H4\7."M&NOW6(26RE-7A./E.#>[4DVV>30RG,\IJ.6$FI1>\=D_1=
M'Z/Y'ZC45_/=XI_:3_X+-?\ !&3QC:?"/Q_X^U1O#\)\K0H=>3^V=!U&WC
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M+XII?,_9SQY\5/AA\+-/_M?XG?$?0?#EIM+?:M>UB"SCP.IW2LHQ7SQ\4O\
M@ME_P2I^#_F+XK_;<\&7CQ<,GABXEUHD^@_L^.85\$> _P#@T6T[6-0_X2#]
MHG]N_6-8NYSNNXM!\*B.0GO_ *3<W$I?ZF(5]$?"W_@UW_X)7^ /+?Q=X<\;
M^-V3!?\ X27Q>\*N?IIZ6V![9_&CZCP=AOXN+J5?\$.7_P!+#DPD=Y-^B_S.
M>^*7_!UI_P $W_!GF6WP_P#"7Q'\8SC/DRV&@06ELQ]WNITD4?2,_2O!]?\
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M7^UA_P EL^!__8]R_P#I,U>Z5X7^UA_R6SX'_P#8]R_^DS4 >Z4444 %%%%
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MVK!=1N?"EX1-&W?.GWXC:/\ &<FOMG]GO_@NY_P2S_:.\BR\._M4:/X<U*?
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M8_CR+^RY%)Z+YTA-L[$\825CGZBO4/@K\>/V/?\ @HS\%O\ A)/ 5_X;\?\
MAFY"KJ>BZQIT5PUG*1_J;JTG4F)^O#+AARI92"?GO]HO_@WI_P""=?QR\_4_
M!W@S5?AUJLV6%UX.U K;E^VZUG$D2K_LQ"/ZBOQC&9?G64XJ>&KIJ<':49IQ
MDGV?6_J>_3CF,(*="K&K%[7[>36_S/MD>(M ;15\21ZU:OI[Q"6.]CG5HG0]
M&5@<,#VQUJCH7Q#\%^)KPZ?HNOQ33\XB*LA;'IN W?A7Y_?L<?\ !*CXA?\
M!-C5_%1O_CY-XR\*Z^+6/0[=(9[1;*1&F:4RVIDDBWL#$%D5B3L?A<X/N8T_
M4M7!TK1[FZAN[I3%;36,[13([# 9'4@HP)R&!!!YKXS,^*\9@,R6']BK*U[W
M;=_Y6M/P>I\?F_&^899FRPOU=65N9-MMW_E:T_!ZGT[KFO:%X9TR76_$FM6F
MGV4"YGN[ZY6**,>K.Q 'XFOGSXO?\%<_^";OP2\V+QG^USX3N9XLAK3PW<OJ
M\H;^Z5L5EVGM\V,=\5\%Z'_P;;?M2_&O4XO$G[9_[?4FHW8;=*MFM[KDS9Z@
M7%]+"5/OL;Z5]"?"'_@VV_X)S?#SRKCQW9^,/'4ZX,BZ]XB-M 6]DL5@8#V+
MM]37U?ML?4^&FH^K_1'V?UC-:OP45'_$_P!$<5\7?^#H7]C_ ,*>;:?![X,>
M-_%]Q'G9-?"WTNTD],.S2RC\8A^->3'_ (+<?\%=_P!J<_9_V.OV"Q96%R?W
M.J0>&=0U<Q ]";IO*ME'N\>*_3+X0_L&_L7? ;RI?A)^R[X'T6YAQY>H0^'H
M)+OCIFXD5I3^+&O6J/J^-J?'5MZ+]0^J9E5_B5[>45^KU/QR_P"&//\ @Y)_
M:X&[XP_M'2_#^PNAF2WE\7PZ6IC/\)AT2-B>/X9,$_Q=ZZ/X=_\ !KG8ZYJ?
M_"2_M.?MF:UK5Y<,&O8?#NC!)6/?_2[N24N?<Q#\:_6JBA9=AV[SO)^;*63X
M1N]6\W_>;9\7_"'_ ((!_P#!,;X4>5<7OP6OO%UY#C;>>+]?N+C=_O0Q-% W
MXQU]0?"[]GOX#?!"U%E\&O@KX4\*1A-I7P[X?MK,L/\ :,2*6/J3DFNPHKJI
MT*-+X(I?([:6&PU#^'!+T04445J;A1110 4444 %%%% !1110 4444 %%%%
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M;6SMUBC0>@50 /PJU17AU\5B<3*]:;D_-M_F8RE*6[N%%%%8$A1110 4444
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MZ_M3_LX_LR:+_;_Q_P#C9X;\)P-&7ACUC5(XY[@#_GE#GS)CUX16/'2OR?\
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M6[/HK]GW_@V%^&4.ICQM^V9^T5KOC75KB3SKW3?#V;2WDD/WA+=3>9/.#_>
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M:QP01*%BAAC"HBCH !P!4E%>)6Q%?$2YJLW)^;;_ #,7*4MV%%%%8B"BBB@
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M1^5:U%%>9*4I.[=V2%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXB$/^"D7P3.W]J3_ ()R):K#_KV.C:OH)('4YNEG ^N,5^QE%5_Q$OAG'?\
M(SX<PL^_L>>A_P"DN5@_L;&TOX&,J+_%:?YV/RM^'_\ P=4?LYZF4'Q2_9;\
M:Z+G&\Z#JEIJ07_OZ;;->X?#_P#X.(_^"7GC;8FM?%?7O"\C](_$'A&[.#Z%
MK5)U'U)Q[U]4?$#]E_\ 9I^+!=OBC^SUX'\1M)G>^N^%+.[8^^98V.?>O#_'
M_P#P1)_X)<_$<R2:O^R3HMA*^<2^']0O--V'U"VTR)^!4CVH_M;P4S#^/EN*
MPO\ UYK1J6_\&I![#B6C\-:G/_%%Q_\ 23N/A_\ \%,_^"?'Q/"+X/\ VR?A
MW)++_J[:^\3V]G,WL(KAD<GVQ7L?AWQ5X8\7Z>NK>$_$=AJEJWW;G3KQ)XS]
M&0D5^>GC_P#X-BO^"?\ XG\R?P;XT^(OAF4Y\N.TURVN8%^JSV[.?^_@KQSQ
M%_P:V>)_"M^VO? 7]NR[T^Z3_4)J/A=X)%],W%O=9_*.C_5OP?S#_=<\JX=]
M%6P[G][INR]0^N<0T?CPT9_X9V_"1^OM%?CF?^"7'_!P/\!QYGP<_;R/B"UA
M_P"/:QC^)&H, !V\C4(?)7Z!B*#\;_\ @Z)^ ./^$Q^$DGC2V@^X/^$>TC4_
M,4?]@MUE/X_-1_Q"G!XW7+,^P57LI572F_2,HO\ ,/[=J4_XV%J1](\R^],_
M8RBOQS_XB$/^"D7P3.W]J3_@G(EJL/\ KV.C:OH)('4YNEG ^N,5W7P__P"#
MJC]G/4R@^*7[+?C71<XWG0=4M-2"_P#?TVV:PQ'@EXCTJ?M*&$5:'\U*I3FO
MDE/F_ J'$N3R?+*IROM*,E^EC]4J*^'?A_\ \'$?_!+SQML36OBOKWA>1^D?
MB#PC=G!]"UJDZCZDX]Z]P^'_ /P4S_X)\?$\(O@_]LGX=R2R_P"KMK[Q/;V<
MS>PBN&1R?;%?(8_@?C+*[_6\NKP2ZNE.WWVM^)Z%+,\NK_PZT7_V\CW*BJ'A
MWQ5X8\7Z>NK>$_$=AJEJWW;G3KQ)XS]&0D5?KYB490DXR5FCM335T%%%%2,*
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\=_;*_:V
M?]DKX;7?CJR^#GB#QA-9Z=-?7$.F*+>TM+:(J'DN+N0%(OO@*BAY'/W4(#,O
ML5?,7_!6SXP?"WP-^Q7X[\ >,?'^DZ9K?B;PO<Q^']*O;U(Y]0=&CW"%"<N1
MN7./44 >J?'S]H<_!S3O#&F>'/ UQXG\5>-=773?"OAJVO4M_M,HA>>6269P
M1##%#&[N^UB, !237"P?M[Z=X3\'_$2Y^.?PHOO#'BGX:_8#JOA?3]3CU+^T
M1J!"6!LIPL8F\^7]T-RH4<$,!UKC/CM\;?A/?_$3]G_]KWP_X^TW5OAUX8\0
MZSI/B3Q1I=R+BTTR6]TQK>*69TR(XUF58V=L*GFC)&17E/[1$I_: \3_ !=_
M:J^#-K/XC\'>&)? L<&HZ/"TT6NC2M5>^U%K8J/WZP12@%ER"48*3MH ^I/A
ME^U'\0-0^-&G_ CX_? <^!=;\0:%<:KX7EMO$T6JVVH1V[1BY@:1(HS%<1B6
M-BF&4J20YQSN?M _M"7WP@UGPM\/O!'P]E\6^,O&MY<P^'M 74DLHC%;1>;<
MW,]PZL(88T* D([%I$55)/'D<OQ>^&?[5/[;_P *O%WP#\96?B?0_AWX:\0Z
MGXJU[2'\ZTLS?06]O;6K2J-HG8K(YA^^JQ9(%4?BU\?OA)<_'SX"_ML6GC!&
M^%VH:)XCT:7Q?=VLUO:6$]T+8VSS^<BM DCVDT6YPH#!<D @T =E#^WWINB_
M#[QA??$?X2:EI'CCP9XFL?#UYX"L]1BNY;_4;_RO[/6UN,(DD=P)E(=E0J%D
M++\O/1_"#]IKQIXG^,]U^SY\;_@O_P (3XI_X1W^WM'CM?$4>J6>I6"S""4I
M.L4166.1XPT93HX8%AS7RC\4KL?$+QSX]_;@\#VEUJGP]TCXT> -1&KV-J\B
MZAIVC1O%J%] JC,\,3W9_>*"K"V<@D*2/</!WQ%\"_M._P#!0'P]\2/@=XGM
M/$?AGP+\--3MM9\2Z1+YUD;V_NK4PV2S+\KRB.WDE903L&W."<4 ?3]%%% !
M7SI\7O%<?Q,\<^"/%R6?V/\ X0O7GU$V_F>9]LS$8_+W87R^N=V&^G>N[^*W
MA3]K/5_%SWGP?^*_A?2-%,"!++5M">XF$@'SL7!'!/05Y5/!)!(4<'KP?6OE
M>*LSS'+,-3EA=+MWE:]MK+6ZUU^X^*XUSC-LHPE*>"5N9OFE9.VUEK=:Z].A
MR7[:_P#P6V^ ?[#ZV>A>/?AKXDUCQ'JMF;G2M'T=5$+1ABN^:YFV(BE@1^[$
MKC'*J""?S9_:,_X.0?V\?C?=OX8^ VAZ)\-[&[D\JU31K7^T]4D#<;//N%V;
MO0QPHP/0],?IWXA_X)^_LV_MGZO8>(?V@OAE:>(9O"88:-'>W]W#''YY4ON2
MWEC$H/D)\LFY1S@<FO<OA+^S-\-O@':R67P/^%?@;PA',@6?_A&O"EO9&8#I
MO:%%+GW8DFOH,@S7-?[/IUIQA"HUJW34Y-7[5.:";6J:A='3ED<ZS?+J=;%5
M/9\RU459^KV:NM=[:['\]ND_\$]?^"NG[<_B;_A-O$_P0^)GB2\GP?[=^(EV
M]B/+;G,<NJ21;H_01[ACH.@KZ4^#'_!K;^U-XH\J[^.?[0/@SP?;OAFM]#L[
MC6;E1W5E;[-&K>ZR.!UYZ5^V/V+QO_T&[+_P&/\ C1]B\;_]!NR_\!C_ (UZ
MN.Q^.S7E^OUJE?EV]I.4E'RC&ZBEV7+9'I4,@RZB^9QYGW;_ ,K?C<^ _@S_
M ,&S'[ '@(Q7GQ7U_P <?$"Y7!FM]2UP:=9L?]E+%8IE'LTS?6OKCX(?L$?L
M6?LW/#<_!#]EWP1X>O(,;-5M/#\+WQQTW74BM.WXN:]$^Q>-_P#H-V7_ (#'
M_&C[%XW_ .@W9?\ @,?\:QC6J4X<D'RKM'W5]RLCUZ5*E1C:G%17DK?D;%%8
M_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-9%FQ16/]B\;_ /0;LO\ P&/^
M-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C
M_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;
MLO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T
M&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]
MB\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT
M?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^
M- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR
M_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;
MLO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+
MQO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]
MB\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT
M ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_
M ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR
M_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&
M_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+
MQO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!
ML45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\
MP&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_
M ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_
M /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&
M_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q
M16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\ ]!NR_P#
M8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_ /0;LO\
MP&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%8_V+QO\
M]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C_C1]B\;_
M /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P# 8_XT ;%%
M8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^- &Q16/]B\;_ /0;LO\ P&/^-'V+QO\ ]!NR_P#
M8_XT ;%%8_V+QO\ ]!NR_P# 8_XT?8O&_P#T&[+_ ,!C_C0!L45C_8O&_P#T
M&[+_ ,!C_C1]B\;_ /0;LO\ P&/^- &Q7"_$#]E_]FGXL%V^*/[/7@?Q&TF=
M[Z[X4L[MC[YEC8Y]ZZ+[%XW_ .@W9?\ @,?\:/L7C?\ Z#=E_P" Q_QK?#XK
M$X2I[2A-PEWBVG]Z)G"%16DKKS/FWQ__ ,$2?^"7/Q',DFK_ +).BV$KYQ+X
M?U"\TW8?4+;3(GX%2/:O#_'_ /P;%?\ !/\ \3^9/X-\:?$7PS*<^7'::Y;7
M,"_59[=G/_?P5^@7V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XU]?@/$GC_++
M?5\SKI+HZDI+[I-K\#SZN3956^.A'[DORL?DUXB_X-;/$_A6_;7O@+^W9=Z?
M=)_J$U'PN\$B^F;BWNL_E'5 _P#!+C_@X'^ X\SX.?MY'Q!:P_\ 'M8Q_$C4
M&  [>1J$/DK] Q%?KI]B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"-?3Q\;N.J
ML5''RHXJ/:M0IR_])C%_B<+X9RN+O24H/^[)K\VS\BS\;_\ @Z)^ ./^$Q^$
MDGC2V@^X/^$>TC4_,4?]@MUE/X_-1_Q$(?\ !2+X)G;^U)_P3D2U6'_7L=&U
M?020.IS=+.!]<8K]=/L7C?\ Z#=E_P" Q_QH^Q>-_P#H-V7_ (#'_&J_XB7P
MSCO^1GPYA9]_8\]#_P!)<K!_8V-I?P,947^*T_SL?F+\/_\ @ZH_9SU,H/BE
M^RWXUT7.-YT'5+34@O\ W]-MFO</A_\ \'$?_!+SQML36OBOKWA>1^D?B#PC
M=G!]"UJDZCZDX]Z^D/B!^RE\(/BP7;XH_!7X=^(VDSO?7?!=I=L??,L;'/O7
MA_C_ /X(>?\ !/#XC%Y-8_9C\,6,K\B30)[W3=A]0MM.B?@5(]J/[6\%,P_C
MY;BL+_UYK1J6_P#!J0>PXEH_#6IS_P 47'_TD]0^'_\ P4S_ ."?'Q/"+X/_
M &R?AW)++_J[:^\3V]G,WL(KAD<GVQ7L?AWQ5X8\7Z>NK>$_$=AJEJWW;G3K
MQ)XS]&0D5^</CK_@V%_8N\2%Y_"/Q \:^')3GRX[358;B%?JL\#.?^^Q7E&N
M?\&MWCGPI>G7?@;^W/)87:?ZA;[PW+;NOI_I%O<Y_*.C_5OP?S#_ '7/*N'?
M15L.Y_>Z;LO4/KG$-'X\-&?^&=OPD?L)17XY_P##KC_@X(^ ZB3X/?MXGQ!;
M0_\ 'O81_$C4&  [>1J$/DK] Q%-D^-G_!T7\ \?\)?\*9O&5O!]P+X>T?4_
M,4?]@QEE/X_-1_Q"G!XW7+,^P57LI572F_2,HO\ ,/[=J4_XV%J1](\R^],_
M8ZBOQHN/^#@/_@IM\%CM_:9_X)^K8K#_ *]I?#VJZ(<#J<W*S ?7&*]Y_8=_
MX+S7O[:WQ*B^%^A_LN>)M.NQ"9M2U&QO+:]LM-B_YZ3ROY!52>  I9CT4\UP
M9GX.\>Y7@IXV6'C.A!7<X5:4HI?^!W_ NGQ)E%27(YN,NSC)?H?H]17CUY^T
M,WA;1K_Q)X[UQ;'3K&!KBXNXM)EN?*C7DYC@5G( YR%. "3@#-9WPS_;F_9?
M^,?EQ_#/]LGX9:O/+C996_B*V6YYZ9@>02#\5KX6619Q&G*I&A.4([RC%N*]
M9)67S._#YC@L3%.$U?LW9_<>Y45B0P>,KB)9X/$%@Z.H9'2WR&!Z$$'D4_[%
MXW_Z#=E_X#'_ !KR=CN-BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -
MBBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_Q
MH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -
MBBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_Q
MH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -
MBBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_Q
MH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -
MBBL?[%XW_P"@W9?^ Q_QH^Q>-_\ H-V7_@,?\: -BBL?[%XW_P"@W9?^ Q_Q
MJUI4&OPR.=8OX)E*_((HMI!H O4444 %%%% !1110 4444 (Z)*ACD0,K##*
MPR"/2DCBCAC$4,:HBC"JHP /I3J* &0V\%LI2W@2,%B2$4 $GOQ2O##+$8)(
ME9",%&7((],4ZB@!$1(T$<:!54850, #TIL%O!;1B&V@2- >%10!^0I]% !1
M110 5X7^UA_R6SX'_P#8]R_^DS5[I7A?[6'_ "6SX'_]CW+_ .DS4 >Z4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^Q?MT?VKR_,\C=\VWUQ7D*,I;(W<HQW99HHHI#"BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KPO]K#_DMGP/_P"Q[E_])FKW2O"_VL/^2V? _P#['N7_
M -)FH ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ([NTM;
M^V>SOK:.:&52LD4J!E<'J"#P17D'Q+_X)Y_L+?&#S)/B+^R/\/M0GE_UEZ/"
MUM#<G_MO$BR?^/5['179@\QS#+JG/A*TJ<N\9.+^]-&=2C1K*U2*:\U<^%_B
M9_P;I?\ !,/Q_P"8^@?#KQ)X0DDZR>&?%=P<'U"WOVA!] N/:OG[X@?\&K7@
M6.Z_M7X&_MCZ_HT\+;[6/Q!X<BNV##I^^MY8"A_V@A^E?K317W>7>+OB3E:2
MHYG4DNU1JK_Z<4CRZW#^35_BHI>GN_E8_)CX,_\ !)S_ (+%?LW?%30;G3OV
M[=7\0> K;4HSK&D>'O']]%=/; \A+:_0VRD\9^?.,X.<5]V1IXFC\2"-3='5
M%N !N8F7S/<GK_A7O=5O[(TS^T_[:^PQ_:O+\OS]OS;?3-<V<^(.9\15E5S"
ME3YXQ:O"$8.5_P"?ET?W(XZG#M**2HU))7V;;MZ=F&D?VG_9D']M>7]K\L>?
MY/W=W?%6:**^"D^:39]'%<L4@HHHI#"BBB@ HHHH **** "BBB@ HHHH ***
M* "O"_VL/^2V? __ +'N7_TF:O=*\+_:P_Y+9\#_ /L>Y?\ TF:@#W2BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPO]K#_DMGP/_P"Q[E_]
M)FKW2O"_VL/^2V? _P#['N7_ -)FH ]THHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *\+_:P_Y+9\#_\ L>Y?_29J]TKPO]K#_DMGP/\ ^Q[E
M_P#29J /=**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_VL
M/^2V? __ +'N7_TF:O=*\+_:P_Y+9\#_ /L>Y?\ TF:@#W2BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ KPO]K#_DMGP/_P"Q[E_])FKW2O"_
MVL/^2V? _P#['N7_ -)FH ]THHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_#7/QP_Z,9\=_P#@3!1_PUS\</\ HQGQW_X$P5[U10!X+_PUS\</^C&?'?\
MX$P4?\-<_'#_ *,9\=_^!,%>]44 >"_\-<_'#_HQGQW_ .!,%'_#7/QP_P"C
M&?'?_@3!7O5% '@O_#7/QP_Z,9\=_P#@3!1_PUS\</\ HQGQW_X$P5[U10!X
M+_PUS\</^C&?'?\ X$P4?\-<_'#_ *,9\=_^!,%>]44 >"_\-<_'#_HQGQW_
M .!,%'_#7/QP_P"C&?'?_@3!7O5% '@O_#7/QP_Z,9\=_P#@3!1_PUS\</\
MHQGQW_X$P5[U10!X+_PUS\</^C&?'?\ X$P5C>"/V\_B9\0=(EUOPK^QEXOO
MK:&\EM9)K+4(7198VVNA)4?,#P1CCUKZ3KPO_@GO_P D3U;_ +'O6?\ TI-
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M7=)^,-CX \0Z=JVJZ1XXOM*\,PWTEQ>6-U):9MENF:*%',1E;<DA^8*,8)H
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MCKX+7]AJ>NZ-IND^$O *ZO8OJ)LK%9W)FE$_V5)9IKAR%\[:BHNYLDX^@Z*
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MKF2*)CYL<7E*7!R<5]@T44 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M8R\0^*O!W@;42WPQTG2/&&A0VDMT 5.LW*W-XDCW&"1"C(! I)P9&W#ZZHH
M^;=4T;X__ O]ISQ?\=O ?[/6I^-]'^)OAG1_M^EZ5KNGVUYHNK6$<T2QR_:9
MXXWADBE4&6-G*M$?E(()X;7/A%^VK\&?V2_#/P1^$_P]NM8UWQAKVJZI\5=<
M\)Z_86MUHT=Y=/=S6]BU]-"IE?SS LXW>6(FDV[F3'V710!\W:3^SEJ7QM^
M/AOX/-\-O%'P'L/ ?B.RO?#VF6U]HNJ&Z%JC/"TBJ;N&11,XE(E&XRQ+(<GF
MG?LM?LU_'[X4_M5?%7XE?$KXP:[KVB:^-(73;K4;+2(_[<>*Q2-IY$M($>!H
M&!A50(E<'<PD.&KZ/HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
' "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2024</div></th>
<th class="th"><div>Nov. 20, 2024</div></th>
<th class="th"><div>Mar. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K/A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124,434,442<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%">None.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentDescription', window );">Amendment Description</a></td>
<td class="text">Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221; or &#8220;Arrowhead&#8221;) is filing this Amendment No. 1 on Form 10-K/A (this &#8220;Amendment&#8221;) to its Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 26, 2024 (the &#8220;Original Report&#8221;) solely to include the information required by Items 10 through 14 of Part III of Form 10-K (the &#8220;Part III Information&#8221;) not included in the Original Report in order to comply with General Instruction G.3 of Form 10-K. The Company&#8217;s Definitive Proxy Statement on Schedule 14A containing the Part III Information was filed with the SEC on January 29, 2025 (the &#8220;Proxy Statement&#8221;) was filed three minutes after the filing deadline on the 120th day after the Company&#8217;s fiscal year end. Except as noted below, the Part III Information included in this Amendment is as of January 28, 2025.Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), this Amendment also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are filed herewith. Because no financial statements have been included in this Amendment, and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.Except as described above, no other changes have been made to the Original Report and this Amendment does not modify, amend or update in any way any of the financial or other information contained in the Original Report or the Proxy Statement. This Amendment does not reflect events that may have occurred subsequent to the date of filing of the Original Report or the Proxy Statement. Accordingly, this Amendment should be read in conjunction with the Original Report and the Proxy Statement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of changes contained within amended document.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>3</ContextCount>
  <ElementCount>38</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>2</UnitCount>
  <MyReports>
    <Report instance="arwr-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-20240930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K/A" isDefinitelyFs="true" isUsgaap="true" original="arwr-20240930.htm">arwr-20240930.htm</File>
    <File>arwr-20240930.xsd</File>
    <File>arwr-20240930_lab.xml</File>
    <File>arwr-20240930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>arwr-20240930_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="1">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arwr-20240930.htm": {
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20240930",
   "dts": {
    "inline": {
     "local": [
      "arwr-20240930.htm"
     ]
    },
    "schema": {
     "local": [
      "arwr-20240930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20240930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20240930_pre.xml"
     ]
    }
   },
   "keyStandard": 38,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 4,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 3,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 147,
   "unitCount": 2,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 37,
    "http://xbrl.sec.gov/ecd/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.arrowheadresearch.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20240930.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r86"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r21",
      "r31",
      "r64"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r24",
      "r34",
      "r67"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r25",
      "r35",
      "r59",
      "r68",
      "r72",
      "r80"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Description",
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r72"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r55"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r54"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r17"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r17",
      "r60"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r49"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r90"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r53"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r10",
      "r21",
      "r31",
      "r64"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r18",
      "r28",
      "r61"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r25",
      "r35",
      "r68"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r25",
      "r35",
      "r68"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r25",
      "r35",
      "r68"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r25",
      "r35",
      "r68"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r25",
      "r35",
      "r68"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r48"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r4",
      "r5",
      "r17"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r25",
      "r35",
      "r59",
      "r68",
      "r72",
      "r80"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r84"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r84"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r84"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Income (Loss)",
        "label": "Net Income (Loss) Attributable to Parent"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r14",
      "r25",
      "r35",
      "r59",
      "r68"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r51"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r23",
      "r33",
      "r66"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r26",
      "r36",
      "r69"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r15",
      "r26",
      "r36",
      "r69"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r52"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r41"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r43"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r18",
      "r28",
      "r61"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r19",
      "r29",
      "r62"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r20",
      "r30",
      "r63"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r16",
      "r27",
      "r37",
      "r70"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r79"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security12b Title",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Award Types",
        "label": "Award Type [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r11",
      "r22",
      "r32",
      "r65"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r50"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r78"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r80"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r46"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0000879407-25-000013-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000879407-25-000013-xbrl.zip
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M +F'S8#I#KZ)0QY$2!@\!E+##=XO5X_*C9K=J[E5Y%Z)WYI'7>$5+P"^R"X
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MT&Z0@MD9C[VX35VKZ&&A=4O'P7HA%RN1(I#80E$3U500C.7 " P]^V5GTW+
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M>8PG"X4'2B^P8,(&M+Q\HYG,>T\25AIZ4C-*2QX2<LA#U\C6E-CQ:A"Z>R$
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M.(RYVL@W?MK+!$H,<6'L @9#$OR"8#?=&(C/T*#B?YH3 4'[TRA&.K[V@(O
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M["W]<)EI8&5Q%,,KR\G$0#U';]DE#^19\+6$=;!XM-Y?>%)PAB?>A%V+@![
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M8\2OQQ7;QJ.Q:I:ND-D]N;C^?8^T-<.&<Y$ X,(*"QQ[BBHA71Y+5V=E96L
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M2L3KGM0.W]<:^(Y;#XO6-48-W6I=;X'I0U'\K0@X*6P%\0[N.W)$O7K2!V?
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M[P'S9BU]3^V,\)P"]!#L_>C29YU=0 _G.2)*A(-D=$-6PDOF]RQGL6[9^DN
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M<_2TX(5F$F00JE9$+!)QC+HT84MBF#TJ\J$K%8BFR C/CSQ5E*[MA%X?!9Q
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MU<2822 -9-2+D/=J9)C/NT6^I&B[0YY7N-_VJS'K-$G$UAMAJE0'V;%/GCS
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M=C^UN9Z*]T50PHY1B;*=-]KJ1S?.E5+>^N4DJ;7^%#R0L@AE*;M)#WNEHPS
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M-?I9=H.H&*/))&4\*\O]"F5O=/5[9[-!7F<HE"A#8=!NW#9;VV8H='N-;O=
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M564DOK(X^9U 5A7WK+7,OOF%RE:^/?PNR^F0(PF=:L/8QXMF'[*6,'TN-_,
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M^A]<5%^JIS\Q,?V6MBJ62VV1IJB(L 7--"2 1JE]I-&2A3B)!=EQ"9?C8.D
M/F\D"G"9SR0"PZD7Q!NVX@I=YLH>#;(P6FO^P6&=J%+-J>0TT! L1XC+;@JR
MQ!0',[KTMDCL* Q!>Q8M&63K#'S'L^?_ /")T8Q9O3* ?,8@,9%8IW06$5/)
M^8R!.5(G='45@#DNBY.Y,678? <7;45"7(HF$>,(N7:RG' *>WW$T>J.3=O
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MX#DYZO0E,Y+CO/>06UU;C['9X5X"X?;5"\(;3<*E!'JFN*L$16T)I7-LWKA
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M#[;K(U#(#CX9@N_9.W*=_;C6P-P$S'7>P@Q@%F]\<*;#+*&V97_H;+(IV/)
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MCI]L[NNM[=<VW=]A'<7Z[6AS&,\?CJOOK^^O<T3J')&2.SXN$=:5U69K8-;
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MS[X= HV"F)G)M\/5L &I1:OGV<B!X(7X1$DR*%A%<R@,3J+>[F-/L96E"@C
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M(H);X;,,I6VD ,"0]P<V*(=NZ"P,-A=:88J29B!B0 Z8*#7N[^X_F0):0C,
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MC<G,AYLMA9[4&NS08)8WEYI0N]FZQ5,@'4YPXDD?\SD]U*<%<C:>)@\3+@6
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M>U93OK'YV;EAN?3H03'8@.LK @#\#C#W*VR*VU$]Y8)+L;:2K6$O9[:2^R,
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MS+#6BY=PV-D$A<F'1Q:V"P%'9?+O:PON.^(+7UG)7-K2'KQQK\N>9:XN<KI
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MTO@D1]V\]<U^L<-ULY"@[]DZT:MOQ%=/9G(629!WXR)E*$;$Z?[]TFB#T*(
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M?6C@8;#(/#<OW*.2;X<M^"U'J-R&TE\GC*6GQ;/AD#-XIA-TI$\8R/.9YF.
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MD/1P% XAI450'C='O#ES]>:'P7*_SL1WX8E57O8 1XCT+[_J?-VQ=VB_M(6
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M4)FOCTB7SP/BQ\-!1XF+B!\O=!@Y'7.6%1-H(#;$"0?;6V1=X-EK-PMLPZQ
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M)YODJPYV5*XRIW),81H:/U1T&'<8V28MI<3T0:Z+=SD4&Z&M'8*J0VX%+9\
MZ]9,(<X$G][L%V49(Y\K-?-U55D6JQN7'[5[G.^C9/2FX4GE'+CNW(?#R^\
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M&813[$YE)O,25!HC-#D]96UUSXP-^@8HOM*:_S2J7#MWC>*<;G0B)ZO9&R3
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M52(9!$XE2#,R4GE=,3MX"!X&Z%>TX6>KO]\?(KV:/; "0.P,$1JLTN5NN'=
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M2VHL])L*,^4G+./JC>SL@NUI?,'3&N62<NP_7DE?ROX_"=5C3G0>F=G!C)A
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MP)%9WZU;%B1H(.=EXL$:;QW5T!V2-4\#V:)XJ/TH@J[/E_-[%B3%QVVZBXU
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MS:GL+B<#HV\ ):K!+F;P,ZP/<^YT3.K!N5]3=K./'<N,+BT>_W[R*!5/A)L
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M>8"&4_Q*G6@>I\RU<2S'2X<1M:6 +!0!2AZ<-PU,'!B9N9CN>,CPW/LA/5$
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M%!%V4(V7L/#Y@RH]O%0\X_>>$O:/>'L(MU<@$R1X![F5/JS_6Z&N,4&S:+!
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MTJ).5O]Q?__VO]O@?G@Y[6W*%:X/9[K;CJ%,K^)31-MO=+Y/.%.<"^+-OY
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M4BM*]]HF_4NEJN"DHPG:(/6++?B>&I3WI3]&P'5LCW&D5+:N[Q6^B?+AX;.
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MC+Z5_L5YWN@V:7Q)(8&J^!]*ZNP' ][H%/"6B[X.$]3\@L5B8FN!.2;(2(V
MI7%$-:XF@$C0O[K\JW?9[>D$URAT0-G"[NUTS,C2$W7=W)R=.3)65W_N":9H
M])W[MJ]YZ?M(KPZE"^@O]B1YA4!9>I B&XL7RC@E4_^HI 1TB5TRBCL86@.A
M94%0R/7]3-">^%@PJ9YA@HY#KA_T9(+>W7RDF\@07R+$T47[4Y@@DOP1R%P9
M0ALYD 1LL%C=7<S#=X]T1?[J\;^^QS=R'/$KV:9Y1K21'!H/N=<O9F=K:^!6
M5U??%".3')A4 ?(_OZ6QY1MN3.QG@N11!!P5A&7$5N[K7L%50SHC;UE$W_I$
MCZ,%R&H=_5!N(O7CH*/M_L/:\T>]D'^CBTIC"!'D5S72!OU1*63+U)H("E.E
M:?1W\>Z=14LQ0;/7!)%M=VC^3%"N&!G'.-#BM&WX5X]_A1Y"R;.HJ7Z\1[O4
M"4=8*[8\,W&C]&U#QJC)AZK#CL*V4]YOY8R_\1YP0=GO76]097"P-$W6PIH5
M1&S8L4*&](M'F:"_>83QW]Y]X_8-]JB_NOS+=^G-.4QO8,C#+PW*C=*4J&)A
M37N3$E]]7;-Z;L0,N"57U_'?AC>3C+2W2]%_8_>*,$ !2TO5<V!T-7HP0:;F
M$?G_JIK^5X]_9_FG'U-=@6*H%!#!H@!'(>X8@3!;(-/*@5O_EU7MT]RKEJ]>
MJ<J"&IB@!J5I[W_^#QBE7H1NF AA+''>#!L+KBS%MC6>[KJ>9E9$(.67TH:N
M<QR?3UM_,7CPQKGBQWVVNXF/+TH_O^&X\M"-1KJ#\_QN+O<AFYB7)>0>7Y[<
M?77WND["KL <CAA!O0SWH:,1^Y;KG/(+PV!=2%%8\.%M7KZR9_()/19#:7@[
MS-V:S/ES%I)G1-NB$BE)Q&/[''$M.%987!F22(;@D>M?\6C!%80&636FTE'-
MC@1]&IQX94CD1G6C77I/@\/5;M5T=2ZM#M&9#_HW[K,M/U1:W)@H(3!!G<L,
M7K@_&=;%_:"GPWZLS4)R+20D/M?3S(7KH[UG1J893/!NA0L\[:"'QP-1MQ0E
M%"FT"SEYJT5?$@!3+](N KL%0,EEH!'C:>]4,:>$Y+5W</"$%5_<=&A,(J/T
M&N+AGW]<VX3=[)J7><3[\?X_<QH-HP&09Z$H)]74TPQ1Q& U$\2S52]UP>1T
M(:HUH^:7N;9L7)K9)Y>K0A>[B]G/NRR>/A@&:<-.[E!B@0FJ/HUM(*C1[#H)
ME\(X,[/*MRHMXWC27"@#72C77N'4 E/]XIJC??=LW$$1HMCDQ?V/]!M_EZY6
MD1W:UCE9IK+@^*E%UWF@Z^VM%D'@7<+AC,,RMZ_<>/_TC"#/(Y[6IB# C@";
MM(<]98($L*Z8HS3GH6U>?@!I.A@,.QQ&M22U'Y_I!+K3(M\-3K^+7X@A+ARQ
MN5>]I=QP-$#W.'F#$-H,FV3#6[0BD]!"F7A(7 .8]!SNLT>XKSD9.9.MV'.N
M&GVRRBJ^X<N<YXWG/(*!.7ELJPE*\]P0 I@82)IJQG%@/3?BT:(^P:42>/#3
M(#.( ""LRNTP-;E</5EK]9CH=R/R;<[T0HQ#;_B!Z'"), QF^9]@@XL(Y; (
M/"P!+A]D$0/F\VU0*C(/!&>7]K\KI;: O@8(7E_-<9X]%-E=*UOB?Y*MX#WF
M@W*PF8DZ_7JW4F*XC<]'"]&@@.7;)$,XLI QQ@1)(O8#.I3D3\!+?+W%TYMP
M*4:OM"A9:>6L;75^<*27E$_9S7%EA[<OYVS.QLBYS9]JEHHL3$1Z@2>F")@V
M7DZX)S '(Y2*X*U&9E*+#6;$JSXR.D9D/D6\SQIY8^5Y+)"K_/F+^GU5-=*&
MH,A3@I:7^%L.>#U-$.([M/_Q]WWCMTH6T GZJO12)LB#->"<,%U#JL$*XUP%
M$$T^ N%=S3F4V#)*";"W[^$:;)S.>]\;D.B6)'*N/O: 0,U;'/T=XQ1B",J+
M]%2-%0]YC@?S>C:QD;50L]_SAHCKO7UOBV56:K3.F:E_ E5WI[64NSQ5.R,Q
M>0FM#(KD_>=*TT*$=?7(6AWZ A<46E%/JV>$A@MJ4;VC2P/6]-E'KI\3%((M
MSI#8]!?NI%E]%OIU"$V%T@( SMF-2<T>O$<"4?^X"2F4JA[FTH[)Z[@W^7QD
M^WWPIUJSN^5^L1XQ=SH%GV?^40@"12;>\-QS>IEWT;>R] *G[:112,J,D*'R
M=;.[^[[JF</G//&XR3A*"+!&:FO%B2.T'8 U0^!Y<&B>UQ\UL:4^D/+@J^LY
MJ_)5]X7LKTJV*;NYGV[V]>U*985-@G HU8'1QP2)Z0O/A"528H9H;AYD=KP@
M CRBRRT27;J.KZS*$,N/J#>QS"((]XB>=@OE.JP ,]BWK2'TBYTXA8=-ULR*
MM"&%&$--'/2\RC4]G;8T^]Y<X(C%(8>OON^-!@U%)@H_AWC'9MD\$'I[OUFY
M6'!S9*OS96!@>,'4C)-=5>5@,TJE7O/:M8MR)AO177,7!0;^X>TZUJ,"UNE7
MZU"7/M<D[):^LC,+%= U.3U4_OIVD1MWU,5CJ:_X1A\I#T#/>B+.T=\C.!@3
M8![](P 31"!BV\T5\,*H4HN2">P38M"*NO"GQW)F+\RQO?,F,A]TW#V.Y4BA
MKBO8T=]AO?5"*1YD,$U0I 4K[%-*T\GUJHM93"7U-ISWH8S5R27_FC)9FOZH
MQ1DHZ]]S,L@_P<[&64Q]'\4=G;^2=>70E.G0FZKD/(_[Q+G;-]OGJT&2Z</#
MV[]0Q+@/C$%] < ,WS\9.(<D&CK/17*V(81\/0Q)\TT\59]1-\XZ[!8HU<=/
MY,E[T"</PS_59VZ\6G+ 6R0WG0A#S6Y$Z\M[XZIX4"0CW$W2L-;D;-/@![=L
MXJ>IKE,QKL.BG?'"KEQ-=B&$Q3L/]FT(VJ0SVG """6X,_V%KAJ9EV"89HS!
MY7_)6-33*SU(K[O3(]4X^[@VL2]&)A-F,>,*.LPV^L\L1^UZ4&;(2"*,>CY,
MU9J>#Y=C&>R.=5;H4Y_C@_IBO.P.=/3MJ(@OOJ,#9799"V6V5QW@/B5_7$SB
M?0&*-/^[[I:D*@+T$'!=T,G0#A:]1'#3W,&\6^BXK$.9^B7%D\##L1MUP\%2
M%\V5 _ K=OR'YV+,#NZ;R)\;/E)*,NO$5182/:@7 *3C(.+,.,#6?B&DM'A%
M6KMIL$&->RM3)$/KIKW[A-_+=S&2[6Z^7X_O1B7=S0+M:2;LME'LZ24T(Z0[
MKP3-GI[78.GQOHVTT[&WF#*C-!1$WA\6-=@).ZWS^>WEFF_/?_'G>7"M[M_T
M1#JCDY"5J'98/$20)D<UGIXT#'\[O3SVT#W.VTT2.?['JK#1QKKRZMN"L.=I
MFB&RF48R40=!D5+_&<A -1@S#V%$"%G@]H ^#UP+$"D%4'.=^7Y#-(,&$BZ^
M<HJ3:'2F_71:[.:B<*P8Z)#G+>6!FHS\!XM-S]X]TG<%4+/HY*PMR&'D?0L0
MXEN-_>E24H5#4TWFW)/)F:R*WEQ'.XUL>M9]#^\;R^\4KDY>.7#\YNU9*51T
MCC PQ-NA&H^KVDAIXH2.>SW\F5RPHL]/.K)*47V?K23T^FN6)63BIEW!YP<B
M?9,)B;6?KNM'LQ[I1D]:9X+NHPZ$E>"?@?F9(#?'"(-*<B&J"B+D&5J3(S-0
M&'_3P4S;I2+5%R,7H*113VNY=I<OHPS2!OTDG4Q6)<1%P2WGF*!Q-7, DA]F
MT<$')-X9W9@?S-IC+(*(!Y]GV9IKIPCXKZBG7'-^HK@_+8RJ^,^=F-_%4'X-
M(3V9H*=9!?&DP#EL<R.L'<FCH12"Q@LMQ=+,"\:A7F=CCP<]T\H\4WGF"TC-
M]*5[<D.54J8&>SOR ,UG["UPF6H0QD9QJQL(AL5D36\W8+GD1[=&<GS%5[]^
MP*T/7=:QCS/DNV T>.SXD;1"$%W+$ 1OS%N&5+F__$!SI'_< D\ O.) M,%@
MI44<FF?;'/'E>C4E^93:=%^Z1+"*RG#:BXP[ZX].$_L[0]<72-'XSB)25R?N
M$.(,HT]:Z?LV*OZ"$!-$4X *T"[A582)VSJ[Q-[/TN;/?Z $KZ98BUK!/Z?N
M7Y*MB'1C/3CR+>T<O;A)F:8#F%#/TJX#W JQZTW2:Y-R2TFZ;II8MP"7XK8\
MW_O6W=INGA-EK@GR^CX!X:9W)%_9C*O_O83+_T[",XG!>,CDY3;T00R4<A,(
MRSE.3B:VAV1$F4W9&KT6^/E+U6#:3#!0_2Z\7$3B=>;Y&ZV-FJSI8#.A9S..
MPZ_2$QN"J?(.B+Z9XP RHM@3%@G#8T3#T&;#;F/;G2_]Q!=7S23BT=_"<PU^
M=H-NQ8A:V:]^J(1,*E$R 1P)VX%D#8D'%1NWI]464=+H8>MKX5A>?Z&@5.Y5
M1NKE^RKRSW8YELR.9SC&?$P0.=\U6'F#O8L).MQ/#"U"#(1"P,C[T/'$]LRL
MGA]-F7.7O0EZ^[8V#B]O7GT[*4L-?:G2GL#6KSF]+FB44'QF&D)$L1.%\!M)
M$!XWP).J&);8;F_S^Y1#"V;:V[I)9L 7/WR<T5<;DQNKDSV^P//ISB-X^PUX
M];'42G3!_3='LH3HE**W$ZL/"^+U6>[04[)&W/=;>4-&VKFH 9TKWY*Z36Y:
MOC21Y#_C-?V/AR3L+Q%C3C+T/-WS)/MMEN&IQL7CP:(S/XP][\LV5CWQ'-#?
M.+>E,EQNK&;$WL,74#L1^)Q+J2T(/8'%B[2CQNN[H)_<:M:)>'#<3EU!QLXH
M0Y$<%[_5:.2(O..9,5?FEU?^^26M*TO]]/J;@]J6,5:L&/4-;]9_?09.D9(8
M8P\SB2*!Y!U*#/UI@TGXA\:>%82@9I/:=_!U4@I*-D'JG45->-J/JV]T?_G.
MM%RY7YS+33DHN&_3IG--=1+3A:Y2?[B4A'691G9@>6C<X4)CC]4;P1V3LL)[
M.7DBD,G,^.!PR:0!?NO#IJ"X<Y+5/R*MWD!7Q0MBW(I6)V4GW:9[\Q[\6*GA
M[Y+]<^C5C/X<>JN$M',<HAI^_SBD*,8E:'![7"7UY18#@6W$$B_-:@$SYWRY
M;@.8^VVYX_R0'K&0?:%:;.=UCV!9%IE-E1E'#-O;=&3C$J"5H>LQ^.,$"]&K
M*L%846Q"Y7D?=6X-L2P)3NT3C>$9$SR<OK=D/YU-W?07>0'9#_'J%:#8DWEI
M C67 079.K_"XM4+(9EDW;6,R^9QEQJQ:7,%&6PGZZC7_'MEG4S;;W\JPM7(
M-TVPH-F4GD\[134-&R(@4F<YD*[$0)9'/=0@<?#YZ.N"Y1FE@=*Q]KIG7B@)
MI]+I'Q84;W>0LL19Y:+&'L7BL7RX$QF:0KL\1^1D"/".\V]T"6M->G[&#BR,
M!.ED)TMO+5SC-PR^T+QZF] ;:[-J].-!9%D"B&PQ+C*+;8<^ANYS)66V)^M+
M*7KW"W@]S'D^Y^![F>@/P"P^?_94V?JR %;ZH!CP?/?2O7W']K.^^4_\HYB*
MD+U$M0MKHY1F=N&.8EU4CP(E+3.'ALW@9P>#4*+W;TR:!>V[]>%':2_^ZHZH
MK$'2HXMYK\0D_/=^_T]1<WN@"4+CI!?J0LE3S<B*T4)")!@/BPU"UJP\M*XO
MG'*Z7U?U)/!*>0_E)2%Y+NW4;3$7#\4!\+,HCKFJ_B?0:DP+>D*U#7( (4#3
MJQO5P(EZ3Y85D6WND'*PSM[!N<;A03N!#N-56]^+GM-^[>_3"K\GG^ZW>"TR
MDZ4%TWF,/OO,3MPC?0E %\?=8$F2;FM&R'QJ)%%>^D:^6XU=ML_553E15!]K
M**#]+-Z(H&QV_.OB:ZH*HA<);A)DC$"%$')P4Z"E;&U2ODD]9LBO2D+E!(38
ME= AXSEO=I5O]KZHJ-7%^#M2WV2UO?;T_]?EJ/E+_L\3YL3_!5!+ P04
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MH^ \N7IZO!&O-UUV[,<;YL05>R9/!;GBN3AR%4>,Y%U<!$E6;'( 1P[HU,S
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MV3#K:EWDC[VV[M>X G\_R0:A@A%+&Y VC3H7WT.=:LZ6.M4/+]0YE62%+IT
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MTBN>?>*9.*-%9+[U"C%-PD/$%"DS4BV"7IU?DD_5?UIG_? 4N'[+:)!S+*,
MV0FSAX$\."W@..;V2K9'71V +>YJ38"1=U/0.\8>;Z_+2L;Z\3'G05S_:3^+
MB@S%]?KSM?Z'5%N883+7^DES 62[ O*/:@W%/_78JV^:?A8;L0J,S2J#C/C-
M!:.54#ABA5_CW0G;\3@IB_UO7@BMK\\*L<'P]P2'3T2&GIY_RX.K/ ZT@W[:
MLTQO*;_Q/(@+3FIEP.C2%V@:WU4T*N"'M(XCU80%CQP]08 /%WT193=&] 3"
M26#HZ0C$S4OUN5P'Y88ER?,5B\,OQ2=>7J1!]L#!CJJ.+-,W*DTO;+\6(A9#
MGHH?2;4>LET0X()$QT(:ER$C&P=X\:%K%P,>*P0Y[MY"1X&].PH W-9]!&0>
MG.B5@UQYQ\#CG]8DP]05FZEJ(P4XWVE#4E,0C0;&M3V0D4]LI*O'%3MI2;)7
MV$0&H%7$1#H Z<_]*DY0Q66NN.FM+WI!CMWI=,./_\F%=+T"8,YV%W)-OV\8
M:(P#^ *R<2,_HA_8C0CO$$IDVO4,NT&=N(@]0Q&%@#8)=R;^W-FGA_,0$KK=
M,=TPKX16(M12Y[12  \!]7\ZT*NY-0)P&+<4F$<-RE: PQ7^Z9!IK^9//ZA6
MN1_%4&QID7>;O/;6865%]K-,7PLT'JJ]2FAED0- -8'PV&"\D5444<)#%!,Y
M1C*@D,A!E.4B(L<03@N(G(Q .G+%69(5_"8[9#Q ,O.Z)9AFR#98L-8L8@5%
MGH:X,CI*GH$FBLN-H>G>#;8#PL/3,,&XF7IJI'C/3R[6KO/7"^W$_^L?/2!!
MZ!TO@CRN*P3=3EV/SZ?.E$ZBT*5NY$24!<RA#IOY\^5\[CBA=@ZY3(%IJA[R
M:QHZ$5E#39/T,W(,H$ N@C#B4HDD0(9E%#4%VD\LDL"1YA?)QF&*K&Y3;"^C
M7<[MRPOR0YSRBY(_J-)K=,48W'?L<Z^SB"@3M9NUJ<3:2+VXL78E #L@:Y-J
M*+!8HU0?;KM6*6 >HO@;>_Y2-.J1X9YI#2GF'FE%4;71'UP 6%S1-0WY]NJQ
MZ8-ME6H#3,-&I*_#L'HJBJNL*%GR/_'C61;R6[8*_8A%$?67BQ5UF1-0+^(.
M#=EBMHHF$R>8 N/296I,AQ)L [=WFE^3K6Y2*2=".S1,76HHM?LS#GP8E['(
M$;'K?< &1+!+Q5J.8^^#=AK-WCL:\47A//\USS:/=6N+ZWN6\_LLJ>9^+E-
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MK4OO5SY8-6Q;.T/,+<C-/2M)M4<@ E_)TOHIK_Z'5"AY 8H4Q/\]U#2W\J>
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MB6X:*<\V!6D_Q\#27$>8]?9H.+C8G1D.*7@W=@H*O0=KB+*Z\SJ%<+S?DHQ
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MZ/60I==E1:;Z!J1H',?>SF9LXLV<&77=^8JZBRBBHG  Y2%?K+R9Y_+E E8
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ML1&# 7UDN*T,9%R"#3$LS4VIQ7[6FRYP:1*<]F3,2V(?NPJYN&C/,D[WO3+
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M10$&Q$\RXD?81R@<1/NV1C7J+4Y+#H+0BF%A1&3FOEK^\SDOJ3M-/13[GA\
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M%@D\H!A,$1;PB(68ZY$X$.%2S_GC+<5J#F%Q:E0'H%;YQ,N-"\M&! 1[, I
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M?-H+;J.X6/\%4$L! A0#%     @ 5(!*6WO"Q)S/^0  PKD) !$
M     ( !     &%R=W(M,C R-# Y,S N:'1M4$L! A0#%     @ 5(!*6\+7
M%=IV @  E0<  !$              ( !_OD  &%R=W(M,C R-# Y,S N>'-D
M4$L! A0#%     @ 5(!*6US@LAWX_@  /5\! !0              ( !H_P
M &%R=W(M,C R-# Y,S!?9S$N:G!G4$L! A0#%     @ 5(!*6\EPO+KJ+0
M*1$" !4              ( !S?L! &%R=W(M,C R-# Y,S!?;&%B+GAM;%!+
M 0(4 Q0    ( %2 2EO[)'C1,Q4  'D< 0 5              "  >HI @!A
M<G=R+3(P,C0P.3,P7W!R92YX;6Q02P$"% ,4    " !4@$I;DH HNOD#  !8
M#P  %P              @ %0/P( 87)W<BTR,#(T,#DS,'AE>#,Q,2YH=&U0
M2P$"% ,4    " !4@$I;%QY:K^X#  !?#P  %P              @ %^0P(
M87)W<BTR,#(T,#DS,'AE>#,Q,BYH=&U02P4&      < !P#0 0  H4<"

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>arwr-20240930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="arwr-20240930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2023-10-01</startDate>
            <endDate>2024-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-03-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2024-11-20</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-36">0000879407</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-37">true</dei:AmendmentFlag>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K/A</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="c-1" id="f-10">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-11">304-3400</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-12">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-13">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-14">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-15">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-16">91105</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-29">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-30" unitRef="usd">3000000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">124434442</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="margin-top:6pt;text-indent:30.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',serif;font-size:7pt;font-weight:400;line-height:120%"&gt;None.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AmendmentDescription contextRef="c-1" id="f-33">Arrowhead Pharmaceuticals, Inc. (the &#x201c;Company&#x201d; or &#x201c;Arrowhead&#x201d;) is filing this Amendment No. 1 on Form 10-K/A (this &#x201c;Amendment&#x201d;) to its Annual Report on Form 10-K for the year ended September 30, 2024 filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on November 26, 2024 (the &#x201c;Original Report&#x201d;) solely to include the information required by Items 10 through 14 of Part III of Form 10-K (the &#x201c;Part III Information&#x201d;) not included in the Original Report in order to comply with General Instruction G.3 of Form 10-K. The Company&#x2019;s Definitive Proxy Statement on Schedule 14A containing the Part III Information was filed with the SEC on January 29, 2025 (the &#x201c;Proxy Statement&#x201d;) was filed three minutes after the filing deadline on the 120th day after the Company&#x2019;s fiscal year end. Except as noted below, the Part III Information included in this Amendment is as of January 28, 2025.Pursuant to Rule 12b-15 under the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), this Amendment also contains new certifications pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, which are filed herewith. Because no financial statements have been included in this Amendment, and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Similarly, because no financial statements have been included in this Amendment, certifications pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 have been omitted.Except as described above, no other changes have been made to the Original Report and this Amendment does not modify, amend or update in any way any of the financial or other information contained in the Original Report or the Proxy Statement. This Amendment does not reflect events that may have occurred subsequent to the date of filing of the Original Report or the Proxy Statement. Accordingly, this Amendment should be read in conjunction with the Original Report and the Proxy Statement.</dei:AmendmentDescription>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-38">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
